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Abstract 
The abundant nuclear enzyme, poly(ADP-ribose) polymerase (PARP) is activated by 
DNA strand breaks and catalyses the transfer of ADP-ribose moieties from its substrate, 
nicotinamide adenine dinucleotide (NAD), to various histone- or non-histone nuclear 
acceptor proteins. The net result is the formation of long, homopolymeric chains, the 
exact purpose of which is not clearly understood. Since this process is thought to 
facilitate DNA repair, the PARP enzyme represents a possible therapeutic target. A well 
known mechanism by which tumours become resistant to anticancer treatments is 
increased DNA repair. Inhibition of PARP may thus be a strategy for the potentiation of 
DNA-damaging agents and PARP inhibitors may function as resistance-modifying agents 
in conjunction with cancer chemotherapeutic agents. 
The aim of this research was to design and synthesise novel heterocyclic inhibitors of 
PARP, based on the existing knowledge of structure-activity requirements. A great deal 
of information has already been gathered from the use of early inhibitors, such as 
nicotinamide and 3-aminobenzamide (3AB). However, these inhibitors lack potency, 
specificity for the enzyme, and aqueous solubility, and so are limited in their use as 
clinical agents. 
NH2 
A B 
A novel series of quinazolin-4-[3H]-ones (structure A) has been synthesised by a high- 
yielding, reproducible pathway, including derivatives bearing electron-withdrawing and 
electron-donating substituents in the 2-position. These derivatives exhibit excellent in 
vitro PARP inhibitory activity, with IC50 values in the micromolar concentration range, 
11 
and the selected compound, NU1025 (8-hydroxy-2-methylquinazolin-4-[3H]-one) has 
been shown to potentiate the effects of a range of mechanistically diverse anticancer 
agents, including y-irradiation. A water-soluble phosphate prodrug derivative of NU1025 
has been synthesised and this shows promising enzyme-mediated conversion to the 
parent compound in plasma. 
A second series of 1H-benzimidazole-4-carboxamides (structure B) has been synthesised 
bearing mono-, di- or trisubstituted aryl rings in the 2-position. Biological evaluation of 
this series has shown that these derivatives are among the most potent PARP inhibitors 
reported to date, with K; values in the low nanomolar concentration range. 
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Chapter One: Introduction 
Chapter One: Introduction 
1.1 DNA Repair 
The damage continually being inflicted upon DNA, by environmental and endogenous 
genotoxic agents, poses a severe threat to the all important maintenance of genetic 
integrity. Although cells may be equipped with a variety of intricate mechanisms to 
enable them to repair or cope with numerous types of DNA damage, the consequences of 
defective DNA repair with respect to human health, may manifest themselves as forms of 
cancer, developmental defects or neurological abnormalities. 
A classical method for investigating any biochemical system involves the inhibition of 
specific steps in a given sequence of reactions and then subsequent evaluation of the 
consequences to the system? However, the complexity in the structural organisation of 
chromatin and its many interactions with component enzymes renders the analyses of 
metabolic processes associated with DNA extremely challenging. In recent years, the use 
of rodent cell mutants for gene cloning and biochemical studies has significantly 
improved the understanding of mammalian repair processes. 
DNA repair is generally considered to involve the removal or bypass of damage-induced 
lesions, although DNA undergoes a whole range of transformations during normal 
growth and development. For example, DNA rearrangements, splicing of sequences and 
rejoining of strand breaks are just some of the ways that DNA is manipulated. Thus, it 
would be reasonable to suppose that biochemical processes and enzymes involved in such 
manipulation of DNA could also be related to the management of DNA damage, or might 
be induced by damage or inhibition of DNA synthesis. 3 
Spontaneous Breakdown of DNA 
DNA, incubated in physiological solutions (pH 7.4,37 °C), shows spontaneous 
breakdown over several days. 3 This breakdown is characterised by the loss and 
1 
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deamination of bases (e. g. cytosine is deaminated to uracil and adenine to hypoxanthine). 
It has been estimated that the number of spontaneous lesions generated per human cell 
per day is around 7000. 
Other Types of DNA Damage 
Damaged DNA can also result from exposure to exogenous factors, such as UV and 
ionising radiation, or treatment with electrophilic chemicals. Extensive damage from the 
cytoplasmic surroundings may also be inflicted upon DNA, for example, through 
exposure to reactive metabolites, which may cause oxidative damage or alkylation of 
DNA. 5 
Since continual DNA damage would amount to a high rate of mutation during genomic 
replication, it is not surprising that many cells have evolved complex but efficient 
methods to counteract potentially lethal damage. The following section describes some 
of the more clearly defined mechanisms for DNA damage repair. 
1.1.1 DNA Excision Repair 
DNA excision repair is comprised of two pathways: nucleotide excision repair (NER) and 
base excision repair (BER). 
Nucleotide Excision Repair (NER) 
NER is the most complicated of the excision repair processes. Several studies have 
shown that a deficiency in NER in humans is associated with the rare but life-threatening 
genetic disorders of xeroderma pigmentosum, trichothiodystrophy and Cockayne 
syndrome, 6 underlying the importance of NER for the maintenance of genomic integrity. 
The process of NER removes damaged DNA as part of an oligonucleotide fragment. The 
intact strand of DNA serves as a template for the new DNA, which is then used to replace 
the removed fragment. NER involves the products of about 30 genes and can recognise a 
broad variety of chemical alterations in DNA. A great deal of progress has been made in 
2 
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the study of NER, and it is likely that in the next few years, the connections between 
clinical phenotypes and molecular defects will be more clearly understood. 
6 
Base Excision Repair (BER) 
The BER pathway has evolved as a cellular protection mechanism, to guard against the 
deleterious effects of endogenous oxidative DNA damage. However, some exogenous 
DNA-damaging agents, such as ionising radiation, result in hydroxyl radicals being 
formed which can be as detrimental as the direct formation of radicals in DNA. BER is 
also important in the repair of spontaneous DNA damage and damage induced by certain 
endogenous factors. 5 
The main enzymes involved in BER are DNA glycosylases. These enzymes catalyse the 
cleavage of the N-glycosylic bond between a damaged or modified base and the 
deoxyribose group of the nucleotide residue. The resulting site is known as an 
apurinic/apyrimidinic (AP)-site, which is then removed by an (AP)-endonuclease or an 
(AP)-lyase. The appropriate phosphodiesterase removes the remaining deoxyribose 
phosphate residue and the gap is filled by a DNA polymerase and sealed by a DNA 
ligase. 5 
The BER process has been much less extensively studied in DNA repair enzymology 
compared to the NER pathway. Since there is no human or animal model which is 
defective in its BER pathway, the significance of BER in protection against mutational 
disorders has proved difficult to determine. 5 
1.1.2 UV Radiation-induced DNA Damage 
Exposure to UV radiation can result in cell death, mutation and neoplastic transformation, 
primarily due to the formation of UV radiation-induced DNA photoproducts. 7 The first 
and second most frequently occurring UV photoproducts are cyclobutane pyrimidine 
dimers and 6-4 photoproducts, respectively (see Figure 1.1.2). 7 
3 
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Figure 1.1.2 The major UV light-induced DNA photoproducts: 7 
A: cyclobutanepyrimidine dimers B: 6-4 photoproducts 
Sugar 
Phosphate 
Backbone 
Sugar 
Phosphate 
Backbone 
A: cyclobutane pyrimidine dimers B: 6-4 photoproducts 
In many species, there may be more than one operative pathway involved in the repair of 
major toxic and mutagenic UV photoproducts. In humans and most other organisms, the 
pathway for the removal of cyclobutane pyrimidine dimers is thought to be NER. 
8 Some 
organisms are able to excise cyclobutane pyrimidine dimers by way of an additional BER 
pathway, although BER is not generally regarded as the method for removal of UV 
photoproducts. 7 
1.1.3 Mismatch Repair 
DNA mismatch repair systems have been extensively studied and genetic defects in 
mismatch repair genes have been associated with cancer susceptibility. 9 Indeed, 
mismatch-repair-defective cell lines have been identified from a variety of tumour types 
including colon, endometrial, ovarian, prostate and uterine tumours. 9 
The mismatch repair pathway involves the repair of mispaired bases, which may be 
formed as a result of exposure to DNA-damaging agents or during DNA replication and 
4 
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genetic recombination. Mismatch repair is also thought to be involved in other vital 
processes, such as certain types of NER and the cell-cycle check-point system .9 
1.1.4 Alkylation-induced DNA Damage 
Alkylating agents cause damage to DNA by reacting with its nucleophilic sites. The net 
result is the formation of alkyl-DNA adducts, which can have mutagenic consequences. 
Exposure of mammalian cells to methylating or ethylating agents gives rise to alkylation 
of guanine at the 06-position. 1° Methylation or ethylation of the 06-position of guanine 
produces a miscoding lesion, which may result in the incorporation of a guanine- 
thymidine base-pair, instead of a guanine-cytosine pair, into DNA during replication. " 
The DNA repair protein 06-methylguanine DNA methyltransferase (MGMT) is 
responsible for the removal of DNA-alkyl groups and stoichiometrically transfers the 06- 
methyl group from the guanine to a cysteine residue. Thus, MGMT has evolved as a 
cellular protection mechanism against the accumulation of pre-toxic alkylation lesions in 
normal, healthy cells. Since the strict definition of an enzyme states that it should not be 
consumed during the course of the reaction, MGMT resembles a `suicide' enzyme, in that 
it is not regenerated after repair of the lesion. 
In certain human tumours and tumour cell lines, MGMT no longer appears active. 
Tumour cell lines lacking the repair activity (known as mer- or mex- cells) are 
particularly sensitive to simple alkylating agents and cells possessing repair activity 
(mer+ or mex+ cells) are generally resistant to such drugs. 
The ubiquitous distribution of MGMT in normal cells infers the presence of endogenous 
DNA methylation damage. S-adenosylmethionine (SAM) is responsible for the shuttling 
of methyl groups around the cell during the course of normal biosynthetic reactions and 
has been identified as a candidate for carrying out endogenous DNA methylation. 12 The 
reaction involves non-enzymatic methyl group transfer but the mechanism of donation to 
an oxygen would occur only slowly and therefore, would be unlikely to produce a 
significant amount of 06-methylguanine. Swann et al reasoned that transfer to a sulfur 
5 
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atom would be easier than to oxygen. 13 They replaced the 06-atom of 06-methylguanine 
with sulfur to give 6-thioguanine, and demonstrated that the transfer was indeed, several 
1000-fold faster to the S6-position than to the 06-position. The facile methylation of 6- 
thioguanine has been suggested to represent the mechanism of cytotoxicity of this 
agent. 13 6-thioguanine is used for the treatment of acute leukaemia. It is metabolised by 
the pathway that recycles purines and is subsequently incorporated into DNA. 14 
Methylation tolerant cells generally develop cross-resistance and have the ability to 
replicate 6-thioguanine-containing DNA without detrimental effects. '5 
Thus, although all of the above repair processes are absolutely critical for ensuring the 
survival of normal cells in an error-free way, the consequences of the repair mechanisms 
present in tumour cells must also to be considered. Since many cancer chemotherapeutic 
agents induce DNA damage as a means of destroying transformed cells, repair of such 
damage by tumour cells may impair the efficacy of antitumour drugs. Drug resistance is 
a major obstacle in cancer chemotherapy and investigations into the mechanisms of 
resistance have been the focus of extensive study over the last two decades. The 
following section gives a brief overview of drug resistance and some of the molecular 
mechanisms involved. 
1.2 Drug Resistance 
Drug resistance has emerged as one of the most important therapeutic problems in 
medical oncology. The identification of new drugs with activity against resistant tumours 
continues to challenge the pharmaceutical industry, largely because the effectiveness of 
chemotherapy is compromised by the development of resistance. 
Drug resistance can be categorised as either intrinsic or acquired, and can develop to a 
single drug or, simultaneously, to a variety of agents. 16 The distinction is derived from 
whether the tumour is resistant from the onset of treatment (intrinsic) or whether the 
tumour responds initially but then gradually becomes resistant during the course of 
treatment (acquired). An increasing body of evidence suggests that mixtures of drug 
6 
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resistance patterns are now emerging in human tumours. It has been estimated that drug 
resistance in general contributes to more than 90% of all cancer fatalities. 16 
Intrinsic Resistance 
Examples of intrinsically resistant tumours include those of the respiratory system, the 
digestive organs, the urinary organs, the brain or the central nervous system. 16 
Intrinsically resistant tumours may often arise from duct cells or cells which line 
excretory organs. 17 These types of cells would normally function in the detoxification, 
transport and elimination of compounds of a toxic nature. However, if these cells were to 
retain their normal functions in malignant tumours, they may then detoxify and eliminate 
chemotherapeutic drugs. 16 
Acquired Resistance 
Acquired resistance refers to the emergence of a resistant strain or cell-line, from a 
population that was initially drug-sensitive. This form of resistance may arise through 
genetic alterations within the tumour cells. However, it is believed that there may be 
several different mechanisms involved, which in some cases may operate 
simultaneously. 17 
1.2.1 Mechanisms of Resistance 
Figure 1.2.1 illustrates some of the many biochemical mechanisms of resistance (see 
main text for details). 17 Chemotherapeutic resistance has been studied in great detail and 
specific mechanisms identified in human tumour cell lines include defective drug 
transport, enhanced detoxification mechanisms and altered DNA repair (e. g. increased 
repair capacity or increased tolerance to damage). 16 However, resistance to any one 
particular drug may occur via more than one mechanism. Resistance to a range of 
compounds, either structurally related or unrelated, is frequently observed (referred to as 
multidrug, or pleiotropic, resistance). 16 
7 
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Figure 1.2.1 Biochemical mechanisms of drug resistance 
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Altered Drug Transport 
Effective delivery of a drug to its target site is of crucial importance for maximum drug 
efficacy. An example of an area which is difficult to target with chemotherapy is the 
brain. Delivering drugs across the blood-brain-barrier is a major obstacle in therapeutic 
treatment, and the brain is often referred to as a `sanctuary site' for tumour cells. 17,18 
Altered drug transport is an example of a mechanism dependent on factors which are 
essentially unrelated to the target cell. 
8 
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Reduced Drug Uptake 
A general mechanism of resistance occurs due to the defective transport of therapeutic 
agents, and involves drugs which are absorbed passively as well as those which are 
actively transported into the cell. '7 Many anticancer drugs (e. g. 5-fluorouracil, nitrogen 
mustard and melphalan) enter cells via active transport mechanisms, and mutations which 
affect these transport processes have been implicated in the resistance of tumour cells to 
these particular drugs. '7 
Increased Drug Efflux 
Resistance to certain compounds arises from alterations in the roles of proteins involved 
in drug efflux. P-glycoprotein is a trans-membrane, energy-dependent, efflux protein and 
is thought to confer resistance to a variety of anticancer drugs in human tumours'9 
(discussed under Section 1.2.2) 
Altered Drug Metabolism 
Drug-metabolising enzymes play an important role in the regulation of the intracellular 
concentration of a drug. For example, there may be a decrease in the expression of drug- 
activating enzymes or an increase in the expression of detoxification enzymes, both of 
which can lead to resistance. It appears that in some model systems, phase I and phase II 
enzymes (oxidation and conjugation, respectively) play an important role in cell 
protection against drug-induced damage. '? 
Target Site Alterations 
In some cases, drug resistance may arise as a result of a structural change in the target 
enzyme or protein, or may reflect the complete absence of a specific receptor. For 
example, a well-known mechanism for hormone-dependent breast cancer results from the 
lack of the oestrogen receptor. 20 Resistance may also occur due to a change in the 
intracellular concentration of the target site. So, although the target site structure remains 
unaffected, there may be an increase in target site abundance. An example of a target site 
alteration is an increase in the levels of the mammalian enzyme dihydrofolate reductase 
(DHFR) in certain tumour cell lines . 
21 DHFR is involved in the de novo synthesis of 
9 
Chapter One: Introduction 
purines and thymidine and in a large number of cases, a direct correlation between the 
level of intracellular DHFR and the degree of resistance to antifolates has been 
21 demonstrated. 
Repair of Drug-induced Damage 
Increased repair of cellular damage is a significant mechanism of drug resistance to 
alkylating agents and radiation. 17,18 In most cases, inhibition of the repair is the logical 
strategy for reversal of the drug-induced resistance. MGMT (Section 1.1.4) has been 
identified as a factor involved in drug resistance, and can provide protection for tumour 
cells against alkylating agents by carrying out its normal function of DNA repair. 22 
Tolerance to DNA Damage 
Some cell lines are able to survive, despite the presence of high levels of DNA damage: 
for example, cells resistant to alkylating agents can incorporate 6-thioguanine into DNA 
without harmful effects. However, the mechanistic details of this tolerance and the 
overall contribution to resistance remain largely unknown, although it is possible that the 
mismatch repair system is involved. 18 
1.2.2 Multidrug Resistance 
Multidrug resistance (MDR) is characterised by the simultaneous expression of cellular 
resistance by tumour cells to a broad variety of structurally and functionally unrelated 
drugs. ' 8 MDR has been largely associated with the activities of the membrane protein, P- 
glycoprotein, as its levels are increased in certain tumour cell lines. However, a variety 
of antitumour agents have been shown to directly y induce P-glycoprotein expression 
and the presence of increased levels of P-glycoprotein has been correlated with poor 
responses to chemotherapy. This raises the interesting possibility that the therapy itself 
could contribute to the development of MDR. 
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MRP-Associated Multidrug Resistance 
Not all cells classified with the MDR phenotype contain increased levels of P- 
glycoprotein. A second MDR-associated transporter protein was discovered by Cole and 
colleagues in 1992 27 The protein, identified as MRP, a 190 kDa ATP-binding membrane 
glycoprotein, appears to be a pump similar to P-glycoprotein, which effluxes drugs from 
the cell. 23 As with P-glycoprotein MDR, high levels of MRP expression are associated 
with resistance to anticancer agents 23 
Despite the grave nature of the problem of drug resistance, there is a good deal of hope 
for the development of novel strategies and combination therapies. By using drugs which 
target the mechanism of resistance in combination with existing anticancer agents, it may 
be possible to circumvent the problems of drug resistance and thus restore the desired 
effects of treatment. 
Selective Toxicity 
It has been stated that the natural resistance of human tumours to currently used 
chemotherapeutic agents is attributed to the non-selectivity of these drugs. 8 Since cancer 
cells arise from normal cells, it has proved difficult to identify a target unique to the 
cancer cell, not present in normal human cells. Most of the currently used anticancer 
agents employed in chemotherapy have resulted from serendipity, screening and 
modification of current active agents. A high proportion of cancer chemotherapeutic 
agents are developed according to knowledge of biochemical pathways. However, it is 
still abundantly clear that more specific therapeutic agents which exhibit selective 
toxicity towards cancer cells are urgently required for use in the clinic. 
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Chapter Two: Poly(ADP-ribose) Polymerase (PARP) 
2.1 ADP-Ribosylation Reactions 
ADP-ribosylation reactions constitute a group of posttranslational modifications of 
protein structures using nicotinamide adenine dinucleotide (NAD), the most abundant of 
the respiratory coenzymes, as a donor of the modifying group. 9 
The study of ADP-ribosylation reactions (or ADP-ribose transfer reactions) is generally 
considered to have originated in the 1960's, with the discoveries of two distinct 
processes: mono- and poly(ADP-ribosyl)ation. The first report on the discovery of a 
polymeric product of an ADP-ribosylation reaction was documented in 1963 by 
Chambon, Weil and Mandel. 30 Data relating to the nature of this novel polymer, known 
as poly(ADP-ribose), and the enzyme responsible for its synthesis, poly(ADP-ribose) 
polymerase [PARP: EC 2.4.2.30], were later reported in 1966.31 The discovery of 
mono(ADP-ribosyl)ation reactions was initiated by the findings of Collier and 
Pappenheimer in 1964, who demonstrated that NAD+ was absolutely necessary for the 
inhibition of protein synthesis in cell-free systems by diphtheria toxin. 32 
In recent years, with the development of molecular and genetic techniques, significant 
advances in the understanding of ADP-ribosylation reactions have been made. Both 
mono- and poly(ADP-ribose) are generally viewed to be involved in signal transduction 
processes: the eukaryotic mono(ADP-ribosyl) transferases being involved in transducing 
signals from extracellular components, and poly(ADP-ribosyl)ation being associated with 
the nuclear compartment 33 
Ten years ago, Lee and coworkers34 reported the discovery of a new metabolite of NAD+ 
that was an effective calcium-mobilising agent in sea urchin microsomes. They later 
confirmed that the metabolite was a cyclic form of ADP-ribose35 and since its discovery, 
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the amount of information regarding the role of this cyclic NAD+ metabolite has steadily 
increased. 
The following sections briefly describe important aspects of mono(ADP-ribosyl)ation 
reactions and cyclic (ADP-ribose) metabolism. Since this thesis is primarily concerned 
with the process of poly(ADP-ribosyl)ation, information relating to this category of ADP- 
ribosylation reactions will subsequently be presented in much greater detail. 
2.1.1 Mono(ADP-ribosyl)ation Reactions 
Mono(ADP-ribosyl)ation reactions involve the addition of a single ADP-ribose unit from 
NAD+ to an acceptor amino acid or protein molecule, and occur in the cytoplasm and cell 
membranes of both prokaryotic and eukaryotic cells. 29 
Several bacterial toxins are classified as mono(ADP-ribosyl) transferase enzymes with 
targets in eukaryotic cells. These enzymes exhibit remarkable specificity for their 
substrates, with respect to particular amino acids and proteins. According to this 
specificity, mono(ADP-ribosyl)ation reactions can be divided into four subtypes: 
diphthamide-, arginine-, asparagine- and lysine-specific ADP-ribosylations 29 
Figure 2.1.1 shows a comparison of the amino acid acceptors for mono(ADP- 
ribosyl)ation and poly(ADP-ribosyl)ation. 29 The arrows indicate the chemical nature of 
the ADP-ribosyl protein bond formed: mono(ADP-ribosyl)ation results in N-glycosidic 
linkages whereas poly(ADP-ribosyl)ation produces O-glycosides. 
Mono(ADP-ribosyl)ation of proteins has been shown to affect the activities of proteins 
involved in crucial metabolic or regulatory pathways, 36 such as signal transduction, 37 
thus, indicating the importance of mono(ADP-ribosyl)ation reactions in biological 
systems. 
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Figure 2.1.1 Acceptor amino acids for mono- and poly(ADP-ribosyl)ation. 29 
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2.1.2 Cyclic ADP-ribose 
Cyclic ADP-ribose (cADPR) is a novel cyclic metabolite of NAD+ involved in calcium 
(Ca2+) signalling 34'35 The mobilisation of Ca2+ from intracellular stores is of critical 
importance to fundamental processes such as fertilisation, muscle contraction and 
morphogenesis 38 cADPR also serves as a second messenger for Ca2+ for insulin 
secretion in pancreatic ß-cells. 39 cADPR is naturally occurring and its endogenous levels 
in various rat tissues have been determined 40 The cyclic nature of this metabolite was 
recently confirmed by X-ray crystallography4' which clearly showed the ß configuration 
of the cyclisation linkage. Jacobson et at42 also demonstrated the ß configuration of the 
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linkage using NMR techniques. From their analyses of the ultraviolet absorption spectra 
of cADPR as a function of pH, they proposed the following structures (illustrated in 
42 Figure 2.1.2) 
Figure 2.1.2 Structures of the protonated and deprotonated forms of cyclic ADP- 
ribose 42 
A pKa value of 8.3 was determined and it was proposed that conformational changes in 
the structure of cADPR might be related to its mode of action in the mobilisation of 
Ca 2+ 42 
cADPR is synthesised by ADP-ribosyl cyclase and the hydrolysis of cADPR is catalysed 
by cyclic ADP-ribose hydrolase. There also exists a class of bifunctional enzymes, 
which exhibit both of the aforementioned catalytic activities towards cADPR. 43 The 
transmembrane glycoprotein, identified as the human lymphocyte antigen CD38, is an 
example of such a bifunctional enzyme. CD38 has been shown to catalyse the formation 
of cADPR from NAD+ and its hydrolysis to generate free ADP-ribose. 4 The rat and 
murine homologues of CD38 also exhibit bifunctional activities. 45,46 It has been 
proposed that an enzyme-stabilised ADP-ribosyl oxocarbenium-ion is involved during 
the synthesis and hydrolysis of cADPR. 47,48 This particular feature of NAD+ hydrolysis 
will be discussed in more detail in Section 2.5. 
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2.2 Poly(ADP-ribose) Polymerase: PARP [EC 2.4.2.30] 
Poly(ADP-ribose) polymerase or PARP [also referred to as poly(ADP-ribose) synthetase 
and poly(ADP-ribosyl) transferase: pADPRT] has been extensively investigated since it's 
discovery in the 1960's. 30'31 The interest in this highly abundant nuclear enzyme soon 
flourished as it was quickly realised that the exact biological role of PARP was far from 
straightforward. Indeed, present day literature continues to indicate that the precise 
functions of PARP have yet to be fully elucidated. 
2.2.1 Poly(ADP-ribosyl)ation 
Poly(ADP-ribosyl)ation involves the posttranslational modification of nuclear proteins. 
Using ß-NAD+ as a substrate, PARP catalyses the transfer of the ADP-ribose moiety 
from ß-NAD+ to a suitable nuclear acceptor protein. The repetition of this catalytic 
activity results in the formation of negatively-charged homopolymeric chains of repeating 
ADP-ribose monomers. 
Table 2.1 illustrates postranslational modifications of DNA, RNA and chromatin 
proteins. 9 Of all the posttranslational modifications, poly(ADP-ribosyl)ation may induce 
the most substantial alteration of chromatin structure. 50 The modifying residues are 
variable in both size and structure and polymers of 200 or more ADP-ribose units have 
been detected. 51 Furthermore, the polymeric chains contain two negative charges per 
monomer and a highly charged poly-anion in close proximity to chromatin would be 
expected to have a profound effect on its structure and function. 
The alteration of chromatin would inevitably influence the processes of gene expression, 
DNA replication, repair and recombination, 50 and consequently PARP has been 
associated with all of these processes and more (in particular, DNA repair). A number of 
roles have been proposed for the function of PARP within the cell and the literature 
concerning these will be discussed in more detail in Chapter Three. 
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Table 2.1 Posttranslational modifications of nuclear macron: olecules49 
Macromolecule Modification 
DNA Methylation 
Cutting and splicing (rejoining) 
RNA Internal methylation 
Polyadenylation 
5'-terminal methylation 
Cutting and splicing (rejoining) 
Chromatin Proteins Phosphorylation 
Methylation 
Acetylation 
ADP-ribosylation 
2.3 Structural Conservation of PARP between species. 
There is clear evolutionary conservation of PARP among eukaryotic organisms and it has 
been suggested that this alone provides evidence for a critical role of PARP in biological 
systems. Purified PARP has been isolated from human placenta, 52,53 calf thymus, 54 fish, 55 
and Helix pomatia. 56 PARP enzymic activity has also been detected in plants and lower 
eukaryotes, such as the slime mould Dictyostelium discoideum, 57 and the diflagellate 
Crypthecodinium cohnii. 58 
Cloning techniques have provided valuable methods which allow the characterisation of 
the PARP enzyme at the molecular level. PARP cDNAs have been isolated from a 
number of phylogenetically divergent species, and a comparison of the amino acid 
sequences revealed a high degree of homology between different classes of animals. 59 
The cDNA for human PARP was cloned by two independent research groups in 1987.60.61 
Subsequently, cDNAs for mouse, 62 rat, 63 bovine, chicken, 65 Xenopus laevis, 66 cherry 
salmon66 and Drosophila melanogaster67 have been cloned. Table 2.2 summarises the 
results obtained from the comparison of PARP cDNAs from different species. 59 
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Table 2.2 Homology in nucleotide and amino acid sequences among PARP 
cDNAs from different species. 59 
aa Human Mouse Bovine Chicken Xenopus Drosophila 
nt 
Human 95 96 88 85 61 
(92) (90) (79) (75) (43) 
Mouse 87 ,.. W-A 94 86 84 61 
(88) (77) (73) (43) 
Bovine 88 85 88 84 62 
(77) (72) (43) 
Chicken 76 74 74 87 61 
(78) (43) 
Xenopus 71 70 69 73 61 
(43) 
Drosophila 50 50 49 51 51 
t `ik 5µ' ; 
k 
` ; MI N^ý 
as = amino acid sequence homology, shown as % similarity (% identity in parentheses) 
nt = nucleotide sequence homology 
The amino acid sequences show a very high percentage of homology among mammals. 
Drosophila PARP, on the other hand, has only 61% similarity (43% identity) in amino 
acid sequence to human PARP, which could be attributable to the evolutionary distance 
between the two species. 59 However, the possibility that Drosophila PARP has a 
function specific to the invertebrate enzyme should not be ruled out. 68 When only the 
vertebrate sequences are considered, the overall conservation is 62%, which is reduced to 
only 32% when the Drosophila PARP sequence is included. 69 The strictly conserved 
regions of the amino acid sequences are largely associated with peptide sequences which 
are required for enzymatic activity. 
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Recently, the cloning and characterisation of the first plant cDNA encoding a PARP 
homologue was reported. 70 Evidence for poly(ADP-ribosyl)ation in plants was first 
obtained from investigations on germinating seeds71 and cytological work with onion 
tissues. 72 The plant PARP homologue shows approximately 62-63% similarity (41-45% 
identity) to the catalytic domains of mammals, Xenopus and insect cDNAs. However, 
there is little similarity between the N-terminal sequences. 70 In line with animal PARP, 
plant PARP has also been suggested to be involved in DNA repair. 
In the following section, important structural features of the PARP enzyme (excluding 
the plant homologue) will be discussed. 
2.4 Modular Organisation of PARP 
PARP is composed of 1014 amino acids and has a molecular weight of 116 kDa. 73 The 
enzyme's activity is strictly dependent on the presence of DNA strand breaks74 and 
PARP has been implicated as a critical regulatory component of the cellular response to 
DNA damage. Zahradka and Ebisuzaki75 demonstrated that PARP is a metalloenzyme 
and requires zinc for its activity. Crucial information about the enzyme structure was 
revealed when Kameshita et al showed that partial proteolysis with papain and/or a- 
chymotrypsin yielded three major proteolytic fragments: 76,77 
(i) a 46 kDa amino-terminal fragment, identified as the DNA-binding domain 
(DBD), 
(ii) a central 22 kDa fragment containing sites for poly(ADP-ribosyl)ation, known as 
the automodification domain, 
(iii) a 54 kDa carboxyl-terminal fragment possessing the site for accepting NAD+ (the 
substrate-binding domain). 
Figure 2.4 shows a schematic representation of the functional domains of PARP 
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Figure 2.4 Schematic representation of the three functional domains of human 
PARP 68,77 
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The arrows indicate the cleavage sites for papain and a-chymotrypsin and, interestingly, 
these sites correspond to the two regions of lowest conservation 68.69 
2.4.1 The DNA-Binding Domain (DBD) 
The DBD consists of three subdomains A, B and C (Figure 2.4). 
The Zinc Fingers 
PARP is a zinc metalloenzyme which has been shown to contain two zinc ions per PARP 
molecule. 78 These zinc ions are coordinated to cysteine and histidine ligands (a total of 
four ligands per zinc ion), resulting in secondary protein structures known as zinc fingers. 
The two zinc fingers of PARP, fI and f II, are located in residues 21-56 and 125-162, 
respectively (domain A, 29 kDa, Figure 2.4). 
Experiments involving metal depletion and restoration revealed that Zn(II) was crucial 
for the DNA-binding capability of domain A. 78 Since the absence of zinc results in a 
D 
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decrease in enzymatic activity, it has been hypothesised that reduced PARP activity may 
be associated with a nutritional zinc deficiency. 79 A nutritional zinc deficiency can result 
in abnormalities of gene expression, cell division and growth, and since PARP has been 
associated with these biological processes, it has been suggested that the decrease of 
PARP activity could be, at least partially, responsible for the effects seen. 79 
The zinc fingers of PARP are rather unusual in their lack of sequence homology to other 
existing zinc-finger classes. 80 They also have longer loops, of 28-30 amino-acid residues, 
81 than those of most other DNA-binding proteins. 
Ikejima et al have demonstrated that each zinc finger has a specific function. 82 It appears 
that on disruption off I, sensitivity to double-stranded DNA breaks is abolished, whereas 
the enzymatic activity which depends on single strand DNA breaks no longer remains 
when f II is disrupted. In other words, the zinc-fingers fI and f II recognise double- and 
single-stranded DNA breaks, respectively. 82 Gradwohl et al confirmed these findings by 
generating a library of PARP-DBD mutants possessing mutations in either one or both of 
the zinc fingers, and testing them for their ability to bind DNA breaks. 83 However, 
regardless of the nature of the activating DNA break, the first zinc finger (f I) is 
absolutely required for PARP catalytic activity. 82 
Since the two zinc fingers are essential for the recognition and binding of damaged DNA, 
it would be reasonable to suggest that these structures may be conserved among the 
eukaryotes. Mazen et al performed experiments in which critical residues, involved in 
metal coordination of the two zinc fingers, were identified. 84 Comparison of the cDNA 
sequences of human, mouse, bovine, chicken, Xenopus and Drosophila PARP revealed 
that all of the ligands of the first and second zinc fingers (Cys2l, Cys24, His53, Cys56 
and Cys125, Cys128, His159, Cys162, respectively) are strictly conserved. The zinc 
finger motifs are of the form CX2CX28-30HX2C, where C= cysteine, H= histidine and X 
= any amino acid. 82 Figure 2.4.1 shows a schematic representation of the zinc finger 
motifs and the conserved chelating amino acid residues. 
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Figure 2.4.1 Schematic representation of the zinc fingers present in the DBD of 
PARP 
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There are also some basic residues in the DBD that are strictly conserved: Argl8, Lys30, 
Arg34, Arg122, Lys134 and Arg138. It has been proposed that these basic residues may 
be significant with respect to their interaction with DNA. 59 
The Nuclear Localisation Signal (NLS) 
Domain B of the DBD contains a nuclear localisation signal (NLS), which consists of a 
short amino acid sequence (residues 207-226) generally rich in basic residues. This 
sequence serves to target proteins larger than 40-60 kDa into the cell nucleus. 68 
Schreiber et al found that the human NLS is composed of two basic clusters, separated by 
eleven amino acids, and belongs to the class of bipartite signals. 85 Site-directed 
mutagenesis located the amino acid residue Lys222, in the second basic cluster and this 
lysine residue was identified as critical for nuclear-targeting activity. 85 
On proteolytic degradation of PARP with plasmin, S6 the cleavage site occurs immediately 
after the crucial residue Lys222, suggesting that this cluster of residues is situated on the 
surface of the PARP molecule. 
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Cleavage of the NLS of PARP is also of significance in the process of apoptosis (or 
programmed cell death). The involvement of PARP in this process will be discussed in 
Section 3.2.7. 
Domain C 
At present, no known function with relation to enzymatic activity has been ascribed to 
domain C of the DBD. However, Trucco et al used random mutagenesis techniques to 
identify two critical residues in domain C and suggested the possibility that this domain 
may contribute, in some way, to stimulation of catalytic activity by DNA strand breaks. 87 
2.4.1.1 Activation of PARP by DNA strand breaks 
Early investigations on the activation of PARP by DNA molecules containing different 
types of strand breaks were carried out by Benjamin and Gill. 74 They constructed a range 
of defined DNA fragments of known structure and determined the stimulatory effects on 
polymer synthesis by PARP. Their results indicated that single-stranded intact DNA was 
ineffective in the activation of PARP whereas double-stranded breaks with blunt ends 
produced the highest stimulation of activity. 74 
In contrast, recent reports have indicated that PARP preferentially binds to single-strand 
breaks in double-stranded DNA. 88'89 Menissier de Murcia et al used a `footprint' assay to 
investigate the interaction between PARP and nicked DNA. They found that PARP 
symmetrically `protects' 7 (± 1) nucleotides of the continuous DNA strand on either side 
of the nick and that the protection is independent of DNA sequence. 88 It is interesting to 
note that, under the experimental conditions used, no footprint was observed between 
PARP and methylated DNA or PARP and blunt-ended double-stranded DNA. The 
authors suggested that this may be due to the enzyme recognising the continuity of the 
DNA ribose-phosphate backbone. 88 
Further information on the binding of PARP to single-stranded DNA lesions was 
presented by Le Cam et al, who used electron microscopy (EM) techniques to visualise a 
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139 base-pair DNA fragment containing a central single-strand break. 89 EM showed the 
nicked duplex to have a V-like structure compared to the intact control duplex. The 
result of incubation of PARP with the nicked DNA construct, was the binding of the 
enzyme to the apex of the V-shape, causing an increase in angle values of the structure. 89 
2.4.2 The Automodification Domain 
The automodification domain (domain D, Figure 2.4) contains the acceptor sites for 
poly(ADP-ribose). Poly(ADP-ribosyl)ation involves the transfer of poly(ADP-ribose) to 
nuclear acceptor proteins including PARP itself. The synthesis of polymers on the PARP 
enzyme is referred to as automodification whereas poly(ADP-ribosyl)ation of other 
nuclear proteins is referred to as heteromodification. The PARP enzyme has been found 
to be the major acceptor protein of poly(ADP-ribose) both in vitro9o'91 and in DNA- 
damaged cells 92 
It has previously been reported that the number of acceptor sites present in the 
automodification domain is fifteen. These sites are all highly conserved glutamic acid 
residues 91 However, in a subsequent report by Desmarais et al, it was found that these 
acceptor sites were not the only sites present in the PARP molecule. 93 The net result of 
automodification of PARP is its catalytic inactivation by dissociation from the DNA 
strand it is bound to. This presumably occurs through electrostatic repulsion between the 
negatively charged enzyme-bound polymers and DNA itself. Desmarais et al found a 
total of 13 acceptor sites outside the automodification domain and suggested that 
modification by PARP at these sites may provide a more efficient way for the enzyme to 
modulate its repulsion from DNA 93 
The Leucine-Zipper Motif 
The presence of a leucine-zipper motif in the automodification domain of PARP was first 
demonstrated in Drosophila melanogaster by Uchida and coworkers. 67 Leucine-zipper 
proteins, with periodic repetitions of leucine residues, have been proposed to mediate the 
formation of homo- and heterodimers. This dimerisation may be involved in the DNA- 
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binding and functions of the leucine-zipper proteins. 67 Uchida et al proposed that the 
leucine-zipper motif of PARP may serve to allow protein-protein interactions between 
PARP and nuclear acceptor proteins. 67 
Despite the automodification domain being less conserved than the DBD and the catalytic 
domain, comparison of the cDNA sequences of human, mouse, bovine, chicken, Xenopus 
and Drosophila revealed that within the leucine-zipper motif, two glutamic acid residues 
(G1u401 and G1u407) are strictly conserved in all six species. 59 These glutamate residues 
may be acceptor sites for automodification. 91 If these sites were poly(ADP-ribosyl)ated, 
dissociation of the PARP dimer may occur67 and automodification of these residues may, 
thus, be a means of regulating dimerisation. 
2.4.3 The Catalytic Domain 
The catalytic domain of PARP (domains E and F, 54 kDa, Figure 2.4) contains the 
NAD+-binding region and is responsible for the catalytic activity of the enzyme. NAD+ 
commonly serves as a coenzyme in electron-transfer reactions and its utilisation as a 
substrate by PARP is rather unusual. 
The carboxyl-terminal region of PARP shows the highest sequence homology between 
species. The sequence from residues 859-908 (domain F, Figure 2.4) is known as the 
PARP signature and is strictly conserved (100 %) among the vertebrates (92 % among all 
species). 68 
Two major NAD+-binding residues, Trp1014 (the C-terminal residue) and Lys893 
(located within the PARP signature), were identified by photolabelling experiments 
carried out by Kim et a1.94 The NAD+ photoaffinity analogue 2-azido-[a 32P]NAD+ was 
used to label residues in the catalytic domain of human PARP. Their results suggested 
that Lys893, but not Trp1014, was crucial for enzymatic activity, although the deletion of 
TrplO14 along with residues 1007-1013, resulted in the abolition of catalytic activity, 
indicating that TrplO14 is in some way necessary. 94 It was also shown, from saturation 
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experiments which determined stoichiometry, that PARP contains a single NAD+-binding 
site. 94 
Simonin et al demonstrated that the PARP catalytic domain can be shortened to a 40 kDa 
unit (domain F, Figure 2.4) without losing basal polymer synthesis activity. 95 
Furthermore, this basal activity is independent of the presence of DNA 95 When the 
cDNA encoding domain F was overproduced and purified in E. Coli, it was found that 
the affinity for NAD+ associated with the 40 kDa fragment was comparable to that of 
full-length PARP. However, the 40 kDa unit had a 500-fold lower specific activity when 
compared to full-length PARP activated by DNA strand breaks 96 
The possibility that the DBD of PARP is capable of transducing some sort of signal to the 
catalytic domain, once bound to a DNA strand break, was investigated by Trucco et al. 87 
They identified the residue Lys97, located in domain A between the two zinc fingers, and 
suggested that this residue could be involved in the relay of information between the 
DBD and the catalytic domain. 87 
2.5 Catalytic Activities of PARP 
2.5.1 Auto modification 
During poly(ADP-ribose) synthesis, PARP is responsible for the catalysis of three 
chemically distinct enzymatic steps: 97 
(i) the glutamate-specific attachment of an ADP-ribose moiety to an acceptor protein 
(initiation reaction), 98 
(ii) the formation of a (2'-1") ribose-ribose glycosidic bond (polymer elongation 
reaction), 99 
(iii) the formation of (2"-1"') ribose-ribose bonds (branching reaction). 10° 
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Figure 2.5.1.1 shows a schematic representation of the structure of NAD+. The initiation 
of polymer synthesis results in the attachment of an ADP-ribose unit to an acceptor 
protein with the elimination of nicotinamide. The broken arrows indicate sites of 
elongation and branching. 
Figure 2.5.1.1 Schematic representation of the catalytic activities of PARP 29 
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Studies to establish the mechanism of cleavage of the ribose-nicotinamide bond indicate 
the involvement of an enzyme-stabilised oxocarbenium-ion intermediate. ' 0'-'03 This 
stabilisation can only occur if the ribose group adopts a conformation within the enzyme 
active-site which results in maximum overlap of the lone-pair electrons on the oxygen 
with the adjacent vacant p orbital. Thus, loss of nicotinamide would be assisted by the 
ribose oxygen lone-pair. 
A recent model for the stabilisation of the oxocarbenium-ion intermediate was proposed 
by Oppenheimer (see Figure Z5.1.2). 103 This model predicts the presence of an anionic 
basic residue, possibly a glutamate, in the active-site. However, the precise mechanistic 
details of the enzymatic cleavage of the ribose-nicotinamide bond are not fully 
understood. 
Figure 2.5.1.2 Proposed mechanism for the inductive stabilisation of an oxo- 
carbenium-ion intermediate by an active-site carboxylate. 103 
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In order to investigate the molecular mechanism of the automodification reaction (i. e. 
where PARP acts as the acceptor for the polymer), Alvarez-Gonzalez and Mendoza- 
Alvarez performed kinetic experiments in which they measured the initial rates of 
automodification at physiological NAD+ concentration. 1°4 Since the initial rates of 
automodification, as a function of PARP concentration, increased with second order 
kinetics, they concluded that two molecules of PARP (i. e. a catalytic dimer) are necessary 
for auto-mono(ADP-ribosyl)ation (the initiation reaction) and auto-poly(ADP- 
ribosyl)ation (elongation and branching). 104 It was also found that the initial rates of 
automodification increased with second order kinetics as a function of substrate 
concentration, indicating that the catalytic PARP dimer requires two molecules of 
NAD+. '°4 
The suggestion of a catalytic dimer is in agreement with the findings of Bauer and 
coworkers, who observed the macromolecular association of PARP into oligomeric 
forms. '05 Furthermore, Panzeter and Althaus demonstrated that optimal polymerisation 
activity of PARP was obtained at a stoichiometry of two enzyme molecules per molecule 
of DNA. 106 However, the individual molecular functions of each monomer in the 
catalytic dimer are presently unclear. It is not known whether one monomer acts as 
catalyst whilst the other acts as acceptor or whether both function simultaneously, as 
catalyst and acceptor. '°4 
The automodification reaction of PARP has been dissected into the individual reactions 
of initiation, elongation and branching, by manipulating the availability of ß-NAD+, the 
ADP-ribosylation substrate. 107 
The Initiation Reaction 
The polymer initiation reaction has been shown to proceed via a distributive 
mechanism. 104 
Simonin et al observed that the carboxyl-terminal domain of PARP shares sequence 
similarities with the NAD(P)+-binding domains of the leucine and glutamate 
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dehydrogenases (L/G DH). 96 Using site-directed mutagenesis, they identified critical 
residues in the active site of human PARP, Lys893 and Asp993. By superimposing the 
C-terminal domain sequence of PARP on the recently solved three-dimensional structure 
of the NAD+-dependent glutamate dehydrogenase (GDH) from Clostridium 
symbiosum, 108 they found that the residues they had identified were conserved between 
the two enzymes and were located near or in the catalytic cleft. 96 
According to Baker et al, there is a cluster of basic residues present in the GDH structure 
which has been proposed to be involved in stabilising glutamate binding. 108 An 
analogous cluster of residues is present in the PARP enzyme, one of which is Lys893, 
identified as being essential for activity. 94,96 Since modification by PARP preferentially 
occurs at a glutamate residue within a polypeptide chain, Simonin et al postulated that the 
cluster of basic residues present in PARP may be involved in stabilisation of the negative 
charge on the acceptor amino acid, allowing its correct positioning with respect to the 
NAD+ molecule. 96 
Asp993, the other important residue identified, is located in a particular type of structure 
known as the Rossman Fold. 109 The Rossman Fold is a characteristic NAD'-binding 
structure for many of the NAD+-dependent dehydrogenases and a similar structure has 
been found in the catalytic domain of PARP. Asp993 has been implicated in the binding 
of the ADP-ribose group of the NAD+ molecule, again according to the GDH model. 6 
However, a second model for the involvement of residues in the initiation reaction was 
proposed by Marsischky et al, who attributed their findings to the sequence similarities 
between the catalytic domain of PARP and the analogous region of the mono(ADP- 
ribosyl)ating bacterial toxins. 110 It is proposed that many of the mono(ADP-ribosyl)ating 
toxins share a similar type of reaction mechanism involving a particular glutamic acid 
residue. " This residue is thought to be involved in the catalysis reaction of the 
mono(ADP-ribosyl) transferases and, since G1u988 of PARP is in the analogous position 
it was suggested to play a similar role. "° 
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In contrast, the cDNA isolated from the slime mould Dictyostelium discoideum was 
found to contain a glutamine residue in position 988.112 The capacity of Dictyostelium 
PARP to synthesise ADP-ribose polymers was clearly demonstrated, with the detection 
of polymers of up to 100 ADP-ribose units in length. ' 12 Its enzymic activity was 
however, found to be markedly reduced compared to the human enzyme. 
The Elongation Reaction 
The elongation reaction catalysed by PARP has been shown by a number of groups to 
proceed via a protein-distal elongation mechanism. 113"115 Distal addition involves the 2'- 
hydroxyl group of the growing polymer (polymer tail) acting as the acceptor for the 
covalent addition of the next ADP-ribose moiety (illustrated in Figure 2.5.1.3). Each 
addition of monomer results in the elimination of a molecule of nicotinamide. 
For every initiation reaction, it has been estimated that PARP has the capacity to catalyse 
5-7 branching reactions and more than 200 elongation reactions, indicating that the 
elongation of the polymer appears to be the main catalytic function. 116 
The Branching Reaction 
Highly complex, branched ADP-ribose polymers have been detected containing over 200 
ADP-ribose units and 5-6 branching points per molecule. 116 These branched structures 
have also been observed using electron microscopy. 117 
2.5.2 Hetero modification 
Heteromodification involves the poly(ADP-ribosyl)ation of histones and DNA 
metabolising enzymes. Details of the molecular mechanism of the heteromodification 
reaction have not yet been elucidated. It is likely that heteromodification will also be 
bimolecular in nature, and it is thought that the heterodimerisation of PARP with 
poly(ADP-ribose) acceptor proteins involves leucine zipper motifs 98 
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Figure 2.5.1.3 The protein-distal addition mechanism for poly(ADP-ribose) elongation 
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2.6 Catabolism of Poly(ADP-ribose) 
A balance must exist between the anabolism and catabolism of the polymer within the 
cell. The accumulation of long negatively-charged polymers in the near vicinity of 
chromatin and its associated proteins could only be expected to be detrimental in the long 
term. 
To recap, PARP is activated by the presence of DNA strand breaks. The enzyme 
recognises and binds to the damaged site via the two zinc fingers present in the DBD, and 
proceeds to synthesise ADP-ribose polymers, using ß-NAD+ as a substrate. These 
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polymers are either covalently attached to PARP itself, or to other suitable nuclear 
acceptor proteins. The automodification of PARP results in its dissociation from the site 
of damage via electrostatic repulsion from DNA, and renders the enzyme covalently 
modified and enzymatically inactive. 
An equally important factor in polymer metabolism is catabolism (degradation of the 
polymer). The main enzymes involved in poly(ADP-ribose) degradation are poly(ADP- 
ribose) glycohydrolase (PARG) and ADP-ribosyl protein lyase. 
2.6.1 Poly(ADP-ribose) Glycohydrolase (PARG) 
The discovery of PARG was first reported in the early 1970's. 118-120 PARG is the 
principle enzyme responsible for the degradation of poly(ADP-ribose). Due to its 
synergistic role with PARP, PARG is present in all eukaryotic cells, except yeast. 121 
Four nuclear isoforms of the purified enzyme have been detected122 and the existence of a 
cytoplasmic PARG has been reported123 although this is in contrast to reports of 
exclusively nuclear PARG. 124,125 
PARG is responsible for the reversal of the automodified state of PARP, and assists in the 
restoration of the DNA-binding ability and catalytic activity of the enzyme. PARG 
degrades both linear and branched polymers by hydrolysing the O-glycosidic bonds 
between each monomer. 121 This results in the generation of free ADP-ribose units. This 
degradative reaction is responsible for the short half-life of poly(ADP-ribose) which, at 
high levels of DNA damage, may be less than 40 seconds. In contrast, a half-life of 7.7 
hours has been observed for constitutive polymer fractions in undamaged cells. 126 
It has been proposed that the mode of action of PARG is a combination of endo- and 
exoglycosidic action. This was initially suggested by Ikejima and Gill127 and later 
demonstrated by Brochu et al. 128 It appears that polymer catabolism is a highly organised 
process, where large polymers (greater than 20 residues) are degraded in a fast and 
processive reaction by endoglycosidic action, and shorter polymers are degraded in a 
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slower, distributive reaction mode with exoglycosidic action. 129,130 PARG also 
hydrolyses branch points of poly(ADP-ribose), although relatively slowly compared to 
linear polymers. 130 
Until recently, PARG was thought to degrade polymers down to the protein-proximal 
ADP-ribose residue, which is then removed by ADP-ribosyl protein lyase. Desnoyers et 
al found that PARG was also able to remove the last residue on PARP, indicating the 
flexibility of the glycohydrolase enzyme. 129 
2.6.2 ADP-ribosyl Protein Lyase 
ADP-ribosyl protein lyase was first discovered by Okayama and coworkers131 and is 
responsible for the hydrolysis of the bond between the protein-proximal ADP-ribose 
residue and the glutamate residue on the acceptor protein. 132 In light of the findings of 
Desnoyers et al, ADP-ribosyl protein lyase may share this activity with PARG. 129 
2.7 Distribution of Poly(ADP-ribose) Metabolising Enzymes Within 
the Cell 
There have been several estimates of the number of PARP molecules present, which 
ranges from 2X 105 to 2X 106 molecules per cell in various cell lines. 133,134 PARG is, in 
contrast, approximately 13- to 50-fold less abundant, 124,135 although its specific catalytic 
activity is higher. 134 
More than 95% of PARP molecules are localised in the nucleus, although the distribution 
is uneven as the bulk of the activity is associated with chromatin. 136 The possibility of 
different functional classes of PARP molecules existing within the nucleus was raised by 
Kaufmann et al. 137 However, knowledge of these putative multiple classes is minimal at 
present. 
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The detection of cytoplasmic PARP has been reported in free ribosomes and polysomes 
of HeLa cells138 and in mouse messenger ribonucleoprotein (mRNP) particles. 139 The 
cytoplasmic PARP isolated from mouse mRNP has an apparent molecular weight of 116 
kDa, as does nuclear PARP. However, the enzymatic activity of cytoplasmic PARP is 
unaffected by the presence/absence of DNA. 139 As mentioned in Section 2.4.1 nuclear 
PARP contains a nuclear localisation signal (NLS) which retains the enzyme in the 
nucleus. The presence of a non-functional NLS has no effect on catalytic activity. 85 It 
has been postulated that a posttranslational modification of the NLS (e. g. phosphorylation 
by a protein kinase), could be responsible for the cytoplasmic localisation of the mRNP 
PARP. 139 
It is also interesting to note that Jesser et al detected the copurification of RNA in the 
cytoplasmic PARP preparation from mRNP. 139 Desnoyers et al also suggested a possible 
interaction between PARP and RNA. '4° The implications of these observations (e. g. the 
possibility that PARP can bind to RNA in vivo), require further investigation. 
2.7.1 Detection of Poly(ADP-ribose) 
Poly(ADP-ribose) is usually characterised by the chromatographic identification of its 
enzymatic hydrolysis products. As discussed in Section 2.6, catabolism of poly(ADP- 
ribose) is mainly carried out by the glycohydrolase PARG. However, the polymer can 
also be hydrolysed by a second class of enzymes, namely the phosphodiesterases. 
The analytical enzyme primarily used for the characterisation of poly(ADP-ribose) is 
snake venom phosphodiesterase [EC 3.1.4.1] (also known as nucleotide 
phosphodiesterase). 49 This enzyme hydrolyses the pyrophosphate bond of poly(ADP- 
ribose) to give one molecule of phosphoribosyl adenosine monophosphate [PR-AMP: 2' 
(or 3')-(5"-phosphoribosyl)-5'-AMP] from every internal residue, and one molecule of 5'- 
adenosine monophosphate (5'-AMP) from every non-reducing terminus. 9'81 This results 
in a ribose-phosphate group covalently attached to the acceptor protein. 
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Thus, the major product from enzymatic hydrolysis by PARG is ADP-ribose, whereas the 
major product of phosphodiesterase hydrolysis is PR-AMP. This is illustrated in Figure 
2. %1.1.49 
Figure 2.7.1.1 Enzymatic hydrolysis of poly(ADP-ribose)49 
Ade Ade Ade Ade Ade 
I I I I I Acceptor 
rib ri b-rib rib-rib rib-rib rib-rib rib- Protein IIIIIIAIIAII 
P-P P-P P-P; P-P: P-P 
AA' 
",, 
a,, 
11, 
",, 
"a, 
I, I1, 
,,, 
11, 
,., 
ý 
ý 
ý 
ý 
phosphodiesterase glycohydrolase 
activity activity 
11 
PR-AMP ADP-ribose 
Ade Ade 
db-rib rib 
Ib 
1I1 
pp P-P 
Ade = adenosine rib = ribose P= phosphate 
PR-AMP and ADP-ribose can be degraded further under different conditions: PR-AMP is 
cleaved by alkaline phosphatase but not cleaved by snake venom phosphodiesterase 
whereas the opposite is true for ADP-ribose (illustrated in Figure 2.7.1.2) 49 
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Figure 2.7.1.2 Hydrolysis of PR AMP and ADP-ribose49 
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2.8 Summary: The Poly(ADP-ribosyl)ation System 
Poly(ADP-ribosyl)ation appears to be a highly organised sequence of events. The total 
ADP-ribose-processing capacity of mammalian cells is impressive, with an estimated 
turnover of approximately 107 ADP-ribose residues per minute per cell for PARP and 
PARG, and about 72 x 106 residues for ADP-ribosyl protein lyase (assuming -109 
molecules of NAD+ per cell). 130 
Figure 2.8 shows a representation of the poly(ADP-ribosyl)ation system and its 
component enzymes. tat A linear polymer with a single branch point is illustrated and 
broken arrows indicate sites of synthesis (e. g. by PARP) or sites of cleavage (e. g. by 
PARG, ADP-ribosyl protein lyase or a phosphodiesterase). 
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Figure 2.8 The poly(ADP-ribosyl)ation system141 
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Since the substrate for poly(ADP-ribosyl)ation is NAD+ it is reasonable to assume that 
activation of PARP, and subsequent polymer synthesis, may influence NAD+ 
metabolism. In undamaged, healthy cells, the cellular enzymatic capacity to synthesise 
NAD+ exceeds normal requirements. 9 In circumstances of severe DNA damage, 
however, the rapid surge in poly(ADP-ribose) synthesis may result in the transient, or 
permanent, lowering of intracellular NAD+ and ATP levels, which can have drastic 
consequences with respect to cell survival. 
Attention will now be drawn to the biological consequences of poly(ADP-ribosyl)ation. 
Exactly what purpose does this system serve? To what extent does it influence not only 
NAD+ metabolism but other biochemical processes? There have been numerous 
speculations on the possible roles of PARP, largely as a result of studies employing 
inhibitors of the enzyme. Chapter Three is concerned with literature evidence 
surrounding the involvement of PARP in various cellular processes. 
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Chapter Three: The Involvement of PARP in Cellular 
Processes 
3.1 Methods for Studying PARP 
To date, the precise biological function of PARP remains unknown. A large proportion 
of studies carried out rely on the use of inhibitors of the polymerase, and the evaluation 
of the functional consequences to the cell as a result of enzyme inhibition. 
3.1.1 The Use of Chemical Inhibitors 
A large number of compounds have been shown to inhibit PARP enzymatic activity both 
in vitro and in vivo. The most commonly used low-molecular-weight inhibitors of PARP 
are structurally related to the nicotinamide reaction product, and function as competitive 
inhibitors of the endogenous substrate, NAD+. The most favoured of these, 3- 
aminobenzamide (3AB), has served as a valuable tool in studies concerning the 
biological significance of poly(ADP-ribosyl)ation. However, an increasing amount of 
evidence indicates that, at high concentrations, 3AB and other benzamides have non- 
specific side effects on cellular metabolism. 142,143 In view of this, the results of enzyme- 
inhibitor studies should be interpreted with caution and definitive conclusions should not 
be based on chemical inhibitor experiments alone. Chapter Four will discuss the 
development of chemical inhibitors of PARP in more detail. 
3.1.2 Molecular Genetic Approaches 
The advantage of using molecular genetic systems as tools for studying the role of PARP, 
is that the non-specific side effects associated with chemical inhibitors can be avoided. 
Modulation of poly(ADP-ribose) metabolism by molecular approaches has allowed the 
assessment of the consequences of gene disruption to living cells. Genetically modified 
mice which completely lack the PARP gene have been produced and now serve as 
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invaluable model systems for the study of PARP)44,145 More detailed examples of 
molecular genetic methods for evaluating the role of PARP will be included in the main 
text of the following sections. 
3.2 Proposals for the Role of PARP 
3.2.1 Modulation of Chromatin Structure by Poly(ADP-ribosyl)ation 
The structure of chromatin largely determines the extent of DNA repair, replication and 
gene expression. Chromatin is composed of nucleosomal subunits which are repeating 
units of 167 base pairs of DNA wrapped around a core histone octamer (two each of 
H2A, H2B, H3 and H4). 50 These histones, classified according to their amino acid 
content, are either lysine-rich (H2A, H2B) or arginine-rich (H3, H4). Each nucleosome 
is organised into a second-order structure by interactions between histone Hi 
(exceptionally lysine-rich) and core histones from an adjacent nucleosome (see Figure 
3.2.1). 50 
Figure 3.2.1 Schematic representation of chromatin structure so 
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The tight association of DNA with histones and chromosomal proteins largely affects the 
accessibility of DNA to enzymes or other proteins. Generally, condensed chromatin is 
viewed as inaccessible or only partially accessible to most nuclear processes. 50 These 
nuclear processes require higher-order chromatin structures, as well as individual 
nucleosomes, to be opened up before the DNA becomes accessible. 
Ueda et al showed that 80-90% of PARP activity is associated with chromatin, although 
it is not clear exactly how polymer synthesis influences chromatin structure and its 
related functions. 146 In addition to the PARP enzyme itself, histones are the main 
acceptors of poly(ADP-ribose) and it has been suggested that PARP may play a role in 
the opening up of higher-order chromatin superstructure. 147 In studies carried out by 
Poirier et al, histone H1 was poly(ADP-ribosyl)ated in vitro and then allowed to interact 
with Hl-depleted chromatin. It was demonstrated that even though HI bound to 
chromatin, its modification by PARP resulted in the prevention of chromatin 
condensation into higher-order structures. 147 This decondensation of chromatin is 
reversible, however, as it was shown that incubation of decondensed poly(ADP- 
ribosyl)ated chromatin with PARG caused the chromatin to re-condense. 148.149 PARG, 
through the degradation of polymers on H1, presumably restores histone-chromatin 
interactions. 
According to Poirier et al less than 5% of the total HI fraction is poly(ADP-ribosyl)ated 
but this still results in dramatic changes in chromatin structure. 147 The correlation 
between poly(ADP-ribosyl)ated HI and decondensed chromatin was confirmed by 
Niedergang and coworkers. 150 It is interesting to note that the observations made by 
Poirier et al and Niedergang et al are in contrast to earlier work by Butt and coworkers, 
who suggested that poly(ADP-ribosyl)ation promoted chromatin condensation. 151 
3.2.2 Poly(ADP-ribosyl)ation of Nuclear Proteins 
Nuclear proteins, other than histones and PARP are modified by poly(ADP-ribosyl)ation. 
These proteins may be involved in nuclear processes associated with chromatin. The 
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effects of modification on the enzymatic activities of several nuclear proteins have been 
investigated and the results are shown in Table 3.1.152 
Table 3.1 Substrates for poly(ADP-ribose)'52 
Protein Consequence of 
poly(ADP-ribosyl)ation 
Reference 
Poly(ADP-ribose) polymerase Inhibition 153 
Cat+, Mgt endonuclease Inhibition 154 
DNA polymerase a Inhibition 155 
DNA polymerase ß Inhibition 155 
Terminal deoxynucleotide transferase Inhibition 155 
DNA ligase II Inhibition 155 
Topoisomerase I Inhibition 156,157 
Topoisomerase II Inhibition 158 
RNA polymerase II Inhibition 159 
Ribonuclease Inhibition 160 
Prolyl hydroxylase Inhibition 161 
Histone Hi Unknown 162 
Histone H2B Unknown 163 
HMG proteins Unknown 162 
SV40 T antigen Unknown 164 
Adenoviral DNA binding protein Unknown 164 
Of all the enzymes which have been directly investigated, poly(ADP-ribosyl)ation results 
in an inhibition of activity. These include topoisomerases I and 11,156"158 DNA 
polymerase 13155.165 and endonucleases. 154 The topoisomerases are involved in DNA 
replication, recombination and chromatin assembly. It has been suggested by a number 
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of groups that inhibition of these enzymes by poly(ADP-ribosyl)ation may serve to 
regulate nuclear processes which are dependent upon them. Thus, having the combined 
effects of inhibition of chromatin condensation and inhibition of enzymes involved in 
DNA synthesis and replication, under conditions of DNA damage, PARP may function to 
ensure that manipulation of DNA (for example, synthesis or replication) does not proceed 
until repair has occurred. 50"36 
3.2.3 PARP, Chromosome Aberrations and Sister Chromatid Exchange (SCE) 
In metaphase chromosomes, genetic damage is measured as chromosome aberrations 
and/or sister chromatid exchange (SCE). 152 Chromosome aberrations generally lead to 
cell death, as they are a result of un-rejoined or mis-rejoined DNA double-strand breaks. 
The inhibition of PARP does not directly induce chromosome aberrations but it has been 
shown that following exposure to alkylating agents or ionising radiation, PARP inhibitors 
potentiate the induction of aberrations in a cell-cycle dependent manner. 152,166 
The mechanism of SCE formation is not understood but inhibitors of PARP have been 
shown to increase SCE frequency in a dose-dependent manner (the more potent the 
inhibitor, the more SCE's are induced). ' 52,167-169 Despite the many conflicting reports 
about the involvement of PARP in cellular responses to DNA damage, the increase in 
SCE frequency appears to be the one agreed-upon cellular consequence of enzyme 
inhibition. 152 
3.2.4 Poly(ADP-ribosyl)ation and Gene Amplification 
Gene amplification in normal mammalian cells is rare but represents a mechanism by 
which tumour cells may increase levels of specific proteins and thereby become resistant 
to certain agents. 152 Gene amplification induced by carcinogens has been studied. 
Bürkle et al showed that methotrexate-resistance and dihydrofolate reductase gene 
amplification were increased when PARP was inhibited by 3AB in cell culture systems. 
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The conclusion of these results was that PARP may act as a negative regulatory factor in 
the induction of gene amplification. 170 
The role of PARP in the induction of viral replication and amplification has also been 
investigated. Bürkle et al reported the enhanced amplification of integrated simian virus 
40 (SV40) sequences in SV40-transformed Chinese hamster C060 cells, which had been 
treated with N-methyl-N -nitro-N-nitrosoguanidine (MNNG) and 3AB. 171 Supportive 
data were presented by Ding and Smulson, who observed enhanced gene amplification in 
cells depleted of PARP mRNA by antisense RNA expression. 172 
3.2.5 Poly(ADP-ribosyl)ation and DNA Repair 
Since the observation, made by Durkacz et al in 1980, that low-molecular-weight 
chemical inhibitors of PARP caused a delay in strand-break rejoining, PARP has been 
associated with the DNA repair process. 173 Its participation in DNA repair has, however, 
remained controversial, largely due to the lack of positive evidence to support the 
proposal. The following sections will discuss proposed models for the role of PARP in 
cellular defence mechanisms. 
3.2.5.1 Histone Shuttle Mechanism 
The histone shuttle mechanism, put forward by Althaus and coworkers, represents a 
model for the involvement of PARP in DNA excision repair. 130 The covalent linkage 
between PARP and acceptor proteins is generally considered to be a pre-requisite for 
enzymatic activity, but Althaus et al suggest that PARP may function primarily via non- 
covalent interactions with nuclear proteins. 130 
The automodification reaction of PARP has been found to follow a processive reaction 
mode in vitro. 174 This processive nature has also been observed in more complex 
systems, such as in isolated nuclei, nucleosomal core particles and intact cells, although 
the polymer patterns identified in vivo differ from those produced 'in vitro. 175-177 Histones 
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Hl, H2A, H2B, H3 and H4 have been identified as key regulatory factors determining the 
numbers, sizes and branching frequencies of polymers. 175 Naegeli and Althaus 
demonstrated that when PARP encountered DNA-bound histones in vitro, it had the 
adaptability to produce histone-type specific polymer patterns which were almost 
identical to those produced in vivo. 175 They concluded that histories may directly 
influence the polymer termination reaction of PARP, although the relevance of these 
histone-specific adaptations in vivo is unclear. 
Investigations of the interactions between histones and ADP-ribose polymers revealed 
that the mode of binding was stronger and more specific than would be expected on the 
basis of electrostatic interactions alone. 178 Panzeter et al used highly stringent assay 
conditions, to eliminate non-specific electrostatic interactions, and investigated the non- 
covalent binding affinities of various proteins towards different molecular classes of 
ADP-ribose polymers. 178 They found that of all the proteins tested, only histones H1, H2, 
H3, H4 and protamine (which replaces histones in the final stages of spermatogenesis) 
bound to the polymers. It is interesting to note that'the primary site of polymer binding 
of histone H1 is the carboxyl-terminal domain178 which is also the domain that is most 
effective in inducing higher order chromatin structure. 179 
The polymer-histone complexes were found to exhibit unusually high binding strengths 
and were resistant to high salt concentrations, detergent and strong acids. 178 The 
interactions between different histone and polymer types were also found to have 
specificity: branched polymers were the most highly preferred binding counterparts, 
followed by long and short linear polymers, respectively. 178 The hierarchy of histone 
binding was established as H1 > H2A > H2B = H3 > H4.178 
In agreement with other suggestions that PARP is somehow involved in nucleosomal 
unfolding, it has been shown that automodified PARP can cause the dissociation of 
histones from a core DNA fragment in vitro. 180 This dissociation is prevented in the 
presence of competitive PARP inhibitors. The negatively charged, enzyme-bound 
polymers are more acidic than DNA and would, therefore, be expected to compete with 
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DNA for histone binding. Realini and Althaus demonstrated that automodified PARP 
was 10-fold more potent in dissociating histone H2B from H2B-DNA complexes when 
compared to free polymers. They also showed that the branch points of ADP-ribose 
polymers had the highest binding affinities for histones and suggested that the polymers 
of automodified PARP may selectively target histones for dissociation from DNA. 18' 
The reverse effect i. e. the reassociation of histone-DNA complexes, is mediated by 
PARG. 18' Briefly, polymers are initially degraded by a combination of endo- and 
exoglycosidic actions and branched polymers are degraded more slowly than linear 
polymers. The avid binding of histones to branch sites has been suggested as the reason 
for the slower degradation of branched polymers. '81 
Thus, to summarise, the histone shuttle mechanism is thought to operate in a processive, 
adaptive, target-specific and reversible fashion. 182 The shuttling of histones on and off 
DNA, effected by PARP and PARG, is proposed to influence chromatin condensation 
and allow enzymes or proteins involved in nuclear processes to gain access to the 
DNA. '83 Figure 3.2.5.1 shows a schematic representation of the histone shuttle 
mechanism. 183 
Although the histone shuttle mechanism has been demonstrated in vitro, evidence for in 
vivo histone shuttling must also be considered. Processivity, adaptiveness and 
reversibility of the shuttle mechanism have been observed in vivo and depletion of PARP 
has been shown to block nucleosomal unfolding in mammalian cells. 184 Thus, it may be 
possible that PARP is involved in the dissociation of histone-DNA complexes. 
However, several features of poly(ADP-ribosyl)ation cannot be explained by the histone 
shuttle mechanism. The most striking example is the presence of the poly(ADP- 
ribosyl)ation system in dinoflagellates despite the fact that these primitive eukaryotes 
completely lack histones in their cell nuclei. 58 Therefore, the involvement of PARP in 
the histone shuttle mechanism should be viewed with caution, as the enzyme may have a 
role other than or beyond this process. 
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Figure 3.2.5.1 Schematic representation of the histone-shuttle mechanism' 83 
1 PARP binds to a DNA strand break 
2 automodified PARP causes the dissociation of histones from DNA 
3 dissociation of the modified enzyme allows access for other enzymes 
4 the polymers are degraded by PARG and the histones reassociate with the DNA 
3.2.5.2 Non-Histone Mechanism 
The role proposed by Satoh and Lindahl (see Figure 3.2.5.2,185) for poly(ADP-ribose) 
formation in the DNA repair process, essentially contradicts the histone shuttle 
mechanism. Using histone-depleted cell extracts, Satoh and Lindahl demonstrated that 
inhibition of PARP by 3 AB resulted in interference with the ability of the cells to repair 
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y-irradiation-induced DNA damage. They suggested that rather than carrying out a 
positive function in DNA repair, PARP may have an equally as important negative 
function to fulfil. 
Figure 3.2.5.2 Proposed model for the involvement of PARP in DNA repair'85 
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1 when a strand break is introduced, PARP, excision enzymes (Exc. ) and DNA 
polymerases (DNA pol. ) compete for binding to the break. 
2 DNA-bound PARP limits access to the strand break for repair enzymes 
3 automodification occurs once PARP is bound to the break 
4 automodified PARP dissociates from the break and allows access for repair enzymes 
5 excision-repair seals the DNA strand break. 
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Whilst the histone-free cell extracts used by Satoh and Lindahl refute the histone shuttle 
mechanism, they agree that heteromodification of histone H1 in chromatin may aid 
chromatin decondensation. Again, their proposal relies on the importance of accessibility 
of the DNA strand breakage to repair enzymes, which is achieved when the DNA-bound 
polymerase is automodified and subsequently dissociates from the DNA. However, 
according to Satoh and Lindahl, the build-up of polymers during automodification may 
serve to prevent biologically inappropriate side reactions from occurring, such as DNA 
recombination. Inappropriate DNA recombination may lead to chromosomal aberrations 
which would be detrimental to the cell, and PARP may thus, have a `protective' role. 
Satoh and Lindahl's proposal concerning PARP and the prevention of homologous 
recombination is supported by Chatterjee and Berger. '86 
Alternatively, Satoh and Lindahl raised the possibility of a signal mechanism perhaps 
elicited by the PARP enzyme, once bound to a DNA break. This signal may negatively 
regulate DNA synthesis and replication to ensure that unrepaired DNA is not 
duplicated. 185 It must be noted, however, that there is no positive, direct evidence for 
either the prevention of DNA recombination or the signalling mechanism. 
3.2.5.3 Poly(ADP-ribosyl)ation and Ligation of DNA 
The DNA repair process can be broadly divided into four stages: 49 
i) incision (at or near the DNA lesion), 
ii) removal of damaged/defective nucleotides and some adjacent DNA, 
iii) resynthesis, to fill the gap (unscheduled DNA synthesis: UDS), 
iv) religation to seal the DNA. 
PARP inhibitors do not affect incision events, which suggests that the active enzyme is 
not required for the early stage of DNA repair. 187 The rate of removal of damaged DNA 
is also unaffected by inhibition of PARP. 187 The effects of PARP inhibitors on UDS have 
been determined by a number of research groups. 188-190 In most cases, PARP inhibitors 
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did not block UDS and, in fact, stimulated UDS depending on the conditions and 
inhibitors used. 
Based on the above data, Creissen and Shall proposed that PARP was involved at or near 
the ligation step of DNA repair. 191 Mammalian cells contain DNA ligase I and II, both of 
which are thought to be involved in DNA repair. 187 Creissen and Shall found that when 
L1210 murine leukaemia cells were treated with the alkylating agent dimethyl sulfate 
(DMS), the overall DNA ligase enzyme activity in the cells was increased. This increase 
in ligase activity was prevented by inhibition of PARP. 191 
It should be noted, however, that Yoshihara et al found that DNA ligase II activity was 
inhibited by poly(ADP-ribosyl)ation. '55 In view of these findings, Cleaver and Morgan 
proposed an entirely different model for the role of PARP within the cell. 192 They 
discarded the notion of DNA ligase II regulation by PARP and focussed on the 
poly(ADP-ribosyl)ation of enzymes which are normally activated on exposure to 
alkylating agents. Since the poly(ADP-ribosyl)ation of most nuclear proteins results in 
their inhibition, Cleaver and Morgan suggested that inhibition of PARP may lead to 
chaotic, non-specific attack of DNA by nuclear enzymes such as Cat+- and Mgt+- 
dependent endonucleases. Random nuclease attack on DNA would create additional sites 
of damage, which would lead to increased DNA damage and cell killing but would not be 
expected to lead to a slower rate of repair. The authors directly measured the rate of 
ligation during DNA repair when PARP was inhibited. The rate was found to be 
unchanged when compared to control cells, and it was concluded that poly(ADP- 
ribosyl)ation did not regulate the ligation step of DNA repair. 
The pathway proposed by Cleaver and Morgan is shown in Figure 3.2.5.3.192 This model 
views the process of poly(ADP-ribosyl)ation as a mechanism by which the overall level 
of enzyme activity is lowered in cells which are exposed to DNA-damaging agents. 192 
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Figure 3.2.5.3 Proposed model for the role of PARP in damaged cells' 92 
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The participation of PARP in the processes of NER and BER has been evaluated using 
molecular genetic techniques. 193,194 Küpper et al demonstrated that the endogenous 
activity of human PARP can be inhibited by the overproduction of its own DNA-binding 
domain (DBD). 193 The 42kDa DBD acts as a dominant negative version of the enzyme 
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DNA strand breaks between endogenous PARP and the overproduced DBD. Figure 
3.2.5.4 depicts the basic principle of trans-dominant inhibition. 195 
Figure 3.2.5.4 Principle of trans-dominant inhibition of poly (ADP-ribose) 
polymerase195 
a) Normal cell b) Normal cell 
no DNA strand breaks few DNA strand breaks 
DBD NBD 
DBD u NBD 
iiiiiiII It It It III 
c) DBD overexpression, 
few DNA strand breaks 
trans-dominant inhibition 
[BD1 
IE DBD NBD 
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d) DBD overexpression, 
abundant DNA strand breaks 
DBD = DNA-binding domain NBD = nicotinamide-binding domain 
a) PARP does not bind to DNA in undamaged cells 
b) if a break is present, PARP binds to it and automodification occurs 
c) trans-dominant inhibition of PARP occurs due to competing resident PARP and DBD 
molecules 
d) the inhibition effect is abrogated when an excess of DNA breaks is present. 
53 
Chapter Three: The Involvement of PARP in Cellular Processes 
Thus, using a dominant negative version of human PARP has the effect of transient 
inhibition and is essentially equivalent to using low molecular-mass chemical inhibitors 
of PARP. In order to evaluate the role of PARP in BER and NER, the consequences on 
DNA repair of exposure of human fibroblasts and CV-l monkey cells to MNNG and UV 
radiation, was assessed. 194 Damage induced by treatment with the alkylating agent 
MNNG would mainly be removed by the BER process, whereas UV radiation-induced 
DNA damage would be eliminated by NER (see section 1.1.1 for more detail). Molinete 
et al observed the trans-dominant inhibition of PARP and the inhibition of UDS in 
MNNG-treated cells. However, in UV radiation-treated cells, no such inhibition was 
noted. 194 These observations point to a role for PARP in the BER process but not in 
NER. 
3.2.6 PARP and DNA Replication 
PARP has been shown to modify the catalytic activities of various replicative enzymes 
(see Table 3.1). These include DNA polymerase a, DNA polymerase ß, terminal 
deoxytransferase, DNA ligase II, topoisomerases I and II and Cat+- and Mgt+-dependent 
endonuclease. 
DNA polymerase a is essential for the initiation of cellular DNA replication. 196 It has 
been suggested by Eki, that since poly(ADP-ribosyl)ation of DNA polymerase a inhibits 
its activity, the initiation of DNA replication may be negatively regulated by PARP. 197 
Other reports have indicated that unmodified PARP directly associates with DNA 
polymerase a and that at high levels of PARP activation, the activity of DNA polymerase 
a is stimulated. 198,199 The association of the two polymerases was demonstrated by their 
co-immunoprecipitation, using antibodies directed at DNA polymerase a, suggesting that 
the enzymes may be part of a complex. 198 The above findings suggest that PARP and 
poly(ADP-ribose) may positively and negatively regulate DNA replication, 
respectively. 198,199 
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PARP has been shown to copurify with multiprotein DNA replication complexes (MRCs) 
which contain DNA polymerases a and 3, DNA primase, DNA ligase, DNA helicase and 
topoisomerases I and 11.200 PARP has also been observed to copurify with DNA 
fragments enriched with replication forks. "? Thus, PARP may control the progression of 
the replication fork under conditions of DNA damage to prevent replication occurring 
prior to repair. 200 
3.2.7 PARP and Cell Death 
Cell death may occur by either one of two pathways: necrosis or apoptosis. 201 Necrosis 
generally follows physical injury to the cell and is independent of genetic control. 
Apoptosis, or programmed cell death, is triggered by developmental or environmental 
stimuli. It is a deliberate, genetically controlled cellular response involving a series of 
specific events that culminate in the death of the-cell. Apoptosis is of fundamental 
importance to normal development and disregulation of the process is associated with an 
increased susceptibility to cancer. 201 There is evidence to show that cells derived from 
human cancers may have a decreased ability to undergo apoptosis, and that this defect 
could be involved in the aberrant survival or development of cancer cells. 202,203 
Both necrosis and apoptosis are characterised by specific morphological changes. 
Necrotic cells display cytoplasmic organelle destruction whereas apoptosis is typified by 
nuclear condensation and DNA fragmentation, resulting from the degradation of the 
internucleosomal linker regions. 04 One of the main distinguishing features of apoptosis 
compared to necrosis is that the efficient and complete elimination of the cell results in 
minimal damage to surrounding tissues and the absence of an inflammatory response. 01 
Apoptosis can also be thought of as a protective mechanism, especially in instances 
where cells are subjected to a substantial amount of irrepairable DNA damage. 
Elimination of such extensively damaged cells via apoptosis would thus protect a 
multicellular organism against the accumulation of cells, which may ultimately be 
detrimental to the survival of that organism. 
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A large number of genes are involved in the regulation of apoptosis and, broadly 
speaking, the genes involved are suppressors/promotors or effectors of apoptosis. 
Suppressors of apoptosis include bcl-2, a 26 kDa protein which prevents a number of 
types of apoptosis in various cell lines, including apoptosis induced by cancer 
chemotherapeutic agents 205 Promotors of apoptosis include other members of the bcl-2 
gene family, such as bax206 and bak. 207 The most important effectors of apoptosis are 
members of the interleukin-lß-converting enzyme (ICE) family of cysteine proteases 208 
A number of ICE-related proteases involved in apoptosis have been identified in 
mammals and the many observations that inhibitors of ICE family members inhibit 
apoptosis, point to essential roles for the ICE proteases in the regulation and 
implementation of cell death. Active ICE proteases cleave cellular proteins and this 
cleavage of critical substrates is thought to produce the apoptotic phenotype. 208 
Another prominent feature of apoptosis is the cleavage of the PARP enzyme. This is 
effected by CPP32ß/apopain, an ICE family protease. 209 In many forms of apoptosis, 
including those induced by chemotherapeutic agents, PARP is specifically cleaved to 
give an approximately 85 kDa fragment containing the automodification and catalytic 
domains, and an approximately 31 kDa fragment containing the DBD 210 Cleavage of 
PARP occurs at a site within the NLS which results in the loss of nuclear retention for the 
larger apoptotic fragment. 11 The appearance of these fragments has become a hallmark 
of the apoptotic process and has provided a sensitive marker for its detection. 212,213 It was 
recently suggested that the degradation of PARP may also provide a sensitive marker for 
the detection of necrotic cell death, as it was observed that cleavage patterns for PARP 
during necrosis and apoptosis are different in human leukaemia cells. 213 
Activation of PARP in heavily damaged cells can result in the substantial depletion of 
intracellular NAD+ and ATP levels, 214 and has been shown to be related to cell lysis. 215 
Apoptosis requires NAD+ and ATP as energy sources and, since PARP uses NAD+ as a 
substrate, inhibition or apoptotic inactivation of the polymerase would be expected to 
preserve intracellular NAD+ and ATP pools, and could be a reason for the cleavage of 
PARP during apoptosis. In some experimental systems, 3AB and its analogues have 
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been shown to `rescue' cells from death, suggesting that PARP has a critical role in 
apoptosis 216-218 
3.2.8 Poly(ADP-ribosyl)ation and the Cell-Cycle Checkpoint 
The involvement of PARP in the progression of the cell cycle has been investigated using 
inhibitor experiments. A variety of cellular responses to DNA damage can be observed in 
the cell, including transient cell-cycle arrest in GI and G2 phases. 219 GI arrest prevents 
replication of the damaged DNA template and G2 arrest prevents the segregation of 
damaged chromosomes. Defects in cell-cycle checkpoint mechanism are thought to be 
involved in cell death, apoptosis, genetic instability and carcinogenesis. 22° 
In studies carried out by Nozaki et al, following y-irradiation, inhibitors of PARP were 
found to suppress Gl arrest in murine 3T3-a cells. 221 Although the exact molecular 
mechanism of the GI arrest pathway has not yet been clarified, suppression of the GI 
arrest by PARP inhibitors indicates that GI arrest may be dependent on poly(ADP- 
ribosyl)ation. On the other hand, G2 arrest was found to be enhanced and prolonged in 
the presence of PARP inhibitors and it was suggested that PARP is not critical for the 
induction of G2 arrest but may be involved in the regulation of G2 arrest release. 221,222 
3.2.9 Poly(ADP-ribose) Activity and HIV-1 Infection 
Apoptotic cell death, following persistent HIV-1 infection is thought to be the most 
important feature of AIDS pathogenesis. 23 Due to the involvement of PARP in 
apoptosis, the relationship between the enzyme and HIV-1 infection has been 
investigated by Tanaka et al. 224 
Nuclear extracts from cells infected with HIV-1 were found to have a decreased level of 
PARP activity resulting from a reduction of levels of the enzyme itself rather than from 
inhibition or modification of its activities 224 The researchers suggested that low levels of 
PARP in infected cells may be necessary for the effective production of the virus and/or 
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for a stable virus/host interaction. Thus, HIV-1 may elicit some kind of mechanism to 
decrease the levels of PARP in host cells and prevent them from entering the apoptotic 
pathway, as a means of ensuring the survival of the virus. 224 
3.3 The Use of Transgenic Model Systems 
Several DNA-repair-deficient model systems are currently available, which allow the 
characterisation and evaluation of DNA-repair-deficient syndromes. The development of 
transgenic animal technology and especially the targeting and manipulation of genes, 
now offers new means for the in vivo analysis of DNA repair and cell-cycle control 
mechanisms. 
Transgenesis is the generation of genetically modified animals by the introduction of 
genes into the germ line 225 The process of homologous recombination allows for the 
precise targeting of a given gene. Murine embryonic stem (ES) cells can contribute to the 
germ cell lineage and, as such, are commonly used as vehicles for introducing heritable 
changes in mice. 225 ES cells can be used to produce mouse strains which are 
heterozygous for a specific gene. These animals can subsequently be bred to obtain mice 
which are homozygous for the targeted gene. Thus, the functional consequences of in 
vivo gene disruption can be assessed in model systems with absent genes: such systems 
are known as `knockout' model systems. 25,226 
3.3.1 The Development of PARP `Knockout' Mice 
Due to the absence of the PARP gene in Saccharomyces cerevisiae (yeast), a convenient, 
simple genetic system for the study of this particular gene has thus far been unavailable. 
Gene targeting and homologous recombination have been used to develop animal and 
cellular model systems which completely lack the PARP gene. 144,145 The results have 
been used to assess the in vivo role of the PARP enzyme. It must be noted, however, that 
different views have been put forth concerning the involvement of PARP in cellular 
processes. These probably stem from the mutational differences in the genes, as one set 
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of mutants are lacking in part of the first zinc finger, f I, 144 whereas the other mutants 
lack the entire fI and part of the second finger f II. 145 
De Murcia et al inactivated both alleles of the PARP gene by gene targeting in mice. 144 
These PARP knockout mice (PARP -/- mice) were viable and fertile, but exhibited a 
marked sensitivity towards DNA-damaging agents, such as y-irradiation and N-methyl-N- 
nitrosourea (MNU). Wang et al generated PARP -/- mice by homologous recombination 
and produced mutant mice which were also viable, apparently healthy and fertile. 145 
These mice, however, were found to develop pathological skin 'aberrations 5-6 months 
after birth. It was suggested that since the skin is constantly exposed to environmental 
stress, the lack of the PARP enzyme in keratinocytes would not allow the elimination of 
cells containing damaged DNA. Thus, the cells may be susceptible to neoplastic 
transformation. Wang et al hypothesised that PARP somehow interferes with cell-cycle 
regulation specifically in keratinocytes. Further results demonstrated that PARP was not 
required for normal cell differentiation and mouse development 227 
In order to test the efficiency of DNA-repair in PARP -/- cells, Auer et al measured the 
recovery of PARP -/- cells after treatment with DNA-damaging agents. 
27 They 
concluded that PARP was not directly involved in BER or NER, which is in contrast to 
the results of Molinete et al'94 but in accordance with the in vitro model put forth by 
Satoh et al. 228 
3.4 PARP and Carcinogenesis 
Numerous studies on animals and cell cultures have shown that PARP inhibitors 
potentiate the cytotoxicity of DNA-damaging agents. However, variations in results have 
served to create confusion, as PARP inhibitors have been shown to both increase and 
decrease the transformation frequency of cultured cells. 50 
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3.4.1 The Relevance of PARP Inhibitors as Clinical Agents 
The inhibition of PARP is thought to lead to a decrease in the repair rate of DNA lesions. 
Thus, due to the rapid growth of cancer cells, the combined action of PARP inhibitors 
with DNA-damaging agents, compared to the effects of the DNA-damaging agents alone, 
may be the preferential killing of cancer cells over normal cells, by the blockage of DNA 
repair. 141 However, the inhibition of repair in normal cells after treatment with PARP 
inhibitors and cytotoxic agents may result in an increase in transformation frequency. 152 
Nevertheless, PARP inhibitors have been shown to potentiate the effects of a variety of 
DNA damaging drugs and, as such, have potential application as therapeutic agents, to be 
used in conjunction with currently used anticancer treatments. Chapter Four is concerned 
with the development of chemical inhibitors of PARP. 
3.5 Summary 
PARP is a truly fascinating enzyme, whose role in cellular defence mechanisms remains 
unclear, despite the numerous investigations undertaken. The speculation that PARP 
facilitates chromatin condensation, along with the regulation of nuclear proteins involved 
in DNA synthesis and replication, is an attractive proposal for a protective role of the 
enzyme in the nucleus. Decondensation of chromatin would thus allow nuclear 
processes, such as DNA repair, to proceed and recondensation of the chromatin would be 
effected by PARG. 
This modulation of chromatin structure is largely dependent on the poly(ADP- 
ribosyl)ation of histones, especially histone H1, which is involved in higher-order 
chromatin superstructure. The histone shuttle mechanism for DNA excision repair, 
proposed by Althaus and coworkers, 130 incorporates this aspect of poly(ADP- 
ribosyl)ation and although this proposal does appear possible, the model put forward by 
Satoh and Lindahl indicates that histone modification by PARP is not of primary 
importance. 1 85 
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The function of PARP according to Satoh and Lindahl, is to prevent inappropriate DNA 
recombination from occurring, an event which, if uncontrolled, could lead to an increase 
in chromosomal aberrations and ultimately cell death. Although there is no conclusive 
evidence to support this proposal, taken together with data from Wiencke and Morgan 166 
suggesting that the inhibition of PARP potentiates the induction of chromosomal 
aberrations, this proposal appears credible. 
The relationship between PARP and DNA ligase II, originally proposed by Creissen and 
Shall191 was refuted by Yoshihara et all55 and Cleaver and Morgan. 192 The latter authors 
proposed an alternative role for PARP during cytotoxic events, and suggested that the 
potentiation of cell killing by inhibitors of PARP' was due to the activation of non- 
specific intracellular endonucleases and not to the regulation of DNA repair. 
In studies using the DBD of PARP as a trans-dominant inhibitor, PARP has been 
associated with the BER process, 194 although recent results obtained from genetically 
engineered PARP -/- cells imply that PARP is neither associated with BER nor NER. 
227 
It was hoped that the production of genetically modified animals might serve to clarify 
the role of the PARP enzyme in vivo. In fact, the construction of PARP -/- mice has 
offered little new positive information. Despite the many proposals put forth for the role 
of PARP in the DNA repair process, the viability of the PARP -/- mice confirms that 
normal DNA repair occurs in the absence of PARP, 144 However, as is in keeping with 
the role proposed by Satoh and Lindahl, 185 in the absence of PARP, there may be an 
increase in chromosomal aberrations due to inappropriate homologous recombination. 
This may manifest as pathological disorders in older animals, and indeed, Wang et al 
detected skin aberrations in PARP -/- mice 5-6 months after birth. 
145 
The role of PARP in the apoptotic process remains to be clarified. The significance of 
the degradation of PARP and its contribution to the apoptotic cascade of events is 
unclear, although PARP cleavage itself represents a sensitive marker for the detection of 
cell death 212,213 The decreased levels of the PARP enzyme in persistently infected HIV-1 
cells may represent a new target for the study of the disease. 223,224 
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Whatever the mode of action of PARP, the fact remains that inhibitors of the enzyme are 
known to potentiate the effects of DNA damaging agents. This activity confers potential 
value to the inhibitors as resistance-modifying agents. Thus, PARP inhibitors can be 
used as adjuncts to cancer treatment, in combination with DNA-damaging agents or 
radiation. 
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Chapter Four: The Development of Chemical Inhibitors 
of PARP 
4.1 Introduction 
As the amount of knowledge concerning the role of the PARP enzyme continues to 
expand, so too does the search for specific, potent PARP inhibitors, with potential clinical 
value. Most of the information surrounding PARP has been gathered from experiments 
utilising PARP inhibitors as biological probes. The most immediate concern with 
chemical inhibitors, however, is the lack of potency and specificity exhibited towards 
PARP. Unfortunately, due to the presence of non-specific side effects with many of the 
inhibitors, the accurate interpretation of enzyme-inhibitor experiments is hampered, both 
with respect to the use of chemicals as biological probes and as clinical agents. Not only 
does this lead to misleading assumptions in the laboratory but the presence of non- 
specific side effects associated with many of the inhibitors would limit their effectiveness 
as clinical agents. 
A large number of compounds are known to inhibit PARP to varying degrees in vitro or 
in vivo. Current attention appears to be directed towards the growing knowledge of 
structure-activity relationships, which are of crucial importance in designing and 
synthesising more potent and specific chemical inhibitors. 
4.2 Development of PARP Inhibitors 
The earliest inhibitors of PARP, identified as nicotinamide 1 and 5-methylnicotinamide 
2, were shown by Clark et al to function as competitive inhibitors of the enzyme. 229 
Other compounds used in early studies include thymidine 3,230.231 theophylline 4231 and 
caffeine 5.49 It was quickly realised, however, that these compounds had activities on 
other biological processes in addition to the inhibition of PARP. Nicotinamide 1 also 
serves as a substrate for nicotinamide-N-methyltransferase deaminase and phosphoribosyl 
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transferase 232 It is an inhibitor of microsomal NADase, mono(ADP-ribosyl)transferases 
and adenosine 3', 5'-cyclic monophosphate phosphodiesterase 233 
Thymidine 3 is converted to a phosphorylated species which subsequently inhibits the 
synthesis of 2'-deoxycytidine phosphate and results in cell division arrest. 34 
Theophylline 4 inhibits cyclic nucleotide phosphodiesterase235 and, along with caffeine 5, 
inhibits DNA repair. 236 Therefore, the effects of compounds 1-5 on cellular metabolism 
cannot be solely attributed to the inhibition of PARP. 
4.2.1 Nicotinamide and Benzamide Analogues 
In 1975, Shall reported the efficacy of the two nicotinamide isosteres, benzamide 6 and 
pyrazinamide 7 as PARP inhibitors. 37 
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Purnell and Whish subsequently investigated the inhibitory activities of benzamide 6 and 
structurally related compounds, in an attempt to find more physiologically specific PARP 
inhibitors. 38 Under their experimental conditions, benzamide was found to be a more 
potent inhibitor than nicotinamide and thymidine. A number of 3-substituted benzamides 
(8-13), were also tested by Purnell and Whish. The introduction of polar substituents 
onto the aromatic ring of benzamide served to increase the aqueous solubility of the 
compounds compared to benzamide alone, without compromising inhibitory activity. 38 
3-Aminobenzamide (3AB) 8 and 3-methoxybenzamide 11 were shown to be competitive 
inhibitors and are generally regarded as `benchmark' inhibitors of PARP. 
Modification of the carboxamide moiety was also investigated in the 3-substituted 
benzamides and the authors concluded that replacement of the carboxamide group with a 
carboxylate group greatly reduced or abolished enzyme-inhibitory activity, as did 
alkylation of the carboxamide substituent. 238 Interestingly, the acylated analogue of 8,3- 
acetamidobenzamide 13 retained potent inhibitory activity. Overall, the absence of a ring 
nitrogen in the benzamide analogues compared to the nicotinamide derivatives serves to 
abolish the metabolism of benzamide analogues by NAD+-metabolising enzymes. 
Since the discovery of the potent inhibitory activity of the 3-substituted benzamides, a 
variety of detailed investigations have been undertaken by independent research groups. 
It is important to note that the many discrepancies reported in the literature on inhibitory 
activity values for given compounds, arise through the wide range of experimental cell 
systems, techniques and cytotoxic agents used. Therefore, direct comparison of 
biological results should be interpreted cautiously. 
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In terms of structure-activity relationships, the first systematic analysis of PARP 
inhibitors was conducted by Sims et al. 190 They tested thirty-three analogues of the 
nicotinamide and adenine portions of NAD+, using a permeabilised cell assay. Of the 
compounds tested, they found benzamide 6,3AB 8 and 3-methoxybenzamide 11 to be 
the most potent PARP inhibitors, causing 96% inhibition of the enzyme under their 
experimental conditions. 190 Sims et al confirmed the earlier assumptions of Purnell and 
Whish regarding the absence of a ring nitrogen in the benzamide derivatives, and also 
demonstrated that a carboxamide group in the 3-position of the aromatic ring was optimal 
for enzyme inhibition. However, derivatives with a carboxamide group in the 2- or 4- 
position (picolinamide 14 and isonicotinamide 15) also exhibited reasonable inhibitory 
activity, although were less potent than nicotinamide itself. 19° 
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CN)CONH2 
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Pyrazinamide 7 was only slightly less potent than nicotinamide, indicating that the 
introduction of a second ring nitrogen did not interfere with inhibitory activity. 190 In 
agreement with Purnell and Whish, 238 Sims et al also found that replacement of the 
carboxamide moiety with a carboxylate group resulted in the abolition of activity. For 
example, at a concentration of 2 mM for each compound, benzamide 6 and 3AB 8 
showed 96% inhibition whereas benzoic acid 16 and 3-aminobenzoic acid 17 showed no 
inhibition. 190 
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It was determined that N-alkylation of the carboxamide (18) or the ring nitrogen (19), 
resulted in a substantial decrease of inhibitory activity, as did reduction of the aromatic 
ring conjugated to the carboxamide group (20). 
CONHCH3 r'N C'N CONH2 CONH2 ("N"*' 
C 
H3 H 
18 19 20 
Cantoni and coworkers investigated the inhibitory activity of sulphur containing 
benzamide derivatives in an attempt to probe further structure-activity requirements. 39 
They carefully selected compounds which had a gradual increase in dipole moments, 
hydrogen bonding strengths and steric hindrance of the amide functional group 
(sulfonamide > thioamide > carboxamide). 
67 
Chapter Four: Development of Chemical Inhibitors 
The sulphonamide 21 and thioamide 22 analogues were found to be much less active than 
benzamide 6, as too was thiophene-3-carboxamide 23, although this compound is 
regarded as a classical bioisostere of benzamide. 239 
4.2.2 Specificity of PARP Inhibitors 
The specificity of the nicotinamide and benzamide PARP inhibitors has been questioned 
by various authors142,143 and important quantitative studies on PARP inhibitors were 
carried out by Rankin et al. 240 Since ADP-ribosylation reactions are carried out by 
PARP, mono(ADP-ribosyl) transferases and NAD+ glycohydrolases, Rankin et al 
evaluated the selectivity of compounds, previously identified as PARP inhibitors, on all 
three classes of enzymes. The results indicated that at the micromolar concentrations of 
inhibitors necessary for the inhibition of PARP, the effects on mono(ADP-ribosyl) 
transferases and NAD+ glycohydrolases were minimal, suggesting that the inhibitors 
were indeed specific for PARP 24o 
However, in a subsequent investigation carried out by Sestili et al, it was demonstrated 
that the in vitro activities of inhibitors did not necessarily correlate with their in vivo 
activities. 241 In terms of structure-activity relationships, Sestili and coworkers confirmed 
earlier findings regarding structural requirements. In accordance with Purnell and 
Whish, 241 they agreed that acylation of the amino substituent of 3AB enhanced potency 
whereas alkylation made no apparent difference. They also concluded that no simple 
relationship between partition coefficients, dipole moments and biological activity 
existed for the benzamide analogues. 241 
4.2.3 Mechanism-Based PARP Inhibitors 
A series of compounds designed to interfere with the ADP-ribosylation reaction catalysed 
by PARP, was synthesised by Slama and Simmons. 101 They replaced the ß-D-ribosyl 
ring of the nicotinamide ribonucleoside moiety of NAD+ with a 2,3- 
dihydroxycyclopentane ring. The resulting compound, carba-NAD+ 24 was expected to 
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function as a mechanism-based inhibitor, as replacement of the oxygen atom would 
render the `nicotinamide-ribose' bond resistant to cleavage by PARP. The derivative 
otherwise closely resembles NAD+ in shape and overall charge. 
Because of this resemblance, however, carba-NAD+ has been shown to be an efficient 
substrate for alcohol dehydrogenases from yeast and horse liver. 101 The diastereoisomer, 
yr-carba-NAD+ 25 has the incorrect geometry for binding and catalysis and is neither a 
substrate nor an inhibitor of either dehydrogenase. 
As a diastereoisomeric mixture, 24 and 25 were shown to be effective inhibitors of the 
mono(ADP-ribosyl) transferases. Surprisingly, when the mixture was separated, the 
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inhibitory activity was attributed to yf-carba-NAD+ 25, the `unnatural' diastereoisomer. 101 
The carba-NAD+ analogues were found to be poor PARP inhibitors and would be limited 
in their effectiveness, because of their abilities to interfere with other NAD+-metabolising 
enzymes. 
4.2.4 Conformationally Restricted Inhibitors of PARP 
Banasik et al identified an interesting class of PARP inhibitors possessing a unifying 
structural feature: the carboxamide group conjugated to the aromatic ring was constrained 
within a ring system. 242,243. Compounds evaluated included 4-amino-1,8-naphthalimide 
26,2-nitro-6-[5H]-phenanthridinone 27,1,5-dihydroxyisoquinoline 28 and 2- 
methylquinazolin-4-[3H]-one 29. 
Compound 26 proved over 100-fold more potent against PARP than benzamide or 3AB 
and was by far one of the most active inhibitors evaluated at the time. 242,243 As with 
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previous studies, Banasik et al found that the majority of these very potent inhibitors 
were selective for PARP over the mono(ADP-ribosyl) transferases. Molecular orbital 
calculations were performed to determine which part of the inhibitors contributed most 
effectively towards inhibitory activity 242 The results indicated that a controlling factor 
for inhibitory activity was the ability of the oxygen atom of the carboxamide group to 
donate zc-electrons to a positively charged region within the enzyme active-site. Thus, 
Banasik et al suggested that the oxygen atom served as an electron donor to a putative 
hydrogen-bond acceptor within the catalytic domain. 42 Since the activity of inhibitors 
bearing N-substituted carboxamides was poor, it was also inferred that an unsubstituted 
carboxamide group is required to act as an electron acceptor to a putative hydrogen-bond 
donor. 
Further information regarding the conformation of the carboxamide group of NAD+ in 
the enzyme active-site was gathered from the computational work of Li and Goldstein. 244 
Their results, based on ab initio calculations of the nicotinamide ring of NAD+, indicated 
that the carboxamide group adopts a specific orientation relative to the enzymic catalytic 
groups within the active-site. Two major orientations of the carboxamide group were 
proposed, as depicted in Figure 4.2.4.1. 
Figure 4.2.4.1 Possible orientations of the carboxamide group of NAD+ 
Li and Goldstein's results demonstrated that the biologically active conformation was 
that with the carbonyl group orientated anti to the 1,2-bond of the aromatic ring. 
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Evidence in support of these findings was provided by Suto et al, who independently 
investigated conformationally restricted compounds. 45 Using the 3-substituted 
benzamides as a template, they synthesised compounds containing an ethane bridge 
linking the benzene ring to the amide nitrogen (see Figure 4.2.4.2) 245 
Figure 4.2.4.2 Design of conformationally restricted benzamide analogues245 
a 
ý 
R= NH2 (3AB) 
I 7-substituted dihydroisoquinolinones 
II 5-substituted dihydroisoquinolinones 
It was found that the 5-substituted dihydroisoquinolinones II, were extremely potent 
inhibitors of PARP, and were 50-75 fold more potent inhibitors of the polymerase than 
the 7-substituted dihydroisoquinolinones I. Suto et al concluded that the positioning of 
the aromatic substituent, along with restriction of the carboxamide rotation into the anti 
configuration, was critical for potent activity, as a decrease in activity was observed when 
the ring substituent was placed in the 6-, 7- or 8-position. 45 The most potent inhibitor 
identified in the dihydroisoquinolinone series was PD128763 (3,4-dihydro-5-methyl-l- 
[2H]-isoquinolinone) 30 which, when tested against calf thymus PARP, proved to be 50 
times more potent than 3AB 8 under the same conditions. 246 It was suggested that owing 
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to its excellent PARP inhibitory activity, compound 30 may act as a radiosensitizer and 
thus be of clinical value for use in conjunction with radiotherapy. 246 
4.2.5 Nucleoside Analogues of Thymidine as PARP Inhibitors 
A series of deoxyuridine and deoxythymidine analogues was evaluated for inhibitory 
activity against the PARP enzyme. 47 Three classes of compounds were examined, as 
shown below (31-33). 
Under the experimental conditions used, various deoxyuridine and deoxythymidine 
derivatives were found to be potent inhibitors, with inhibition constant values (K; ) five- 
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fold lower than the corresponding value for 3AB. Interestingly, the same compounds are 
also known to exhibit antiviral and/or anticancer activities. 47 
4.2.6 Design and Synthesis of Heterocyclic PARP Inhibitors 
As part of the Anticancer Drug Discovery Initiative (ADDI) programme at Newcastle 
University, a number of novel heterocyclic PARP inhibitors were developed. Using 3- 
hydroxybenzamide 10 as a template, a series of O-alkylbenzamide 34 and substituted 
benzyloxybenzamides 35 was synthesised. 248 These compounds were designed to 
explore the ribose nucleotide-binding domain of PARP, and the steric, electronic and 
hydrogen-bonding properties of the compounds were widely varied. 248,249 
From the variety of substituents introduced at the three-position of the benzamides, the 
authors concluded that the ribose nucleotide-binding domain appears to accommodate 
relatively bulky groups. The activities of the compounds as PARP inhibitors were 
described as unexceptional and no clear structure-activity requirements were gained from 
these analogues 249 A second novel approach was used for restricting the carboxamide 
moiety into the anti position. The benzoxazole-4-carboxamides 36 are electron-rich 
heterocycles and, as such, should enhance the hydrogen-bond donor properties of the 
carbonyl oxygen. An intramolecular hydrogen bond between the amide and oxazole 
nitrogens constrains the carboxamide group into the necessary conformation. 249 
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The benzoxazole-4-carboxamides 36 were found to be more potent as PARP inhibitors 
than the benzyloxybenzamides 35.249 As was observed previously, replacement of the 
carboxamide group of 2-methyl benzoxazole-4-carboxamide to give the corresponding 
carboxylate, resulted in loss of inhibitory activity, confirming the necessity of the amide 
functionally. N-methylation of the carboxamide group also resulted in a loss of activity, 
which indicating the importance of an unsubstituted amide group 249 
4.3 Summary of Structure-Activity Requirements 
Thus far, it has been established that analogues of the natural substrate, NAD+, are 
effective inhibitors of PARP. Potent enzyme-inhibitory activity appears to be associated 
with the following features: 
i) an unsubstituted aromatic or polyaromatic heterocyclic system 
(saturated analogues show poor activity) 
ii) the presence of a carboxamide group 
(carboxylate and thiocarboxylate analogues have no activity) 
iii) restriction of the carboxamide moiety into the anti conformation 
(derivatives with unrestricted carboxamides are less active) 
iv) the presence of at least one amide proton for putative hydrogen bonding 
(N-alkylation of the carboxamide moiety results in loss of activity) 
v) a non-cleavable bond at a position corresponding to the 3-position of the 
benzamides 
(serves to reduce the enzymic metabolism of the inhibitor) 
These features are summarised in Figure 4.3. 
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Figure 4.3 Summary of the structure-activity requirements for potent PARP 
inhibition 
Carboxamide group 
Unsubstituted constrained to 
aromatic O the anti 
ring 11 conformation 
At least 
one amide 
proton 
Non-cleavable bond 
With regard to the design of novel inhibitors, other factors must also be taken into 
consideration. Ideally, the inhibitor should possess functional sites which allow for 
elaboration of the molecule, in order to probe the enzyme-active site. If the inhibitor is to 
be of clinical value as a therapeutic agent, then solubility problems must be addressed 
and a water-solubilising group may be necessary. 
4.4 The Structure of the Enzyme-Active Site 
The recently solved crystal structure of the catalytic fragment of chicken PARP has 
provided conclusive information with regard to enzyme-inhibitor binding. 50 Since the 
catalytic domains of human and chicken PARP share 100% homology in amino-acid 
sequence, the information gained from this crystal structure is of potential value in the 
design of novel PARP inhibitors. Interestingly, the catalytic fragment of chicken PARP 
(PARP-CF) was found to be similar in structure to the catalytic domains of microbial 
toxins although the amino-acid sequence homology is relatively low. 250 
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PARP-CF was crystallised with and without a nicotinamide-analogue inhibitor bound 
within the active-site. 50 The inhibitor chosen was PD128763 30, the 
dihydroisoquinolinone derivative. The inhibitor was shown to be bound to PARP-CF by 
two hydrogen bonds from the carboxamide group to the peptide backbone of G1y863, and 
a third hydrogen bond from the carbonyl oxygen to the side chain of Ser904 250 It was 
assumed that the inhibitor binds to PARP-CF in an analogous manner to the nicotinamide 
portion of NAD+. Non-polar interactions between PD128763 and the adjacent Tyr907 
were also identified. 25° 
As mentioned in Section 2.5, G1u988 has been identified as a residue involved in 
catalysis. 110 This residue is located at a distance of only 4A from the methyl carbon atom 
(C9) of PD128763. It is thought that at this distance, the glutamate may act either as a 
general base to activate the substrate for nucleophilic attack, or to stabilise the 
intermediate oxocarbenium ion, formed during the course of the normal reaction. Figure 
4.4 shows a schematic representation of the enzyme-inhibitor interactions between 
PARP-CF and PD128763.251 
Figure 4.4 Enzyme-inhibitor interactions between PARP-CF and PD128763.25I 
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This crucial information has undoubtedly confirmed the earlier predictions regarding the 
structure-activity requirements of PARP inhibitors. These encouraging results indicate 
that the conformationally restricted inhibitors may bind in a manner analogous to 
PD128763 and the crystal structure can now be carefully examined and used to maximise 
enzyme-inhibitor interactions when designing new compounds. 
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Chapter Five: Development of the Quinazolinone Series 
5.1 Quinazolinones as Pharmaceutical Agents 
Certain compounds containing a quinazolinone moiety exhibit biological activities 
towards a variety of conditions. Many of these compounds have been developed as 
pharmaceutical agents, and Figure 5.1 illustrates some examples of clinically useful 
quinazolinone derivatives. 
Figure 5.1 Examples of Biologically Active Quinazolinones 
The compounds of general structure A are 3-(5'-pyrazoyl)-3,4-dihydroquinazolin-4-ones 
and have been found to exhibit analgesic activity. S2 Compounds of structure B have 
been shown to be purine nucleoside phosphorylase inhibitors, which are used in the 
treatment of cancer, gout, malaria and organ rejection. 253 
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Compounds of structures C, D, and E have antiallergic, antihypertensive and antifolate 
properties, respectively. 254-256 
5.2 General Methods of Quinazolinone Synthesis 
There are a number of methods available for the preparation of quinazolinone derivatives. 
Scheme 5.2 illustrates some of the many ways that quinazolinone formation can be 
achieved [for methods I, II, III, V and VIII, R2 = H]. It is well established that the 
quinazolinone skeleton can be readily formed from anthranilamide or anthranilic acid 
derivatives. In most cases, the reaction involves an intramolecular cyclisation (e. g. I, II, 
III, IV, V and VIII). 
Method I is an example of the Radziszewski reaction whereby the oxidation of suitably 
functionalised o-amidobenzonitriles by sodium perborate leads to the facile cyclisation 
and formation of quinazolin-4-[3H]-ones. 257 Compounds synthesised by methods II and 
VIII are intermediates in the synthesis of anti-hypertensive agents (structure D, Figure 
5.1) 255,258 Method III has been used for the preparation of the hypnotic drugs 
meclaqualone (Scheme 5.2, A: Rl = CH39 R2 = 2-Cl-C6114) and methaqualone (A: R' = 
CH3, R2 = 2-CH3-C6H4)259 and quinazolinones obtained from method IV have proved to 
be of use as antiallergic agents 254 Method VI represents a mild, efficient synthesis 
involving an intramolecular aza-Wittig reaction260 and method VII is one of the few 
examples of quinazolinone formation by transition-metal catalysed reductive N- 
heterocyclisation. 261 
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Scheme 5.2 General methods of quinazolinone synthesis 
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5.3 Quinazolinones as PARP Inhibitors 
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Quinazolinone derivatives have been largely neglected with respect to their inhibitory 
activity towards PARP, despite reports of 2-methyl quinazolin-4-[3H]-one exhibiting 
potent activity against the enzyme. 32,249,262 
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5.3.1 Rearrangement of Benzoxazole-4-carboxamides to 8-Hydroxyquinazolin-4- 
[311]-ones 
Previous studies, directed at the development of more selective and potent PARP 
inhibitors, identified a series of benzoxazole-4-carboxamides which displayed good 
activity. 249,263 During the attempted synthesis of target compounds in the series, an 
unexpected rearrangement was observed which resulted in the formation of 
quinazolinone derivatives. These derivatives were assayed for inhibitory activity against 
PARP and were found to be extremely potent 263 The rearrangement was observed by 
chance, under conditions expected to convert methyl benzoxazole-4-carboxylates to the 
corresponding amides. 249,263 Scheme 5.3 shows the postulated mechanism for the 
rearrangement of the methyl benzoxazole-4-carboxylates 263 The initial step involves 
nucleophilic attack by ammonia at the C2-position of the benzoxazole, resulting in the 
ring-opening of the oxazole ring. Depending on whether aminolysis of the ester occurs 
prior to ring opening, subsequent intramolecular ring closure to form the quinazolinone 
would result in the elimination of either methanol or ammonia. 263 
The two quinazolinone derivatives identified from this rearrangement, 8-hydroxy-2- 
methylquinazolin-4-[3H]-one 37 (NU1025) and 8-hydroxy-2-(4'-nitrophenyl)quinazolin- 
4-[3H]-one 38 (NU1057), were found to have IC50 values of 0.4 µM and 0.2 µM, 
respectively, when evaluated in a permeabilised cell assay. 63,264 [IC50 : inhibitory 
coefficient value, defined as the concentration of inhibitor required to reduce PARP 
activity to 50% of the control]. The excellent inhibitory activity of these compounds 
indicates that the quinazolinones are among the most potent PARP inhibitors known to 
date. 
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Scheme 5.3 Rearrangement of methyl benzoxazole-4-carboxylates to 
8-liydroxyquinazolin-4-[3H]-ones263 
OCH3 
i 
OH 
Reagents :i liquid NH3, bar pressure, 55 °C. 
37 R= CH3 
38 R= 4'-N02-C6H5 
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5.3.2 Quinazolinone Structure-Activity Relationships 
The requisite structural features for efficient PARP inhibition (as discussed in Section 
4.3) are incorporated into the basic quinazolinone architecture (see Figure 5.3.2). 
Figure 5.3.2 Structural Features of Quinazolinone Inhibitors 
Unsubstituted Conformationally 
aryl- or heteroaryl \ constrained carboxamide 
ring moiety 
At least one 
amide proton 
present 
X 
ýv 
Variation of 
substituents possible 
The compounds can be structurally elaborated by variation of the X and R substituents 
which may provide further information regarding structure-activity requirements. 
5.4 Aims of Quinazolinone Research 
Although quinazolinone formation was previously achieved through the rearrangement of 
methyl benzoxazole-4-carboxylates, 263 these conditions do not represent an efficient route 
to novel PARP inhibitors. Biological evaluation of the two previously identified 
quinazolinones, 37 and 38, highlighted the potency of these compounds towards PARP 
and further quantities of NU1025 (37) were required for use in potentiation studies (see 
Chapter Seven, Section 7.4). 
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The initial aim of this research was to design an alternative, reproducible and high- 
yielding synthetic route to quinazolinone derivatives. A novel series of quinazolin-4- 
[3H]-ones of the following general structure was proposed (see Figure 5.4) 
Figure 5.4 Proposed general structure of quinazolinone PARP inhibitors 
Compounds would be synthesised with substituents acting as electron donors in the 8- 
position, in an attempt to establish whether or not the electronic nature of these 
substituents is of importance to enzyme-inhibitor interactions. Likewise, it was hoped 
that variation of the 2-substituent to include functional groups which were either electron- 
withdrawing or electron-donating in nature, would enable structure-activity relationships 
to be established for the quinazolinones. All purified quinazolinones would be 
biologically evaluated as potential inhibitors of PARP. 
5.5 Syntheses of Quinazolinone PARP Inhibitors 
5.5.1 Synthesis of 2-Alkylquinazolinones 
The preparation of 2,8-disubstituted quinazolin-4-[3H] -ones was undertaken based upon 
the knowledge that quinazolinones can be formed from anthranilamide derivatives. It 
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was proposed that such derivatives could be synthesised from commercially available 2- 
nitrobenzoic acid derivatives. Scheme 5.5.1.1 shows the synthetic route used to 
synthesise the requisite 3-methoxy-2-aminobenzamide 41 and 3-methyl-2- 
aminobenzamide 44. 
Scheme 5.5.1.1 Synthesis of 3-methoxy-2-aminobenzamide 41 and 3-methyl 
-2-aminobenzamide 44 
39 X= OCH3 40 X= OCH3 (97 %) 41 X= OCH3 (99 %) 
42 X= CH3 43 X= CH3 (95 %) 44 X= CH3 (97 %) 
Reagents :i SOCIZ/DMF, dry THF, 25 °C, ii NH4OH, iii HZ/Pd/C, methanol. 
Commercially available 3-methoxy-2-nitrobenzoic acid 39 was converted into the 
corresponding acid chloride using 1.5 mol. equivalents of thionyl chloride and a catalytic 
amount of DMF. The resulting 3-methoxy-2-nitrobenzoyl chloride was reacted further in 
situ with concentrated ammonia solution to give 3-methoxy-2-nitrobenzamide 40 in 97% 
yield. The product was found to be homogenous by thin layer chromatography (TLC) 
and analysis by proton nuclear magnetic resonance (1H NMR) indicated that the crude 
product was suitable for subsequent reaction. The excellent yield of 40 obtained from 
this method of synthesis is comparable to the crude yield achieved in a previously 
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reported synthesis of the same compound. 65 Compound 40 was readily reduced under an 
atmosphere of hydrogen in the presence of 10% palladium on activated carbon catalyst. 
3-Methoxy-2-aminobenzamide 41 was obtained in 99% yield and was also used without 
further purification, on the basis of 1H NMR analysis. 
Following the high-yielding synthesis of compound 41, commercially available 3-methyl- 
2-nitrobenzoic acid 42 was subjected to the same reaction conditions to produce 3- 
methyl-2-nitrobenzamide 43 and 3-methyl-2-aminobenzamide 44, in 95% and 97% 
yields, respectively. The anthranilamide derivatives 41 and 44 were found to be slightly 
light-sensitive and large quantities of these compounds were accordingly stored under 
nitrogen in dark glass bottles. 
Compound 41, when treated with 1.1 mol. equivalents of acetyl chloride in dry THF, in 
the presence of 1.3 mol. equivalents of pyridine, was acetylated at the 2-position to give 
3-methoxy-2-N-acetylaminobenzamide 45. The structure of this compound was 
confirmed by 'H NMR, infrared and mass spectral analysis and treatment of 45 with 2% 
aq. sodium hydroxide (NaOH) solution facilitated an intramolecular cyclisation reaction 
to give the ring-closed quinazolinone 46 (see Scheme 5.5.1.2). The yields of the 
individual steps were 31 % for compound 45 and 67% for compound 46 to give an overall 
yield of only 20% with regard to 41.8-Methyl-2-methylquinazolin-4-[3H]-one 46 was 
also synthesised in a `one-pot' procedure. The crude intermediate 45, obtained after 
removal of the mother liquor, was simply redissolved in aq. NaOH solution and 
converted to 46. It was hoped that this would minimise loss through handling and 
purification of the intermediate and lead to a higher overall yield. In fact, yields of up to 
97% were obtained for the one-pot method. 
The synthesis of 2,8-dimethylquinazolin-4-[3H] -one 48 was carried out in order to 
establish whether the presence of an 8-substituent with reduced capacity to form 
hydrogen-bond interactions, would appreciably affect the activity of the compound. 
Compound 44 was converted to 2,8-dimethylquinazolin-4-[3H]-one 48 in 81% yield, 
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using the one-pot method. It was assumed that the intermediate would be compound 47, 
although this was not isolated. 
Scheme 5.5.1.2 
X 
Synthesis of 8-methoxy-2-methylquinazolin-4-[3H]--one 47 
and 2,8-dimethylquinazolin-4-13HJ--one 48 
41 X= 0CH3 
44 X= CH3 
0 
II %-- --i 
NH2 45 X= OCHS 
0 (31%) 
% 'C 
H3 
H 
11 
47 X= CH3 
46 X= OCHS 
Y 
37 Y =OH (65 %) 
48 X= CH3 (8 1u 7, ) 
Reagents :i CH3COCI, dry pyridine, dry THF, 25 °C, ii 2% aq. NaOH, 25 °C, iii BBr3/DCM (1.0 
M), reflux, iv 10% aq. NaOH, v aq. HCI. 
Compound 46,8-methoxy-2-methylquinazolin-4-[3H]-one, is the direct precursor of 
NU1025,37. Demethylation of 46 was carried out following a literature method, using a 
1.0 M solution of boron tribromide in dichloromethane (BBr3 in DCM) 266 The authors 
proposed the use of one equivalent of BBr3/methoxy group and one equivalent/atom 
bearing lone pairs. Thus, a 1: 4 mole ratio of 46: BBr3 in DCM was gently heated under 
% from 41) 
CH 
.4v ýN' 
'CH 3 33 
NH iii, iv r/ ( 'NH (67 % from 45) 
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reflux for 48 hours. The reaction generates the toxic gas methyl bromide and care must 
be taken to ensure that this by-product is efficiently trapped and destroyed. Following 
removal of the solvent from the reaction vessel, hydrolysis of the crude residue with 10% 
aq. NaOH solution gave the sodium salt of 37. The desired phenolic product was 
obtained in 65% yield, after acidification of the reaction mixture with aq. HCl and 
recrystallisation. 
Analytical data obtained for the product, including elemental analysis, infra-red, NMR 
and mass spectra, indicated that the product was identical to 37. Although it has already 
been established that this compound exhibits excellent PARP inhibitory activity in vitro, 
in order for further biological assays to be conducted, larger quantities of 37 were 
required, which were not available from the previous method. In view of the reasonable 
yield (61% overall yield with regard to the commercially available starting material), the 
method presented above provides a successful alternative synthesis of the target 
compound 37. Since the two quinazolinones 46 and 48, are the corresponding analogues 
of NU 1025 37, they were also submitted for biological evaluation against PARP. 
5.5.2 Synthesis of 2-Arylquinazolinones 
It was necessary to synthesise 2-aryl derivatives for a comparison of structure-activity 
relationships with the 2-alkylquinazolinones (compounds 37,46 and 48). It was 
proposed that the route employed to synthesise the 2-alkylquinazolinones should be used, 
as this would establish whether or not this could serve as a general method for the 
synthesis of 2-substituted quinazolinones. 
8-Methoxy-2-phenylquinazolin-4- [3 H] -one 51 and 8-methyl-2-phenylquinazolin-4-[3H]- 
one 52 were prepared as shown in Scheme 5.5.2, in 65% and 72% yields, respectively. 
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Scheme 5.5.2 Synthesis of 2-arylquinazolinones 
X 
49 X= OCHS (41 %) 
NH2 i r, 
ý, -NH2 50 X= CH3 (74 %) 
0 
41 X= OCH3 
44 X= CH3 
0 
11 
51 X= OCHS (65 %) 
52 X= CH3 (72 %) 
53 Y=OH (67%) 
Reagents :i C6H5COCI, dry pyridine, dry THF, 25 °C, ii 2% aq. NaOH, 25 °C, iii BBr3/DCM 
(1.0 M), reflux, iv 10% aq. NaOH, v aq. HC1. 
The N-benzoylaminobenzamides 49 and 50 were obtained using benzoyl chloride as the 
acylating agent and were readily cyclised in 2% aq. NaOH solution. 8-Hydroxy-2- 
phenylquinazolin-4-[3H]-one 53 was prepared by demethylation of 51 using the same 
method as before, and obtained in 67% yield. Compounds 51-53 were purified and 
submitted for biological evaluation. In view of the moderately high yields obtained for 
these compounds, the pathway appears to be applicable to the synthesis of 2- 
arylquinazolinones. 
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5.5.3 Synthesis of 2-(4'-Substituted-phenyl) Quinazolinones 
8-Hydroxy-2-(4'-nitrophenyl)quinazolin-4-[3H]-one 38 was previously identified as a 
highly potent PARP inhibitor. 263 Syntheses in the quinazolinone series were extended to 
include derivatives bearing 4'-substituents on the aromatic ring in the 2-position. It was 
decided to vary the electronic nature of the 4'-substituent to include either electron- 
withdrawing or electron-donating functional groups. 
5.5.3.1 Synthesis of Quinazolinones Bearing Electron-Withdrawing Substituents 
Compounds bearing electron-withdrawing functionalities, including nitro, 
trifluoromethyl, cyano, carboxylate and azido groups, were synthesised according to 
Scheme 5.5.3.1.1. The synthesis of 8-methoxy-2-(4-nitrophenyl)quinazolin-4- [3 H] -one 
55 was proposed from 3-methoxy-2-N-(4'-nitrobenzoyl)aminobenzamide 54. a The 
presence of the 4'-nitro substituent was expected to render the acyl carbonyl carbon more 
susceptible to nucleophilic attack and cyclisation. Thus, the cyclisation was initially 
attempted using 2% aq. NaOH solution as before. However, the main problem 
encountered was the insolubility of the acylated starting material 54 in the aqueous 
solvent. Although analogous reactions were carried out at room temperature, it was clear 
that more vigorous conditions were required to facilitate the ring closure of compound 
54. It was found that complete dissolution could be achieved by heating 54 in 10 % aq. 
NaOH at 100 °C. 'H NMR data obtained from 55 were convincing although, again, the 
product was found to be virtually insoluble in various organic solvents, rendering 
purification of this compound problematic. The compound was finally recrystallised 
from aq. DMF at 100 °C. A hot filtration removed an insoluble cream product which was 
believed to be a salt. The required compound was obtained after concentration of the 
filtrate, in 66% yield. 
' Prepared by Mr R Davison, from 3-methoxy-2-aminobenzamide 41 and 4-nitrobenzoyl chloride. 
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Scheme 5.5.3.1.1 Synthesis of quinazolinones bearing electron-withdrawing 
substituents 
X 
i 
0 54 X= OCH3, R= NO2 
56 X= CH3, R= N02 
58 X= OCH3, R= CF3 
60 X= CH3, R= CF3 
64 X= OCH3, R= CN 
66 X= CH3, R=CN 
41 X=OCH3 
44 X= CH3 ii 
55 X=OCH3, R=N02 (66%) 
57 X= CH3, R= NO2 (86 %) 
59 X=OCH3, R=CF3 (64%) 
61 X=CH3, R=CF3 (65%) 
65 X= OCH3, R= CN (27%) 
R 67 X= CH3, R= CN (21%) 
38 Y=OH, R=NO2(38%) 
62 Y=OH, R=CF3 (19%) 
68 Y=OH, R=CN 
71 X= OCHS, R= CO2H (100 % crude) 
72 X= CH3, R= CO2H (92 % crude) 
80 X= OCHS, R= N3 (80%) 
81 X=CH3, R=N3 (71%) 
Reagents :i RC6H4COCI, dry pyridine, dry THF, 25 °C, ii 54,56: 10% aq. NaOH, 100 °C, 58, 
60,63,65: 2% aq. NaOH, 25 °C, iii, BBr3/DCM (1.0 M), iv 10% aq. NaOH, v aq. HCI. 
8-Methyl-2-(4'-nitrophenyl)quinazolin-4-[3H]-one 57 was obtained using the one-pot 
procedure, in 86% yield after purification. As with compound 55, more vigorous 
conditions were necessary to effect cyclisation, despite the presence of the strongly 
electron-withdrawing nitro group. Compound 57 was also poorly soluble in organic 
solvents and was purified as for 55. 
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Demethylation of 55 afforded 8-hydroxy-2-(4'-nitrophenyl)quinazolin-4-[3H]-one 38, in 
38% yield after purification, a much lower yield than had been previously obtained for 
similar demethylation reactions. All purified (4'-nitrophenyl)quinazolinones were 
submitted for biological evaluation. 
The trifluoromethyl derivatives, 59 and 61, were prepared according to the one-pot 
procedure, using 4-trifluoromethylbenzoyl chloride as the acylating reagent. As with the 
4'-nitrophenyl derivatives, the electron-withdrawing trifluoromethyl group should 
activate the compound towards cyclisation and, indeed, mild conditions were employed 
to facilitate ring closure of the intermediates 58 and 60, to give 59 and 61 in 64% and 
65% yields, respectively. Demethylation of 59 afforded 8-hydroxy-2-(4'- 
trifluoromethylphenyl)quinazolin-4-[3H]-one 62 in only 19% crude yield and the product 
proved difficult to purify owing to solubility problems. As a result, only compounds 59 
and 61 were submitted for biological evaluation. 
The quinazolinone series was further extended by the addition of the (4'- 
cyanophenyl)quinazolinones. The (4'-cyanophenyl)quinazolinones would be useful 
precursor compounds as the cyan substituent can be converted, using standard 
methodology, into a range of functionalities, including the amine, carboxylate, amide, 
aldehyde, ketone and tetrazole. 8-Methoxy-2-(4'-cyanophenyl)quinazolin-4- [3 HI -one 65 
and 8-methyl-2-(4'-cyanophenyl)quinazolin-4-[3H]-one 67 were prepared using 4- 
cyanobenzoyl chloride 63 as the acylating agent, which was readily synthesised from the 
corresponding acid. 51 Cyclisation to form the quinazolinones was effected with 2% aq. 
NaOH solution. 
A general observation, concerning the poor solubility of some intermediates in both 
aqueous and organic solvents, was noted during the synthesis of quinazolinones bearing 
electron-withdrawing substituents. It appears that the stronger the electron-withdrawing 
substituent in the 4'-position, the poorer the solubility of the molecule in aqueous base. 
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This was reflected by the marked insolubility of the (4'-nitrophenyl)quinazolinones and 
to a lesser extent, with the (4'-trifluoromethylphenyl)quinazolinones. 
In the case of the (4'-cyanophenyl)quinazolinones, the yields of 65 and 67 were only 27% 
and 21%, respectively. These poor yields were mainly attributable to the insolubility of 
the N-acyl aminobenzamide precursors in aqueous media. The cyano group is almost as 
powerfully electron-withdrawing, both by resonance and inductive effects, as the nitro 
group but in light of the basic reaction conditions employed, the high reactivity of the 
cyano group poses a problem. 
Identification of a second major product isolated during the purification of compound 67 
by 1H NMR, indicated that after 24 hours in 2% aq. NaOH solution at room temperature, 
a substantial amount of compound remained uncyclised. However, unlike with the (4'- 
nitrophenyl)quinazolinones, which are stable in basic media, the conditions used for 
cyclisation must be kept as mild as possible, otherwise the cyano group is hydrolysed to a 
carboxylate group. Therefore, in the case of the (4'-cyanophenyl)quinazolinones, an 
alternative reagent should be considered to avoid nitrile hydrolysis during the cyclisation. 
8-Hydroxy-2-(4'-cyanophenyl)quinazolin-4-[3H]-one 68 was synthesised directly by 
demethylation, from the 8-methoxy precursor 65. However, it is well known that nitriles 
react readily with Lewis acids to form non-ionic addition compounds, through the lone- 
pair electrons of the cyano group, and coordination compounds of nitriles and boron 
halides are well documented. 267 Initially, the demethylation reaction was carried out over 
a 24 hour period when TLC analysis indicated the presence of three products. These 
products were isolated by column chromatography and identified by 'H NMR analysis, as 
the required product 68, the amide 69 and also the hydrolysis product 70 (see Scheme 
5.5.3.1.2). 
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Scheme 5.5.3.1.2 Demethylation of 8-methoxy-2-(4 =cyanophenyl) quinazolin- 
4[3H]--one65 
I, ii 
-s 
Iii 
CN 
65 68 R= CN 
69 R= CONH2 
70 R= CO2H 
Reagents :i BBr3/DCM (1.0 M), reflux, ii 10% aq. NaOH, iii aq. HCI. 
The reaction was repeated and carefully monitored by TLC to detect by-product 
formation. It was found that after three hours, the amide was detected and despite the 
reaction being immediately worked up, a substantial amount of the amide was present. 
The reaction conditions for this particular reaction obviously need to be re-examined and 
an alternative non-Lewis acidic demethylating agent considered. Once again, the 
reactivity of the cyano group posed a problem when subjected to certain reagents in the 
general synthetic pathway. Although the by-products obtained may prove useful for 
biological evaluation, they should be synthesised under more controlled reaction 
conditions and isolated as major, not minor products. 
(4'-Carboxyphenyl)quinazolinones, 71 and 72, were added to the quinazolinones series. 
Initially, the compounds were synthesised from the (4'-cyanophenyl)quinazolinones by 
base-catalysed hydrolysis. 68 However, in view of the low isolated yields of the (4'- 
cyanophenyl)quinazolinones, it was deemed inappropriate to use these compounds as 
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starting materials. It was proposed that hydrolysis and cyclisation of 3-methoxy-2-N-(4'- 
cyanophenyl) aminobenzamide 64, could be effected by using a stronger concentration of 
NaOH. This would ensure that any uncyclised material, which remains under mildly 
basic conditions, would also be converted to the (4'-carboxyphenyl)quinazolinone. This 
method could also be carried out as a one-pot procedure, starting from the appropriate 3- 
substituted-2-aminobenzamide. 
Analytical data obtained for the (4'-carboxyphenyl)quinazolinones, 71 and 72, indicated 
that these compounds had been isolated as salts. Data proved satisfactory with the 
exception of elemental analysis and mass spectra. It was hoped that the potency of the 
(4'-carboxyphenyl)quinazolinones would rival that of their isosteric counterparts the (4'- 
nitrophenyl)quinazolinones. Attempts to purify these compounds, however, proved 
unsuccessful and 71 and 72 were not submitted for biological evaluation. 
It was hoped that the (4'-carboxyphenyl)quinazolinones would be sufficiently pure to 
allow the synthesis of compounds 73-76 (see Scheme 5.5.3.1.3). However, in each 
reaction, multiple products were observed which rendered purification of the products 
difficult. With the exception of compound 76, satisfactory combustion analysis results 
were not obtained and only compound 76 was submitted for biological evaluation. It was 
proposed that a side reaction may be occurring between the quinazolinones and thionyl 
chloride. 
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Scheme 5.5.3.1.3 Synthesis of (4. carboxamidophenyl)quinazolinones 73 and 74, 
and (4'carboxymethylphenyl)quinazolinones, 75 and 76 
I 
50 % of 
reaction ii 
mixture 
73 X= OCHS (31 %) 
74 X=CH3 (25 %) 
Iii 
50%of 
reaction 
mixture 
75 X= OCH3 (33 %) 
76 X= CH3 (24 %) 
Reagents :i SOCl2/DMF, dry THF, 25 °C, ii NH4OH, iii dry methanol. 
CI 
To investigate the possibility of a side reaction taking place, a model reaction was carried 
out using 8-methoxy-2-phenylquinazolin-4- [3 H] -one 51. 
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Compound 51 was treated with: 
i) SOC12 (2 eq. ), DMF (catalytic), dry THF, 25 °C, and 
ii) SOC12, at reflux. 
After one hour, no starting material was evident in either reaction, indicating that thionyl 
chloride may not be compatible with the basic quinazolinone structure. A multi-spot 
product was detected by TLC and no product was isolated. A possible solution to this 
problem would be to convert the (4'-carboxyphenyl)quinazolinone to a mixed anhydride, 
as this could be carried out under much milder conditions. The mixed anhydrides could 
then be reacted with a variety of amines or alcohols to give the corresponding substituted 
amides or esters. 
The (4'-azidophenyl)quinazolinone 80 was synthesised in 80 % yield, following the usual 
synthetic route. b The acylating species, 4-azidobenzoyl chloride 79, was readily prepared 
according to Scheme 5.5.3.1.4. 
Reagents :i NaN3, NaNO2,5M HCI, <5 °C, ii SOCI2, DMF, dry THF, 25 °C. 
8-Methyl-2-(4'-azidophenyl)quinazolin-4-[3H] -one 81 was prepared in a similar manner 
to 80 in 71% overall yield. c The (4'-azidophenyl)quinazolinones 80 and 81 are useful 
b Prepared by Miss H. C. Mullen, vacational research student. 
` Prepared by Mr R. Davison. 
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precursor compounds, as the azido group can be converted to a range of functionalities. 
However, the lack of time available did not allow subsequent reactions to be carried out. 
5.5.3.2 Synthesis of Quinazolinones Bearing Electron-Donating Substituents 
Compounds bearing electron-donating functionalities in the 2-aryl ring, such as methoxy 
and hydroxy groups, were synthesised according to Scheme S. S. 3.2.1. 
Scheme 5.5.3.2.1 Synthesis of quinazolinones bearing electron-donating 
substituents 
41 X= OCH3 
44 X= CH3 
86 Y=OH (47%) 
87 Y=CH3(76%) 
iii, iv 
V 
85 X= CH3, R= OCH3 
(58%) 
OH v-R 
Reagents :i RC6H4COCI, dry pyridine, DMAP (5 mol. %), dry THF, 25 °C, ii 10% aq. NaOH, 
reflux, iii BBr3/DCM (1.0 M), reflux, iv 10% aq. NaOH, 25 °C, v aq. HCI. 
11 
84 X=OCH3, R=OCH3 
(63 % from 76) 
NH (70 % from 41) 
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Compound 84 was also prepared without isolation of the intermediate 82, as was 8- 
methyl-2-(4'-methoxyphenyl)quinazolin-4-[3H]-one 85, in 70% and 58% yields, 
respectively, and both compounds were submitted for biological evaluation. 
8-Hydroxy-2-(4'-hydroxyphenyl)quinazolin-4-[3H]-one 86 and 8-methyl-2-(4'- 
hydroxyphenyl)quinazolin-4-[3H]-one 87 were obtained by demethylation of compounds 
84 and 85, respectively. The chemical similarity between the two methoxy substituents 
present in 84 led to both groups being cleaved by BBr3. Clearly, the synthetic route 
employed in the general synthesis of the quinazolin-4-[3H]-ones was not appropriate for 
the synthesis of 8 -hydroxy-2-(4'-methoxyphenyl)quinazolin-4- [3H] -one or 8-methoxy-2- 
(4'-hydroxyphenyl)quinazolin-4- [3 H] -one and an alternative route using suitable 
protecting group chemistry is required. Compounds 86 and 87 incorporate hydroxyl 
moieties into their structures and would thus be suitable candidates for prodrug 
modification. 
The (4'-aminophenyl)quinazolinones were synthesised directly from the corresponding 
(4'-nitrophenyl)quinazolinone derivatives, by palladium-catalysed reduction of the 
aromatic nitro groups (Scheme 5.5.3.2.2). The moderate yields obtained were attributed 
to the insolubility of the starting materials in methanol. Unlike the derivatives bearing 
electron-withdrawing substituents, solubility in organic solvents was found to be 
adequate with quinazolinones bearing electron-donating substituents, and these were 
purified by recrystallisation from methanol. 
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Scheme 5.5.3.2.2 Synthesis of (4'-aminophenyl)quinazolinones 
55 X= OCHS 
57 X= CH3 
38 X=OH 
i 
NO2 " 'NH2 
88 X=OCH3 (46%) 
89 X= CH3 (52 %) 
90 X= OH (57 %) 
Reagents :i H2/Pd/C, methanol, 25 °C. 
5.6 Synthesis of Control Compounds 
It has previously been shown that methylation of the N3-position of NU1025 (37), results 
in a significant loss of PARP inhibitory activity. 263,264 The N3-methylated quinazolinones 
91 and 92 were synthesised as control compounds for use in PARP inhibition studies. 
Compound 91 was prepared in 56% yield, by treating 8-methoxy-2-methylquinazolin-4- 
[3H]-one 46 with methyl iodide, in the presence of potassium carbonate, using 
acetonitrile as solvent. 63 Compound 92 was synthesised in 57% yield, by demethylation 
of 91 (Scheme 5.6). 
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Reagents :i CH3I, K2CO3, dry MeCN, reflux, ii BBr3/DCM (1.0 M), reflux, iii 10% aq. NaOH, 
iv HCI. 
5.7 Limitations of Quinazolinone Synthesis 
The synthetic pathway used to synthesise the majority of the quinazolinone derivatives is 
shown in Scheme S. 7. 
The above scheme works efficiently in practice but a number of limitations are apparent, 
due mainly to the poor stability of functional groups under the reaction conditions 
employed, e. g. 
i) hydrolysis of the (4'-cyanophenyl)quinazolinones under basic conditions, 
ii) formation of nitrile and trihalide complexes with the Lewis-acidic reagent, BBr3 
iii) incompatibility of quinazolinones with thionyl chloride. 
There are a number of compounds in the current series which are unaccessible by the 
above route and alternative methods need consideration. 
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Scheme S. 7 General synthetic pathway for quinazolin-4 j3HJ--ones 
0 
X 
X= OCH3 
X=CH3 
0 
Y 
vi, vii 
viii 
0 
0 
V 
0 
0 
Y=OH 
Reagents :i SOCI2/DMF, dry THF, 25 °C, ii NH4OH, iii H2/Pd/C, methanol, iv RCOCI, dry 
pyridine, dry THF, 25 °C, v aq. NaOH. 
If X= OCHS : vi BBr3/DCM (1.0 M), reflux, vii 10% aq. NaOH, viii aq. HC1. 
5.8 Design of Quinazolinone Prodrugs 
The design of quinazolinone prodrugs was undertaken in an attempt to circumvent the 
problems associated with the insolubility of the quinazolinone derivatives in aqueous 
media. There are a number of factors which should be considered when selecting a 
suitable candidate compound for prodrug modification: 
i) the parent compound should exhibit potent inhibitory activity in vitro; 
ii) an appropriate functional group for prodrug modification, such as hydroxyl or 
amino, should be present in the parent compound; 
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iii) the prodrug should be biologically inactive, chemically stable and readily soluble 
in aqueous media; 
iv) the prodrug should be non-toxic, as should the prodrug modification itself, when 
cleaved from the parent compound in vivo; 
v) the prodrug should undergo facile metabolic activation in vivo to the parent 
compound (normally via enzymatic cleavage); 
vi) consideration must also be given to the bioavailability of the prodrug, as it should 
not be readily eliminated from the body. 
NU1025 37, was chosen for development as a potential prodrug, since the compound 
exhibits excellent in vitro PARP inhibitory activity and contains a phenolic hydroxyl 
group amenable to prodrug modification. 
5.8.1 Synthesis of Carbamate Ester Prodrugs 
Several drugs containing phenolic hydroxyl groups are known to undergo extensive first- 
pass metabolism, mainly by way of sulfation, methylation or glucuronidation of the 
phenolic moieties. 69 Phenyl carbamates have been used as prodrug modifications in an 
attempt to reduce the extent of first-pass metabolism of the vulnerable phenolic 
group 270'271 Carbamate ester modifications have proved to be extremely successful with 
a number of pharmaceuticals, including physostigmine, neostigmine and carbachol. 272 
The anticancer agent, combretastatin A4 was converted to a glycine carbamate prodrug, 
which served to greatly enhance the overall aqueous solubility of the molecule and 
provided a safe vehicle for the administration of the drug in vivo. 273 
It was proposed that a similar derivative could be synthesised using NU1025 (37), as the 
parent compound. It was hoped that the glycine carbamate derivative of 37 could be 
isolated as a water-soluble salt and metabolic activation of the prodrug would result in the 
elimination of the non-toxic glycine moiety. Compound 37 was converted to the glycine 
carbamate ethyl ester 93, using 1.1 mol. equivalents of ethyl isocyanatoacetate, in the 
presence of dry triethylamine (Scheme 5.8.1.1). 
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Reagents :i Et02CCH2NCO, dry THF, dry NEt3,25 °C, ii THF: 0.5 M H2SO4 (1: 1 ratio) 
The reaction was found to be high-yielding and clean, with a simple recrystallisation 
giving the protected carbamate 93 in 79% yield. Deprotection of 93 was effected with a 
1: 1 ratio of THE and 0.5 M H2SO4, to give the target glycine carbamate 94 in 63% yield. 
Promising 1H NMR data were obtained for the deprotected product and the compound 
was found to readily dissolve in aqueous sodium bicarbonate solution, indicating the 
formation of a sodium salt. However, 111 NMR analysis of the product isolated from 
alkaline solution revealed that instead of forming a chemically stable salt, the carbamate 
ester was unstable and underwent hydrolysis to give the parent quinazolinone 37. 
Numerous investigations concerning the stability of carbamate esters towards alkaline 
hydrolysis have been carried out. 272,274,275 It has been proposed that the hydrolysis of aryl 
carbamates formed from isocyanate derivatives, proceeds via an isocyanate intermediate 
(i. e. the formation and decomposition reactions share a common mechanistic pathway)275 
With regard to producing a water-soluble quinazolinone which would undergo enzymatic 
cleavage in plasma, the carbamate ester was considered too unstable, as its degradation to 
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the parent compound was pH and not enzyme-dependent. It was decided to abandon this 
type of prodrug modification in favour of more chemically stable derivatives. 
5.8.2 Synthesis of Phosphate Prodrugs 
Certain phosphate derivatives make ideal prodrugs, as they can be metabolically activated 
by non-specific, endogenous phosphatases 276 The phosphate prodrug modification has 
been applied successfully to a number of anticancer agents, including combretastatin 
A4,276 Taxol, 277 and Etoposide278 In all cases, the introduction of a phosphate group 
greatly enhanced aqueous solubility and resulted in the formation of chemically stable 
prodrug derivatives. 
Again, NU1025 (37), was used as the parent compound for prodrug modification. Using 
the same method employed to convert etoposide to etopophos, 37 was treated with 1.1 
mol. equivalents of commercially available diphenyl chlorophosphate, in the presence of 
N, N-diisopropylethylamine [EtN('Pr)2], using acetonitrile as solvent279 (see Scheme 
5.8.2.1). The resulting diphenyl phosphate ester 95 was obtained in 46% yield. 
Scheme 5.8.2.1 Attempted synthesis of NU1025 phosphate prodrugs 
37 
I 
0 
PhO---*P-, u HO--'P 
11 11 
CH3 Y "N' ýCH-n 
Ph0 : HO 
95 (46%) 
0 
96 
Reagents :i dry EtN('Pr)2, (PhO)2P(O)CI, dry MeCN, 25 °C, ii Pt02/H2,45-50 psi, ethanol. 
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Deprotection of the diphenyl phosphate ester was attempted using a Parr hydrogenation 
procedure at 45-50 psi 279 A mixture of the diphenyl ester and platinum oxide (Adam's 
catalyst) in ethanol, was placed under an atmosphere of hydrogen for 4 hours, in an 
attempt to produce the phosphate 96. However, it was found that under these conditions, 
compound 37, the parent quinazolinone could be detected, suggesting that the phosphate 
group had been cleaved at the P-OAr bond during the hydrogenation. The product 
isolated gave unsatisfactory 1H NMR data and alternative methods of phosphorylation 
were considered, with regard to the ease of removal of the phosphate protecting groups. 
The dibenzyl phosphate ester 98 was synthesised in the expectation that the benzyl 
groups would be more easily removed by catalytic hydrogenation than the phenyl groups, 
to give the required phosphate 96. Compound 98 was synthesised in an analogous 
manner to 95, by treating compound 37 with dibenzyl phosphorochloridate 97, in the 
presence of dry EtN('Pr)2 279 
The dibenzyl phosphorochloridate 97 was generated in situ, by treating dibenzyl 
phosphite with N-chlorosuccinimide 280 In contrast to the literature procedure, the 
reaction was carried out using dry acetonitrile as the solvent and not benzene. Separation 
of the succinimide by-product from the reaction mixture initially proved to be 
problematic, due to the partial solubility of succinimide in dry acetonitrile. In order to 
overcome this problem, three parallel reactions were carried out using dry acetonitrile, 
dry dichloromethane and dry ether as solvent. It was found that the by-product was least 
soluble in dry ether, in comparison with the other solvents used, and that the succinimide 
could be more easily separated from the reaction mixture. In order to quantify the 
amount of dibenzyl phosphorochloridate present in the reaction mixture, after removal of 
the succinimide by-product, aqueous ammonia was added. The resulting white 
precipitate was identified as dibenzyl aminophosphonate by 1H NMR and the yield was 
calculated to be 65%. Subsequent preparations of dibenzyl phosphorochloridate were 
carried out in dry ether, and quantities were calculated according to an assumed yield of 
65%. After removal of the succinimide, the dibenzyl phosphorochloridate was 
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redissolved in dry acetonitrile and used, as a solution, for the phosphorylation of 
compound 37. 
Removal of the benzyl groups of 98, to give the free phosphate 96 was effected using a 
1: 1 mixture of redistilled THE (the THE was distilled from sodium/benzophenone and 
then redistilled from LiA1H4)281 and water as solvent. Hydrogenation was carried out 
under ambient temperature and pressure, using palladium/carbon catalyst (see Scheme 
5.8.2.2). 
Reagents :i (BnO)2P(O)C1, dry MeCN, dry EtN('Pr)2,25 °C, ii redistilled THF: water (1: 1), 
H2/Pd/C. 
A white precipitate formed on completion of the reaction, which was redissolved in an 
excess of water in order to remove the catalyst by filtration. The product obtained was 
readily soluble in aqueous sodium bicarbonate solution and was submitted for initial 
HPLC studies. The preliminary results were extremely promising and indicated that 
compound 96 is stable in aqueous solution over several days. It also appears that the 
conversion of 96 back to the parent quinazolinone is indeed enzyme-dependent and not 
pH-dependent, as observed with the carbamate ester 93. 
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Following the success in synthesising a quinazolinone phosphate prodrug, it was 
necessary to produce sufficiently large quantities of the compound to facilitate in vivo 
investigations. 
The formation of the dibenzyl phosphate ester 98 was found to proceed in only 28% 
yield. Although it is possible to recover unreacted starting material 37 and repeat the 
reaction, this is a time-consuming and tedious process. Another disadvantage of this 
reaction is the preparation of the phosphorylating species, dibenzyl phosphorochloridate 
97. The reagent is extremely unstable and decomposes readily on standing or on 
exposure to air/moisture. 82 The reagent must be freshly prepared, prior to use to 
minimise decomposition. Thus, reaction conditions employed here are not satisfactory 
for large scale synthesis of the required prodrug. 
According to the literature, 283 phosphorylation of amines using dibenzyl 
phosphorochloridate is almost quantitative. However, with alcohols, comparatively low 
yields are obtained. Phosphorylation of alcohols is generally carried out in the presence 
of a tertiary base and it has been proposed that there is a tendency for the tertiary base 
hydrochloride, produced during the reaction, to debenzylate the initial reaction product. 
Early phosphorylation reactions were carried out using pyridine as the base. However, it 
was found that dibenzyl phosphorochloridate is completely destroyed by pyridine in 2 
hours 30 min. at 34 °C. Studies were conducted to find a less destructive base than 
pyridine and 2,6-lutidine was found to fulfil this requirement. 283 
The reaction has been carried out using the hindered base N, N-diisopropylethylamine. 
However, the yield obtained is still very low. An extensive review of the literature 
uncovered an alternative method for the phosphorylation of phenols. 284 This method 
provides a much more convenient 'one-pot' synthesis, quoting high yields of 
phosphorylated phenols. Scheme 5.8.2.3 shows the reaction pathway. 
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Scheme 5.8.2.3 Alternative synthesis of 8-(O-dibenzyl phosphoryl)-2-methyl 
quinazolin-4 [3HJ--one 98 
OH 
CH3 
I, ii 
-a 
iii 
BnO 
BnO- PýO 
ii 0 
37 98 (48 %) 
CH3 
Reagents :i dry CC14i dry acetonitrile, -10 °C, ii dry EtN('Pr)2i DMAP, iii dibenzyl phosphite. 
Care was taken to ensure that the internal temperature of the reaction mixture did not rise 
above -10 °C until the reaction was complete, as determined by TLC. Not only was the 
reaction convenient, mild and clean, but it was complete within 1 hour. The yield 
obtained when compound 37 was phosphorylated with this method was 48%, almost 
double the yield of the previous method used. 
According to the literature 285 it is assumed that the reaction occurs in two stages: initially, 
carbon tetrachloride reacts with dibenzyl phosphite to generate a trichloromethyl 
phosphonate derivative (Eqn 1: in this mechanism, dibenzyl phosphorochloridate is not 
the intermediate phosphorylating species): 
Eqn 1: 
(BnO), -P-H II -_, _.. _.. ._n 00 
+ CCI4 + Base , (BnO)2-P-CCI3 + B. HCI 
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The trichloromethyl phosphonate then reacts with a molecule of primary/secondary 
amine, to give chloroform and an amino- or substituted aminophosphonate (Eqn 2) : 
Egn2: 
(BnO)2-P-CCI3 + 
11 
0 
+ R'R"NH (BnO)2-P-NR'R" 
11 
0 
CHCI3 
The aminophosphonate can then react with a phenol to give a phosphorylated phenol and 
an amine. With regard to the synthesis of compound 98, the sequence of events is shown 
in Scheme 5.8.2.4. 
Scheme 5.8.2.4 Mechanism of phosphorylation of NU1025 (37) 
O 
Bn0 ; -P, 
+ CC14 + EtNPr2 IN 
BnO Fi 
0 11 1 
BnO iPýCCI + EtNPr2. HCI 
BnO s 
1 BnO Me 
BnO--**P_N oN 
+ CC130 
Me 
0 n 
BnOýPýCC13 
+ BnO 
e 
+ 
Rnn 
CH3 
BnOý-P, O 
p 98 (48%) 
me , 
N,, 
Me 
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The alternative `one-pot' phosphorylation method is convenient, mild, clean and 
amenable to scale-up. A sufficiently large quantity of 96 (0.65 g) was synthesised and 
submitted for preliminary in vivo investigations. 
8-Methyl-2-(4'-hydroxyphenyl)quinazolin-4-[3H]-one 87 was also phosphorylated using 
the one-pot procedure, to give the dibenzyl phosphate ester 99, in 26% yield. 
Unfortunately, time constraints did not allow the deprotection of this compound to give 
the free phosphate. 
5.9 Summary 
An efficient high-yielding synthetic pathway has been developed for the quinazolin-4- 
[3H]-ones. The scheme works effectively in practice and has led to the synthesis of a 
large series of compounds exhibiting potent PARP inhibitory activity. Limitations of the 
synthetic route are, however, apparent and modifications to the scheme should be 
considered. A mild, rapid phosphorylation procedure has been used to prepare a water- 
soluble prodrug derivative of NU1025 (37). The prodrug 8-(O-phosphoryl)-2- 
methylquinazolin-4-[3H]-one 96, has been submitted for preliminary in vivo studies. 
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Chapter Six: Development of the Benzimidazole Series 
6.1 Benzimidazoles as Pharmaceutical Agents 
Benzimidazole derivatives are known to possess a wide range of biological activities, 
including antibacterial, antifungal and anthelmintic 286 Figure 6.1 illustrates some 
examples of commercially significant benzimidazole derivatives. 
Figure 6.1 Examples of Biologically Active Benzimidazoles 
Compounds of general structure A have been shown to interfere with the renin- 
angiotensin system and are effective in the treatment of hypertension and congestive 
heart failure287,288 Currently used clinical agents include the angiotensin converting 
enzyme (ACE) inhibitors captopril and enalopril288 However, it is hoped that non- 
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peptide angiotensin II receptor antagonists of type A will be longer acting when 
administered orally. 287°288 Compounds of structure B are 2-(4-substituted-l-piperazinyl) 
benzimidazoles and exhibit potent H1-antihistaminic activity both in vitro and in vivo. 89 
Compound C has been identified as a novel topoisomerase I poison 290 Relatively few 
topoisomerase I poisons are known but they represent a class of pharmacological agents 
with interesting antineoplastic activity. 290 Compound D exhibits growth-stimulating 
activity on the roots and cotyledons of Zea mays291 and compounds of general structure E 
have been shown to possess antimicrobial activities against different strains of bacteria 
and fungi 292 
6.2 General Methods of Benzimidazole Synthesis 
The conventional method of benzimidazole synthesis, known as the method of Phillips, 
involves the reaction of 2-phenylenediamine 100 with the appropriate carboxylic acid, in 
the presence of a mineral acid catalyst (see Scheme 6.2.1 293,294 
Variations of the Phillips method have been investigated in order to improve yields. For 
example, the use of polyphosphoric acid (PPA) as catalyst and solvent (Scheme 6.2.2, 
method I) usually gives higher yields of benzimidazoles. 
295 [For methods IN, R' = H]. 
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Scheme 6.2.2 General methods of benzimidazole synthesis 
I 
NH2 
NH2 
180 °C 
R2 CHO 
nitrobenzene 
150 °C 
R2CO2H, 
H3BO3,200 °C 
\RI 
Ru3(CO)t2 
V 
base IV 
i) R2 CN 
ii) NCS 
NH2 
Method II was used for the preparation of potential topoisomerase I poisons, similar to 
compound C (Figure 6.1). 290 Method III, a variation of the Phillips method, was used 
for the preparation of 2-substituted benzimidazoles which were investigated for growth- 
regulating activity. 91 Method IV illustrates a method of benzimidazole synthesis from 
an amidine intermediate, which is formed through the reaction of aniline with an aryl 
nitrile and N-chlorosuccinimide (NCS). 251 Method V is an example of transition-metal 
catalysed formation of 2-substituted benzimidazoles from 2-substituted nitrobenzenes296 
and method VI shows a novel synthesis of 1,2-disubstituted benzimidazoles, formed by 
the photolysis of imidoylbenzotriazoles 297 
R2 C02H, 
PPA, 
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6.3 Benzimidazoles as PARP Inhibitors 
As part of the ongoing research at Newcastle University, a novel series of benzimidazole- 
4-carboxamides, exhibiting extremely potent PARP inhibitory activity, was developed. 25 i 
Following the synthesis and biological evaluation of the benzoxazole-4-carboxamides, 263 
the benzimidazole-4-carboxamides were examined as isosteric counterparts. The 
carboxamide group is constrained via an intramolecular hydrogen bond, in an analogous 
manner to the benzoxazoles but the presence of the N' imidazole nitrogen allows an 
additional site on the compounds to be elaborated. 
6.3.1 Benzimidazole Structure-Activity Relationships 
The benzimidazoles are similar in electronic configuration to the benzoxazoles and 
possess the structure-activity requirements previously determined for optimal PARP 
inhibition (see section 4.3). Figure 6.3.1 shows the structural features of the 
benzimidazole-4-carboxamides 251 
Figure 6.3.1 Benzimidazole structure-activity relationships2st 
Unsubstituted 
aromatic 
ring 
/ R, 
H } 
Amide group constrained 
to the active anti conformation 
via an intramolecular 
hydrogen bond 
Sites for structural elaboration 
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6.3.2 Proposed Synthetic Route to Benzimidazole-4-Carboxamides 
Scheme 6.3.2 Synthesis of benzimidazole-4-carboxamides 
101 r, 102 p 
NO2 N02 0 
iii 
OCH3 
t- 
NH2 T 'NH2 
R 
vi 
NH2 NO2 
105 104 
Reagents :i NH4OH, ii KOH, Br2, H2O, 60 °C, 3h, iii HCI (g), MeOH, iv H2/Pd/C, MeOH, 
v RCOCI, NEt3, DMAP, dry THF, -10 °C, vi CH3CO2H, 120 °C, vii NH3 (1), 80 °C, 40 atm. 
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The synthetic route developed for the synthesis of benzimidazole-4-carboxamides is 
shown in Scheme 6.3.2. S1 Starting with commercially available 3-nitrophthalic 
anhydride 101, reaction with aq. ammonia gave 3-nitrophthalamic acid 102, which 
underwent Hofmann degradation to give 3-nitroanthranilic acid (3-nitro-2-aminobenzoic 
acid) 103. Conversion into the methyl ester 104 was achieved using HCl gas and 
methanol. The resulting ester was catalytically reduced to give methyl 2,3- 
diaminobenzoate 105 which was selectively acylated with a range of acid chlorides at 
reduced temperature. The N-acyl derivatives were cyclised using glacial acetic acid to 
give the methyl benzimidazole-4-carboxylates. These were converted to the target 
benzimidazoles by high pressure reaction with ammonia. 
A series of 2-substituted benzimidazole derivatives was synthesised by this route and the 
2-substituents included alkyl, aryl and substituted-aryl functionalities. The 
benzimidazoles were found to be significantly more potent than the corresponding 
benzoxazoles. Although no clear structure-activity relationships were established for the 
benzimidazole-4-carboxamides, they are among the most potent PARP inhibitors known 
to date. 51 Compounds bearing electron-withdrawing and electron-donating groups in the 
4'-position were both found to exhibit excellent PARP inhibitory activity in the 
nanomolar concentration range (see Figure 6.3.2). 251 
It was found that substitution at the 3'-position did not significantly alter inhibitory 
activity, as indicated by compounds 111 and 112. A second series of compounds bearing 
substituents on the N' imidazole nitrogen was synthesised. Introduction of a methyl 
group at the N'-position was tolerated (114) but any further increase in steric bulk 
resulted in a decrease in activity (115 and 116). The 2-alkyl benzimidazole, 2-methyl- 
1H-benzimidazole-4-carboxamide (NU1064) was selected for use in potentiation studies 
and was shown to enhance the cytotoxicity of the alkylating agent temozolomide 251 Data 
from kinetic experiments indicated that NU 1064 acts as a competitive inhibitor. 251 
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Figure 6.3.2 Benzimidazole PARP Inhibitors251 * 
It was deemed necessary to continue the expansion of the benzimidazole series, as these 
derivatives possess excellent PARP inhibitory activity, and further quantities of 
benzimidazole-4-carboxamides were required for use in potentiation studies. 
6.4 Aims of Benzimidazole Research 
A benzimidazole prodrug, analogous to the quinazolinone prodrug (Chapter Five, Section 
5.8.2) was previously -synthesised in low yield, from 2-(4'-hydroxyphenyl)-lH- 
benzimidazole-4-carboxamide 109.251 It was necessary to synthesise bulk quantities of 
109 for subsequent prodrug modification and this was initially attempted using the 
original synthetic pathway (Scheme 6.3.2). It was hoped that this pathway would not 
only allow scale-up preparations to be carried out but also the synthesis of 2', 3'- 
disubstituted benzimidazoles, to expand the existing series of compounds. 
'See Chapter Seven, Section 7.2.1 for assay details 
119 
Chapter Six: Development of the Benzimidazole Series 
6.5 Syntheses of Benzimidazole PARP Inhibitors 
Compound 103 was prepared in bulkI for the subsequent preparation of 2-(4'- 
hydroxyphenyl)-1H-benzimidazole-4-carboxamide 109. The derivative was synthesised 
in good yield and stored in a dark glass bottle until needed. Conversion of 103 to the 
corresponding methyl ester, methyl 2-amino-3-nitrobenzoate 104, was performed in order 
to improve the solubility characteristics of the molecule. 251 The ester 104 was obtained 
by saturating a solution of 103 in methanol at -10 °C, with dry HCl gas. The saturated 
solution was allowed to warm up to room temperature and heated under reflux under dry 
conditions, for six hours. After cooling and removal of the resulting bright yellow 
precipitate by filtration, the mother liquor was found by TLC to contain only product and 
unreacted starting material. These compounds were separated by column 
chromatography and a corrected yield of 86% was recorded for compound 104 (lit. 
yield251 60%). 
Small scale reactions using the pathway in Scheme 6.3.2 initially proved successful? S' 
However, subsequent attempts to reproduce comparable yields under the same conditions 
were unsuccessful. 
6.5.1 Limitations of the Proposed Synthetic Route 
Methyl 2,3-diaminobenzoate 105 is known to be extremely light-sensitive and readily 
decomposes on exposure to light. 251 For this reason, it was proposed that 105 should be 
freshly prepared, prior to N-acylation. The ester 105 was prepared by catalytic 
hydrogenation of 104, using 10% Pd/C catalyst and methanol as solvent. 51 Once 
hydrogen absorption was complete, the resulting colourless solution was rapidly seen to 
colour during the subsequent handling and isolation of the compound, the end result 
being the formation of a dark brown tar-like substance. Immediate 1H NMR analysis of 
the crude product showed the required compound to be present. 
I Prepared by Mr R. Davison 
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However, difficulties were encountered in the calculation of yields, due mainly to the 
presence of breakdown products. Attempts to carry out the reaction work up with 
minimal exposure of the compound to light and air did not help, and attention was 
directed towards improving the handling properties of compound 105 (see Section 6.5.2). 
Preparation of the N-acyl derivative, methyl 2-amino-3-N-(4'-methoxybenzoyl) 
aminobenzoate 117 was previously achieved using 4-methoxybenzoyl chloride in the 
presence of dry NEt3 and DMAP in cold, dry THE 251 The compound was prepared in 
62% yield251 It was reasoned on the basis of electronic and steric factors, that the 3- 
amino group should be more nucleophilic than the 2-amino group and a single acylation 
at the 3-position should occur. However, when acylation of crude 105 was attempted 
using the above reaction conditions, multiple products were detected by TLC, both under 
short wave and long wave light. TLC comparisons with authentic material indicated that 
the required monoacylated product was present, albeit in low yield. The major product, 
isolated in 19% yield, was found to be the diacylated compound 118 (see Scheme 
6.5.1.1). 
Scheme 6.5.1.1 Attempted monoacylation of methyl 2,3-diaminobenzoate 105 
OCH3 
OCH3 
117 
OCH3 
118 (19%) 
Reagents :i dry THF, p-CH3C6H4COCI, dry NEt3, DMAP (5 mol. %), -10 °C. 
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Hence, it was found that under these conditions, the slightly enhanced nucleophilicity of 
the 3-amino group did not result in the selective mono-acylation of 105. 
The last two synthetic steps were found to be non-problematic. Cyclisation of the mono- 
acylated derivative 117 in glacial acetic acid at 120 °C resulted in the formation of the 
ring-closed methyl benzimidazole-4-carboxylate, which was isolated as its acetate salt 
120 in 74% yield (lit. yield251 75%). High pressure reaction of 120 with freshly 
condensed, liquid ammonia gave 2-(4'-methoxyphenyl)-lH-benzimidazole-4- 
carboxamide 121 in 87% yield (lit. yield251 80%). Compound 121 is the direct precursor 
of 2-(4'-hydroxyphenyl)-1H-benzimidazole-4-carboxamide 109. Demethylation of 121 
was carried out using BBr3/DCM in an analogous manner to quinazolinone 
demethylation. The required phenolic benzimidazole 109 was isolated in 44% yield (lit. 
yield251 57%). 
Following the original synthetic route, preparation of 109 was achieved in 21% overall 
yield, with respect to 105.251 Repetition of the synthesis on a slightly larger scale led to 
ineffective N-acylation, due to the lack of selectivity between the two amino groups of 
105. This resulted in a reduced overall yield of only 7% for 109, with respect to 105. 
Clearly, the route employed is not high-yielding, reproducible or amenable to scale-up. 
For the purpose of producing larger quantities of 109, it was necessary to introduce 
modifications to the original synthetic route. 
6.5.2 Modifications to the Proposed Synthetic Route 
It appears that the two major problems involved are the instability of compound 105 and 
the non-selectivity of the acylation step. In an attempt to improve the handling 
characteristics of 105, it was proposed that the derivative could be isolated as a 
hydrochloride salt. Methyl 2-nitro-3-aminobenzoate 104 was dissolved in cold, dry 
methanol. Two equivalents of acetyl chloride were added in order to generate HCl in situ 
and the reaction mixture was hydrogenated in the presence of 10% Pd/C catalyst. The 
resulting colourless solution was treated as light-sensitive and care was taken to minimise 
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exposure to light and air. The product was identified as the monohydrochloride salt 119 
and was isolated as a pink solid in 88% yield. The salt proved to be more easily 
transferable than the previously obtained brown oil. Although some discolourisation was 
evident, the reaction was considered an improvement on the original procedure. Despite 
the stability of 105 being improved by isolating the compound as a salt, this did not lead 
to any significant difference in the yield of 117 (25% yield from 119). Selectivity 
between the amino groups was still found to be a problem and it was decided to tackle 
this step with a different approach. 
6.5.3 Synthesis of Benzimidazoles from Diacylated Precursors 
Since the formation of diacylated compounds appeared unavoidable, it was proposed that 
benzimidazole synthesis could be attempted from diacylated precursors. A recent review 
in the literature details the p-toluenesulfonic acid-promoted synthesis of 2-substituted 
benzoxazoles and benzimidazoles from diacylated precursors, and quotes excellent yields 
for a range of compounds containing electron-withdrawing or electron-donating 
substituents in the 2-position. 298 
Reagents :i p-TsOH, xylene, 140 °C. 
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An analogous reaction was attempted with compound 118. Although multiple products 
were, detected by TLC, the major product appeared to be the required methyl 
benzimidazole-4-carboxylate. However, in view of the poor yields of 118 obtained, it 
was deemed inappropriate to use this compound as a starting material. 
6.5.4 Synthesis of Benzimidazoles from Isatin Derivatives' 
In order to address the selectivity problem of the acylation step, it was proposed that 
benzimidazole formation could be achieved from isatin derivatives. These have been 
employed as important synthetic intermediates in both the pharmaceutical and dye 
industries for many years. 99 The most frequently used method of synthesis for isatin is 
the Sandmeyer procedure (Scheme 6.5.4.1) 300 
Reagents :i CCl3CHO, hydroxylamine hydrochloride, ii H2SO4 (conc. ) 
The procedure involves the formation of an isonitrosoacetanilide 123 from an aniline 122 
chloral hydrate and hydroxylamine. The isonitrosoacetanilide 123 can then be converted 
to an isatin 124 by treatment with concentrated sulfuric acid. Scheme 6.5.4.2 outlines the 
proposed route to benzimidazoles from isatin derivatives. The amino group at the 
corresponding 2-position of 103 is effectively restricted along with the carbonyl function 
into a ring system. 7-Aminoisatin 128 could then be monoacylated to give 129. 
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Scheme 6.5.4.2 Synthesis of benzimidazoles from isatin derivatives 
125 
NO2 
NH2 
I, ii, 
iii 
126 
IV, V 
-Do 
127 
NO2 
0 
VI 
viii 
NH2 
128 
OCH3 
Ix 
OCH3 
X 
OCH3 
OCH3 
121 
Reagents :i Na2SO4i H2O, CCI3CHO, 40 °C, ii HCI, iii hydroxylamine hydrochloride, H2O, 
reflux, iv conc. H2SO4, v H2O (s), vi H2/Pd/C, MeOH, vii 4-OCH3C6H4000I, dry NEt3, DMAP 
(5 mol. %), dry THF, -10 °C, viii mCPBA, DCM, ix NH4OH, x CH3CO2H, 120 T. 
without interference from other functional groups. It is well known that isatin derivatives 
can be oxidised to give isatoic anhydrides. 
99 Subsequent treatment of the isatoic 
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anhydride 130 with ammonia would result in nucleophilic attack of the carboxylate 
carbon, followed by elimination of carbon dioxide to give 2-amino-3-N-(4'- 
methoxybenzoyl) aminobenzamide 131, which could then be cyclised as before, to give 
the target benzimidazole 121. 
The synthesis of 7-nitroisatin 127 was reported by Buchman et al in 1947.301 However, 
no subsequent reports on the preparation of this compound have appeared since. 
Following the method of Buchman et al, based on the Sandmeyer procedure, the 
synthesis of isonitrosoacet-o-nitroanilide 126 was attempted from commercially available 
o-nitroaniline 125. Anhydrous sodium sulphate and chloral hydrate were heated to 40 °C 
in water to effect complete dissolution. A mixture of o-nitroaniline and concentrated 
hydrochloric acid in water was added and the reaction mixture was vigorously stirred. A 
solution of hydroxylamine hydrochloride in water was added and the reaction mixture 
was rapidly heated to boiling and maintained at boiling point for fifteen minutes. On 
cooling, a bright yellow precipitate formed, which was collected by filtration. The crude 
product was formed in 32% yield and was identified by 1H NMR analysis to be the 
required product 126. 
As was previously noted with the synthesis of isatin, a considerable amount of tarry 
material is formed during heating if the aniline derivative is not in solution. 302 This 
problem was encountered during the synthesis of 126, due to the insolubility of o- 
nitroaniline 125. Careful heating of 125 in water containing concentrated HCl gave a 
clear orange solution and served to eliminate the majority of the tarry residue. However, 
there was no significant improvement in the yield of 126. The presence of the strongly 
electron-withdrawing nitro group would severely reduce the nucleophilicity of the amino 
group nitrogen and subsequent reaction at this nitrogen would not readily occur. 
Repeated attempts to improve upon the yields of 126 were unsuccessful and since 7- 
nitroisatin was required as a starting material, it was decided to abandon the synthesis of 
benzimidazoles from isatin derivatives. 
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6.5.5 Copper-catalysed Benzimidazole Synthesis 
The synthesis of 2-phenylbenzimidazole-4-carboxamides has been reported by Denny et 
a1.303 The benzimidazoles were synthesised according to Scheme 6.5.5.1, via the 
oxidative condensation of 1,2-diaminobenzoic acids and aldehydes with cupric ion. 304 
Reagents :i NaOH, H20, H2/Pd/C, ii ArCHO, Cu(OAc)2, iii Na2S, HCI. 
The advantage of this method is that the light-sensitive 2,3-diaminobenzoic acid 133 is 
generated in situ and reacted further without isolation. The insoluble benzimidazole- 
copper complexes can easily be separated by filtration, and the copper is removed by 
treatment with sodium sulfide in acidic media. 
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Using the above method, a series of substituted benzimidazoles were synthesised. 
Conversion of the benzimidazoles to the target carboxamides was achieved by treating 
the carboxylic acids with thionyl chloride, DMF and aqueous ammonia. Figure 6.5.5 
shows the compounds synthesised by this method. 
Figure 6.5.5 Benzimidazole Derivatives 
Structure No. X RI R2 R3 Yield 
A 133 OH Cl H H 80% 
A 134 NH2 Cl H H 47% 
A 135 OH OH H H 17% 
A 109 NH2 OH H H 75% 
A 136 OH H OCH3 H 50% 
A 137 ' NH2 H OCH3 H 75% 
A 138 OH H OH H 67% 
A 139 NH2 H OH H 92% 
A 140 OH OH OCH3 H 44% 
A 141 NH2 OH OCH3 H 46% 
A 142 OH OCH3 OCH3 H 46% 
A 143 NH2 OCH3 OCH3 H 31% 
A 144 OH OCH3 OCH3 OCH3 40% 
A 145 NH2 OCH3 OCH3 OCH3 30% 
A 146 OH N(CH3)2 H H 48% 
A 147 NH2 N(CH3)2 H H 36% 
A 148 OH CO2Et H H 31% 
A 149 NH2 CO2Et H H 66% 
B 150 OH 33% 
B 151 NH2 46% 
The benzimidazole-4-carboxylates were prepared by reaction of 103 with the appropriate 
mono-, di- or tri-substituted benzaldehyde derivative. The yields given for the synthesis 
of the benzimidazole-4-carboxylates are with respect to compound 103, and the yields for 
the benzimidazole-4-carboxamides with respect to the corresponding carboxylates. 
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In most cases, the requisite benzimidazole-4-carboxylate readily precipitated from the 
crude aqueous reaction mixture. However, the presence of polar functionalities, such as 
hydroxyl groups, marginally increases the solubility of the compound in aqueous media 
and di- or trihydroxyl substituted benzimidazoles may be more appropriately synthesised 
directly from the corresponding di- or trimethoxy substituted benzimidazoles. 
Compound 148 was obtained during the attempted synthesis of 2-(4'- 
carboxybenzylphenyl)-1H-benzimidazole-4-carboxylate 152. The 4'-carboxylate group, 
masked as a benzyl ester, would allow conversion of the 1-carboxylate to a carboxamide 
and subsequent deprotection would give 2-(4'-carboxyphenyl)-1H-benzimidazole-4- 
carboxamide (Scheme 6.5.5.2). 
4-Carboxybenzaldehyde 154 was benzylated using N, N-diisopropyl-O-benzyl isourea 
155, which was prepared from benzyl alcohol and N, N-diisopropyl carbodiimide. 305 The 
reaction of 132 with 4-benzyloxycarbonyl benzaldehyde 156 led to the formation of 2- 
(4'-ethoxycarbonylphenyl)-1H-benzimidazole-4-carboxylate 148, possibly due to acid or 
copper-catalysed ester exchange. 148 was converted to the carboxamide 149 in 66% 
yield. In this case, the carboxylate is masked as an ethyl ester and still allows the 
selective conversion of the carboxylate in the 1-position. Unfortunately, time did not 
permit the deprotection of compound 149 to give the mono-acid 153. 
The successful synthesis of the benzimidazole-4-carboxamides has expanded the existing 
series to include di- and tri-substituted derivatives. The copper-catalysed method of 
benzimidazole synthesis gives reasonable yields compared to the original proposed 
synthetic route and appears to be amenable to scale-up. 
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Scheme 6.5.5.2 Attempted synthesis of 2-(4 -carboxyphenyl)-1H-benzimidazole- 
4-carboxamide 153 
HO 
° 
154 
I 
OH 
Reagents :i Copper (I) chloride, 0 °C, ii Cu(OAc)2, MeOH, iii Na2S, HCI, iv SOC12, DMF, dry 
THF, v aq. ammonia, vi H2/Pd/C, MeOH, vii KOH, MeOH. 
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6.6 Synthesis of Benzimidazole Prodrugs 
It was hoped that combining the improved method for the synthesis of 109 and the one- 
pot phosphorylation procedure developed for the quinazolinones, 284 would lead to an 
increased yield of the benzimidazole phosphate prodrug. Phosphorylation of 109 was 
achieved in an analogous manner to the phosphorylation of the quinazolinone 37, to give 
the dibenzyl phosphate ester 157 in 66% yield (Scheme 6.6). 
Scheme 6.6 Synthesis of benzimidazole phosphate prodrugs 
IV 
0 /, 
109 
OH O-PýOBn 
157 OBn 
V 
159 
0 % O-P` O-Ný4 
O NH4 
Io O-P` OH 158 OH 
Reagents :i dry CCl4i dry MeCN -10 °C, ii dry EtN(Pr)2, DMAP, -10 °C, iii, dibenzyl phosphite, 
-10 °C, iv THF: water (1: 1), H2/Pd/C, v aq. NH4OH. 
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The yield previously recorded for the synthesis of 157 was only 29% 251 Thus, the 
improved one-pot phosphorylation procedure led to a significant increase in the yield of 
the dibenzyl phosphate ester 157. Deprotection of the dibenzyl ester was effected using a 
1: 1 mixture of redistilled THE and water, by hydrogenation in the presence of 10% Pd/C 
catalyst. 81 However, the required phosphate was found to be only sparingly soluble in 
aqueous media and was converted to the ammonium salt 159 in 74% yield. It is hoped 
that synthesis of the phosphate prodrugs will be amenable to scale-up as, unfortunately, 
time did not permit large-scale reactions to be carried out. 
6.7 Summary 
An improved method has been found for the synthesis of novel benzimidazole-4- 
carboxamides. The method gives reasonable yields and has allowed the synthesis of 
mono-, di- and tri-substituted derivatives. The one-pot phosphorylation procedure has 
been successfully applied to the synthesis of the benzimidazole prodrugs with increased 
yields. The benzimidazole prodrug was isolated as an ammonium salt to increase its 
aqueous solubility properties. 
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Chapter Seven: Biological Results and Discussion 
7.1 Introduction 
Biological studies were conducted on the quinazolinone series of compounds by 
members of the Cancer Research Unit, Medical School, University of Newcastle upon 
Tyne. PARP inhibitory activity was determined in permeabilised murine leukaemia 
L1210 cells (Section 7.2.1). Potentiation studies were also undertaken using 8-hydroxy- 
2-methylquinazolin-4-[3H] -one, NU1025, (37) which was evaluated for its ability to 
potentiate cytotoxicity in L1210 cells together with a range of mechanistically diverse 
anticancer agents. Preliminary HPLC results from the evaluation of the quinazolinone 
phosphate prodrug 96, will also be presented. 
7.2 Inhibition Studies with PARP Inhibitors 
7.2.1 Permeabilised Cell Assay 
Penneabilised L 12 10 cells were used for PARP inhibition assays, following a variation of 
the method of Halldorsson et al. 306 The L1210 cells were permeabilised by exposure to 
hypotonic buffer and cold shock. The cells were then incubated at 26 °C for five minutes 
in isotonic buffer, with [32P]NAD+, the inhibitor under investigation and a synthetic, 
palindromic oligonucleotide (CGGAATTCCG). The oligonucleotide was included in 
order to stimulate PARP activity, as it forms a double-stranded hairpin loop with a blunt 
end. 307 Following incubation, the incorporation of [32P]NAD+ into acid precipitable 
material was estimated. Polymer precipitation was effected by the addition of 1% 
trichloroacetic acid (TCA). After collection of the precipitate and washing with 1% TCA 
and 1% sodium phosphate, the [32P] incorporation into the precipitate was measured 
using a scintillation counter. The results are presented as the percentage of [32P] uptake 
in drug-treated cells relative to the control cells. Inhibitory activity was expressed as an 
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IC50 value (inhibitory coefficient value): defined as the concentration of inhibitor 
required to reduce PARP activity to 50% of the control. 
7.2.2 96-Well Plate Assay 
The benzimidazole inhibitors were evaluated by Agouron Pharmaceuticals Inc., San 
Diego, USA. Using a 96 well plate assay, the inhibitors were assayed at 25 °C, pH 8.0. 
The components of the assay included 50 mM Tris (Tris[hydroxymethyl]aminomethane), 
10 mM MgC12,1 mM Dithiothreitol (DTT), 8 µM/ml DNA, 500 µM [32P]NAD+, 20 nM 
PARP and the inhibitor under investigation. The assays were run in triplicate and the 
reactions were terminated by the addition of 1 °. /o TCA solution. The mixtures were 
transferred to glass fiber filter well plates, vacuum filtered and washed. Activity was 
quantitated using a phosphorimager. 
7.3 Results of Inhibition Studies with Quinazolinones 
The inhibitory activities of 8-hydroxy-2-methylquinazolin-4- [3 H] -one, NU1025, (37) and 
8-hydroxy-2-(4'-nitrophenyl)quinazolin-4-[3H] -one, NU1057, (38) were previously 
determined using the permeabilised L1210 cell assay. 263,264 ICso values of 0.44 ± 0.13 
µM and 0.23 ± 0.033 µM were determined for compounds 37 and 38, respectively, 
indicating that the 4'-substituted aryl quinazolinone is slightly more potent than the 2- 
alkyl quinazolinone 308 Both compounds are an order of magnitude more potent than 
benzamide 6 and 3-hydroxybenzamide 10, which were found to have IC50 values of 19.1 
± 5.9 µM and 13.7 ± 6.9 µM, respectively, under the same assay conditions. 264 
Figure 7.3.1 shows the results of inhibition studies on 2-alkylquinazolinones. The 2- 
alkyl quinazolinones 46,48 and 37 show good activity against PARP. The interactions 
between these compounds and the enzyme may be attributed to a number of effects, 
including lipophilicity, electronic and steric effects. 
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Figure 7.3.1 Results of inhibition studies on 2-alkylquinazolinones 
0 
Compound No. Structure IC50 value 
N H M o. ) ouse ( (µ ) 
X R 
48 CH3 H 0.39 
(NU 1069) 
37 OH H 0.44 
(NU 1025) 
46 OCH3 H 0.78 
(NU1063) 
91 OCH3 CH3 >100 
(NU1088) 
92 OH CH3 8% inhibition 
(NU1055) at 10 µM 
As expected, the two control compounds, 8-methoxy-3-N-methyl-2-methylquinazolin-4- 
[3H]-one 91 and 8-hydroxy-3-N-methyl-2-methylquinazolin-4-[3H]-one 92, were found 
to be weakly active as PARP inhibitors, with 91 having an IC50 value of >100 µM, and 92 
causing only 8% inhibition at 10 µM. 
Figure 7.3.2 shows the results of inhibition studies on 2-arylquinazolinones. 
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Figure 7.3.2 Results of inhibition studies on 2-arylquinazolinones 
0 
Compound No. Structure ICso value 
(House No. ) X R (µM) 
57 CH3 N02 0.13 
(NU1087) ýý 
85 CH3 
OCH 
0.15 
(NU1075) s / 
87 CH3 OH 0.22 
(NU1095) ýý 
38 OH 0.23 
(NU1057) 
N02 \/ 
67 CH3 CN 0.27 
(NU 1097) \/ 
86 OH 
-& OH OH 
0.29 
(NU1094) 
89 CH3 -- 0.44 
(NU1083) \/ NH2 
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Figure 7.3.2 continued 
Compound No. Structure IC50 value 
(House No. ) X R (µM) 
90 OH - 0.46 
(NU1081) \/ NH2 
55 OCH3 0.85 
(NU 1072) N02 \/ 
52 CH3 0.87 
(NU1073) 
53 OH 1.06 
(NU1068) 
65 OCH3 1.34 
(NU1089) CN \a 
80 
(NU1106) 
OCH3 
N3 1.93 
84 OCH3 OCH 2.0 
(NU1071) 3 \/ 
51 OCH3 4.2 
(NU1065) 
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Figure 7.3.2 continued 
Compound No. Structure IC50 value 
(House No. ) X R (µM) 
76 CH3 - 4.8 C02CH3 
(NU1108) 
59 OCH3 
-0-CF3 
39 
(NU 1074) 
88 OCH3 -' 
NH 
13% inhibition 
(NU1082) 2 \/ at 0.3 µM 
61 CH3 CF 
22.3% inhibition 
(NU1078) 3 at 10 µM 
The IC50 values for the above compounds are in order of potency, starting with the most 
potent inhibitor. The introduction of a2 phenyl substituent did not significantly increase 
the potency of the inhibitors compared to the 2-alkylquinazolinones. Again, the majority 
of the compounds are an order of magnitude more potent than benzamide 6. The 
insolubility of compounds bearing strongly electron-withdrawing substituents rendered 
the evaluation of some of these compounds difficult. 
It is interesting to note that the derivatives 57 and 85 bear substituents of opposing 
electronic nature but are equipotent with respect to their PARP inhibitory activities, with 
IC50 values of 0.13 and 0.15 µM, respectively. These results suggest that the electronic 
nature of the substituents on the aryl ring is not of primary importance for enzyme 
inhibitory activity. 
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Disappointingly, no clear structure-activity relationships have emerged from the 
evaluation of this series of compounds. However, previously determined structural 
requirements have been confirmed and this is reflected by the excellent inhibitory activity 
exhibited by the quinazolinones. 
7.4 Evaluation of the Quinazolinone Prodrugs 
The IC50 values for the carbamate and phosphate quinazolinone prodrugs are shown 
below. 
Figure 7.4 Results of inhibition studies on quinazolinoneprodrugs 
0 
CH3 
R"O 
Compound No. Structure ICso value 
(House Number) R (µM) 
93 H 
(NU 1084) 
Et02CýN,, r 2.23 
0 
95 
0 
11 
(NU 1096) P hO iP. 
Inactive at 1µM 
PhO 
98 0 
(NU1102) 
11 
BnO , P,,, 
> 100 µM 
BnO 
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As previously described in Section 5.8, an ideal prodrug should be chemically stable and 
inactive. The glycine carbamate ester 93 was found to be moderately active against the 
PARP enzyme. However, the carbamate prodrugs were considered unsuitable 
derivatives, owing to their instability under physiological conditions. The more 
chemically stable phosphate esters 95 and 98 were found to be relatively inactive against 
the enzyme but the insolubility of these derivatives in aqueous media limits their utility. 
7.4.1 Preliminary Results from In Vivo Studies 
The quinazolinone prodrug NU1100 (96), was evaluated for its ability to liberate 
NU1025 (37) in plasma at 37 °C. Control studies showed that in pure water, pre-boiled 
plasma and EDTA-treated plasma, no liberation of NU1025 was evident, in agreement 
with expectations. In fresh plasma, the prodrug was converted to NU1025 in three 
minutes. Figure 7.4.1.1 shows the data for the enzymatic breakdown of the 
quinazolinone prodrug 96 in plasma. 
Figure 7.4.1.1 Enzymatic breakdown of NU1100 (96) to NU1025 (37) 
Concentration of NU1025 liberated 
from 50µg/ml (equivalent to 35µg/ml 
NU1 025) NU1100 at 37C 
Time (min) 
--- NU 1100 fresh 
-"- NU1100 EDTA 
-'- NU1100 boiled 
NU1100 water 
-+- NU1 025 fresh 
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High Performance Liquid Chromatography (HPLC) Evaluation of the Quinazolinone 
Prodrug NU1100 
Preliminary HPLC studies were conducted by Dr. J. A. Calvete, Cancer Research Unit, 
Medical School, University of Newcastle upon Tyne. Obvious problems were 
encountered with regard to the differing solubility properties of the prodrug NU 1100 and 
the parent quinazolinone NU1025, as the stock solutions were prepared in aqueous and 
organic media, respectively. 
Figure 7.4.1.2 shows an overlay of separate HPLC traces from the prodrug and parent 
drug, displaying different retention times. The run was carried out as a gradient assay, 
starting with 0% methanol in acetic acid and increasing to 20% methanol, over 10 
minutes, with a flow rate of 1 ml/minute and sample injections of 3 µl. 
Optimal HPLC conditions are currently being determined and validated. The aim of the 
study is to detect and quantitate the amount of prodrug and parent drug present under the 
same conditions and ultimately, to measure prodrug turnover in vivo. 
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Figure 7.4.1.2 HPLC traces from the prodrug NU1100 (96) and NU102S (37) 
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7.5 Results from Potentiation Studies 
NU1025 (37) has been evaluated against a panel of diverse anticancer therapies, 
including y-radiation, MTIC, bleomycin, AGG337, gemcitabine, camptothecin and 
etoposide (VP-16). The following sections will briefly overview the results from these 
potentiation studies. 
7.5.1 Potentiation of Alkylating Agents 
NU1025 (37) was evaluated in conjunction with the alkylating agents, temozolomide (8- 
carbamoyl-3-methylimidazo[5,1-d]-1,2,3,5-tetrazin-4-[3H]-one) 160 and MTIC 161. The 
chemically stable imidazotetrazinone 160 is presently undergoing clinical trials as an 
antitumour agent. 309 The compound is activated in vivo by hydrolysis and loss of carbon 
dioxide, to yield the intermediate MTIC 161, believed to be the active form of 
temozolomide. Figure 7.5.1 shows the mechanism of activation of temozolomide 160.310 
A study has been made using L1210 cells, comparing the effects of NU1025 (37) and 
PD128763 (30), with the less effective PARP inhibitors benzamide 6 and 3AB S. 264 The 
study showed a good correlation between the ability of the inhibitors to potentiate the 
effects of temozolomide and the potency of the compounds as PARP inhibitors. 
Micromolar concentrations of NU1025 and PD128763 were shown to give the same 
effects as millimolar concentrations of benzamide and 3AB, demonstrating a difference 
in concentrations of an order of magnitude. It was shown that 50-100 µM NU1025 was 
required to potentiate the cytotoxic effects of MTIC (161) 4-7 fold, whereas 5 mM 
benzamide brought about only a 4-fold potentiation effect264 These results suggest that 
NU1025 would be a possible candidate for clinical development, to be used in 
conjunction with anticancer agents and that MTIC also appears to be an appropriate 
cytotoxic agent for the pre-clinical evaluation of PARP inhibitors. 
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Figure 7.5.1 Proposed mechanism of activation of temozolomide 160310 
7.5.2 Potentiation of Ionising Radiation 
The effects of NU 1025 (37) and 3AB (8), on the repair of potentially lethal y-irradiation- 
induced DNA damage were investigated. Exponentially growing L1210 cells were 
exposed to y-irradiation, followed by a2 hour recovery period, in the presence or absence 
of NU1025 or 3AB 311 As can be seen from Figure 7.5.2.1 both NU1025 and 3AB 
potentiate the effects of y-irradiation. The effects of 200 µM NU1025 were more 
pronounced than 10 mM 3AB. It was also found that 10 mM 3AB alone caused a 
reduction in cell survival of 18 ± 13%, compared to a3± 5% reduction for NU1025, 
which may be due to cytotoxicity unrelated to the inhibition of PARP. Figure 7.5.2.2 
shows the effects of NU1025 and 3AB on the repair of potentially lethal damage 
(PLD). 11 3 
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Figure 7.5.2.2 The effects of NU1025 and 3AB on the repair of potentially lethal 
damage (PLD) 
Recovery from potentially lethal y-irradiation damage in the presence/absence of NU1025/3AB. After 
exposure to 8 Gy y-irradiation, cells were allowed to recover for up to 4 hours in control medium (0) or 
medium containing 200µM NU1025 (0), or 10mM 3AB (V) prior to seeding for colony formation. Data are 
mean ± SD of triplicate colony counts from each of the cell populations exposed in duplicate, from a single 
representative experiment. 312 
Following exposure to 8 Gy y-irradiation, the L1210 cells were allowed to recover in the 
presence/absence of NU1025/3AB. It was found that in the absence of the inhibitors 
slight recovery was evident, which was inhibited in the presence of 200 µM NU1025 or 
10 mM 3AB. 311 Repair of y-irradiation DNA damage was measured by alkaline elution. 
The results indicated that NU1025 hindered DNA repair. The additional cell killing 
observed with 3AB may, again be due to cytotoxicitiy unrelated to the inhibition of 
PARP. 
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7.5.3 Potentiation of Other DNA-Damaging Agents 
7.5.3.1 PARP Inhibitors and Bleomycin 
Bleomycin is an antitumour antibiotic which has been found to be particularly useful for 
the treatment of lymphomas, testicular carcinomas and squamous cell carcinomas. 12 The 
drug inhibits prokaryotic and eukaryotic cell proliferation and DNA synthesis. 
Bleomycin-induced DNA fragmentation is predominantly single-stranded but double- 
strand breakages also occur. 312 It has been hypothesised that one mechanism by which 
human tumours may become resistant to bleomycin is through increased DNA repair, 
although no exact mechanisms have been defined 
312 
7.5.3.2 PARP Inhibitors and Antimetabolites 
NU1025 failed to potentiate the cytotoxicities of the classical antifolate thymidylate 
synthase (TS) inhibitor, AGG337 and the antimetabolite, gemcitabine 311 The 
cytotoxicity of TS inhibitors is believed to involve BER, resulting from increased deoxy- 
uridine-triphosphate (dUTP) pools and the mis-incorporation of uridine into DNA. The 
subsequent removal of the wrongly incorporated base by a specific BER enzyme leads to 
a DNA strand breakage and ultimately cell death. 312 Failure of NU1025 to potentiate the 
effects of antimetabolites suggests that these drugs may not be suitable for use in 
conjunction with PARP inhibitors. 
7.5.3.3 PARP Inhibitors and Topoisomerase Inhibitors 
The topoisomerase enzymes (Class I and II) are responsible for the catalysis of a three- 
step process: 313 
i) cleavage of one (topo I) or both (topo II) strands of DNA, 
ii) the passage of a segment of DNA through the break, and 
iii) resealing of the break. 
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Topoisomerase I Inhibitors 
The only currently known drugs in use as topoisomerase I (topo I) inhibitors are 
camptothecin and its derivatives. 312 One of the more soluble analogues is CPT-11 (163), 
which is currently undergoing clinical trials. 12 NU1025 was found to potentiate the 
cytotoxic effects of camptothecin. 
Topoisomerase II Inhibitors 
Etoposide (VP-16) 163 is an inhibitor of topoisomerase II (topo II) in eukaryotic cells, 
effective in the treatment of lung and testicular cancers. 12 Topo II makes a double strand 
incision in DNA and forms a `cleavable' complex (the complex is termed `cleavable' 
since a permanent DNA double-strand break would result from the removal of the 
protein). 312 Topo II inhibitors stabilise the cleavable complex and prevent any further 
enzymatic topological changes from occurring in the DNA. Resistance to etoposide 
commonly arises as the classical MDR-phenotype, characterised by overexpression of the 
levels of P-glycoprotein (see Section 1.2.2). NU1025 failed to potentiate the cytotoxic 
effects of etoposide (VP- 16). 
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These results are in agreement with the findings of Menissier de Murcia et a188_ but in 
contrast to the earlier work of Benjamin and Gill. 74 Since the inhibition of topo I or topo 
II would result in a permanent single or double-strand DNA break, respectively, the 
inhibition of PARP would be expected to potentiate the effects of topo I but not topo II 
inhibitors. Table 7.5 summarises the results of the potentiation studies using NU1025 
and a variety of DNA-damaging agents. 
148 
Chapter Seven: Biological Results and Discussion 
Table 7.5 Results of potentiation studies using NU1025 (37) 
DNA-Damaging Agent Fold Potentiation 
MTIC 3.6±0.5 
Camptothecin 2.6 ± 0.3 
Bleomycin 2.0 ± 0.5 
y-Irradiation 1.4 ± 0.2 
AGG337 None 
Gemcitabine None 
Etoposide None 
7.6 Results of Inhibition Studies with Benzimidazoles 
Figure 7.6.1 shows the results of inhibition studies using the benzimidazole-4- 
carboxamides. The K; values given below are in order of potency, starting with the most 
potent. Unfortunately, no clear structure-activity relationships have emerged from the 
evaluation of the benzimidazole inhibitors. It appears that substitution in the ortho 
position of the 2-aryl ring is not well tolerated by the enzyme, as is reflected by the lower 
activity of NU1098 (137). Interestingly, the addition of a third methoxy group, as in 
compound 145 resulted in a substantial loss of activity, since the K; values for the di- and 
tri-methoxyphenyl benzimidazoles, 143 and 145, are 6.2 nM and 128 nM, respectively. 
The benzimidazole derivatives clearly exhibit exceptional inhibitory activity against 
PARP, and are among the most potent inhibitors known to date. 
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Figure 7.6.1 Results of inhibition studies with benzimidazoles 
NH2 
Compound No. Structure KI value 
(House No. ) 
R 
(nM) 
134 
(NU 1109) Cl -a cl 
- 3.3 ± 0.7 
OH 
139 
(NU 1117) 4.8 ± 0.8 
147 - 
N(CH3)2 5.1 ± 0.7 (NU1111) ýý 
149 
(NU1116) 
- 
CO2Et 5.3±0.6 
151 O 
5.6 ± 0.4 
(NU 1118) 
0 
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Figure 7.6.1 continued 
Compound No. Structure K; value 
(House No. ) 
R 
(nM) 
109 
OH ý 6t1.3 
(NU1085) 
143 OCH3 
- 6.2 t 0.3 (NU1114) OCH3 ý 
OCH3 
141 
(NU1113) OH -d -OH 
13±1.5 
157 - 
OP(O)(OBn)2 66 t 18 
(NU1115) ý 
H3CO 
137 
(NU1110) 
ý 
124 t 49 
OCH3 
145 
(NU1112) 
*OCH3 
128 t 22 
OCH3 
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7.7 Results from Kinetic Experiments 
Kinetic studies were conducted with the quinazolinone NU 1025 (37) to determine the 
nature of PARP inhibition by the compound. The results showed that NU 1025 increased 
the KM for NAD+ and decreased the V,,, ax of PARP, which indicates that the predominant 
nature of the inhibitor is competitive but with a `mixed-type' inhibition component 311 
This was found to be the case using both permeabilised cell assays and purified `Super' 
PARP* assays 311 Figure 7.7 shows the KM and V,,, ax values determined for the NU1025 
in the permeabilised cell and `Super' PARP assays. 311 
Figure 7.7 Results of kinetic analysis of NU1025 (37) 
i) Permeabilised cell assay: 
Km (µM) Vmax 
Control 617 1049 
0.4 µM NU 1025 854 760 
ii) Purified PARP assay: 
Kni (µM) Vmpx 
Control 170 1115 
0.3 µM NU 1025 220 786 
Carries a mutation at residue Leu 713 (Leucine-*Phenylalanine) 
152 
Chapter Seven: Biological Results and Discussion 
7.8 Summary 
From the results of inhibition studies carried out with the quinazolinone derivatives, it is 
clear that the majority of the compounds are effective PARP inhibitors. The potency of 
compounds 57 and 85 indicate that the electronic nature of the 4'-substituent may not be 
important with regard to interactions with the enzyme active site. Methylation of the N3- 
position, as in compounds 91 and 92, resulted in a significant decrease in inhibitory 
activity, as would be expected on the basis of previously determined structure-activity 
requirements. The diphenyl and dibenzyl phosphate derivatives 95 and 98 were found to 
be relatively inactive against PARP. However, these derivatives are insoluble in aqueous 
media and, as such, are of limited use. 
NU1025 (37), has been shown to potentiate the effects of a range of mechanistically 
diverse anticancer agents. 264'311 The inhibitor is relatively non-toxic alone and effective 
in micromolar concentrations, compared to the millimolar concentrations of benzamide 
(6)/3AB (8) needed to achieve the same effects. These data suggest that NU1025 has the 
potential to be developed as a clinical agent to be used in conjunction with existing 
anticancer treatments. The most suitable DNA-damaging agents for the preclinical 
evaluation of PARP inhibitors appear to be monofunctional alkylating agents 
(temozolomide and MTIC), y-irradiation, bleomycin and topoisomerase I inhibitors but 
not antimetabolites or topoisomerase II inhibitors 264,311 
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Chapter Eight: Experimental 
8.1 Index of Compounds Synthesised Page No. 
40 3-Methoxy-2-nitrobenzamide 
41 3-Methoxy-2-aminobenzamide 
43 3-Methyl-2-nitrobenzamide 
44 3-Methyl-2-aminobenzamide 
45 3-Methoxy-2-N-acetylaminobenzamide 
46 8-Methoxy-2-methylquinazolin-4-[3H]-one 
48 2,8-Dimethylquinazolin-4- [3H] -one 
37 8-Hydroxy-2-methylquinazolin-4-[3H]-one 
49 3-Methoxy-2-N-benzoylaminobenzamide 
50 3-Methyl-2-N-benzoylaminobenzamide 
51 8-Methoxy-2-phenylquinazolin-4- [3 H] -one 
52 8-Methyl-2-phenylquinazolin-4- [3H] -one 
53 8-Hydroxy-2-phenylquinazolin-4-[3H]-one 
55 8-Methoxy-2-(4'-nitrophenyl)quinazolin-4-[3H]-one 
57 8-Methyl-2-(4'-nitrophenyl)quinazolin-4-[3H]-one 
38 8-Hydroxy-2-(4'-nitrophenyl)quinazolin-4-[3H]-one 
59 8-Methoxy-2-(4'-trifluoromethylphenyl)quinazolin-4- [3 H] -one 
61 8-Methyl-2-(4'-trifluoromethylphenyl)quinazolin-4- [3H] -one 
62 8 -Hydroxy-2-(4'-trifluoromethylphenyl)quinazolin-4- [3 H] -one 
63 4-Cyanobenzoyl chloride 
65 8-Methoxy-2-(4'-cyanophenyl)quinazolin-4-[3H]-one 
66 3-Methyl-2-N-(4'-cyanobenzoyl)aminobenzamide 
67 8-Methyl-2-(4'-cyanophenyl)quinazolin-4-[3H]-one 
68 8-Hydroxy-2-(4'-cyanophenyl)quinazolin-4-[3H] -one 
71 8-Methoxy-2-(4'-carboxyphenyl)quinazolin-4 [3H]-one 
162 
162 
163 
163 
164 
164 
165 
166 
166 
167 
167 
168 
168 
169 
169 
170 
171 
171 
172 
172 
173 
173 
174 
174 
175 
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72 8-Methyl-2-(4'-carboxyphenyl)quinazolin-4 [3 H] -one 
73 8-Methoxy-2-(4'-carboxamidophenyl)quinazolin-4 [3H] -one 
74 8-Methyl-2-(4'-carboxamidophenyl)quinazolin-4 [3H] -one 
76 8-Methyl-2-(4'-methoxycarbonylphenyl)quinazolin-4[3H]-one 
82 3-Methoxy-2-N-(4'-methoxybenzoyl)aminobenzamide 
84 8-Methoxy-2-(4'-methoxyphenyl)quinazolin-4-[3H]-one 
85 8-Methyl-2-(4'-methoxyphenyl)quinazolin-4-[3H]-one 
86 8-Hydroxy-2-(4'-hydroxyphenyl)quinazolin-4-[3H] -one 
87 8-Methyl-2-(4'-hydroxyphenyl)quinazolin-4-[3H]-one 
88 8-Methoxy-2-(4'-aminophenyl)quinazolin-4-[3H] -one 
89 8-Methyl-2-(4'-aminophenyl)quinazolin-4-[3H]-one 
90 8-Hydroxy-2-(4'-aminophenyl)quinazolin-4-[3H]-one 
91 8-Methoxy-3-N-methyl-2-methylquinazolin-4-[3H]-one 
92 8-Hydroxy-3-N-methyl-2-methylquinazolin-4-[3H]-one 
93 8-0-(Glycine carbamate ethyl ester)-2-methylquinazolin-4-[3H]-one 
94 8-0-(Glycine carbamate)-2-methylquinazolin-4-[3H]-one 
95 8-(O-Diphenylphosphoryl)-2-methylquinazolin-4-[3H]-one 
96 Attempted preparation of 8-(O-phosphoryl)-2-methylquinazolin-4-[3H]-one 
97 Dibenzyl phosphorochloridate 
98 8 -(O-Dibenzylphosphoryl)-2-methylquinazolin-4-[3H] -one 
96 8-Methyl-2-(4'-O-dibenzylphosphorylphenyl)quinazolin-4- [3 H] -one 
99 8-Methyl-2-(4'-O-dibenzylphosphorylphenyl)quinazolin-4-[3H] -one 
104 Methyl 2-amino-3-nitrobenzoate 
105 Methyl 2,3-diaminobenzoate 
117 Methyl2-amino-3-N-(4'-methoxybenzoyl)aminobenzoate 
118 Methyl 2,3-N, N-bis-(4'-methoxybenzoyl)aminobenzoate 
119 Methyl 2,3-diaminobenzoate hydrochloride salt 
120 Methyl 2-(4'-methoxyphenyl)-1H-benzimidazole-4-carboxylate acetate salt 
121 2-(4'-Methoxyphenyl)-1 H-benzimidazole-4-carboxamide 
175 
176 
176 
177 
178 
178 
179 
179 
180 
180 
181 
181 
182 
183 
183 
184 
185 
185 
186 
186 
187 
188 
189 
190 
190 
191 
191 
192 
192 
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109 2-(4'-Hydroxyphenyl)-1H-benzimidazole-4-carboxamide 193 
126 Isonitrosoacet-o-nitroanilide 194 
127 Attempted preparation of 7-nitroisatin 194 
133 2-(4'-Chlorophenyl)-1H-benzimidazole-4-carboxylate 195 
134 2-(4'-Chlorophenyl)-1H-benzimidazole-4-carboxamide 195 
135 2-(4'-Hydroxyphenyl)-1H-benzimidazole-4-carboxylate 196 
109 2-(4'-Hydroxyphenyl)-1H-benzimidazole-4-carboxamide 196 
136 2-(2'-Methoxyphenyl)-1H-benzimidazole-4-carboxylate 197 
137 2-(2'-Methoxyphenyl)-1H-benzimidazole-4-carboxamide 197 
138 2-(2'-Hydroxyphenyl)-1H-benzimidazole-4-carboxylate 198 
139 2-(2'-Hydroxyphenyl)-1H-benzimidazole-4-carboxamide 198 
140 2-(4'-Hydroxyphenyl-3'-methoxy)-1H-benzimidazole-4-carboxylate 199 
141 2-(4'-Hydroxyphenyl-3'-methoxy)-1H-benzimidazole-4-carboxamide 199 
142 2-(3', 4'-Dimethoxyphenyl)-1H-benzimidazole-4-carboxylate 200 
143 2-(3', 4'-Dimethoxyphenyl)-1H-benzimidazole-4-carboxamide 200 
144 2-(3', 4', 5'-Trimethoxyphenyl)-1H-benzimidazole-4-carboxylate 201 
145 2-(3', 4', 5'-Trimethoxyphenyl)-1H-benzimidazole-4-carboxamide 201 
146 2-(4'-NN-Dimethylaminophenyl)-1H-benzimidazole-4-carboxylate 202 
147 2-(4'-NN-Dimethylaminophenyl)-1H-benzimidazole-4-carboxamide 202 
148 2-(4'-Ethoxycarbonylphenyl)-1H-benzimidazole-4-carboxylate 203 
149 2-(4'-Ethoxycarbonylphenyl)-1H-benzimidazole-4-carboxamide 203 
150 2-(3', 4'-Methylenedioxyphenyl)-1H-benzimidazole-4-carboxylate 204 
151 2-(3', 4'-Methylenedioxyphenyl)-1H-benzimidazole-4-carboxamide 204 
155 N, N-Diisopropyl-O-benzylisourea 205 
156 4-Benzyloxycarbonylbenzaldehyde 205 
157 2-(4'-O-Dibenzylphosphorylphenyl)-1H-benzimidazole-4-carboxamide 206 
159 2-(4'-O-Phosphorylphenyl)-1H-benzimidazole-4-carboxamide ammonium salt 207 
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8.2 General Experimental Details 
Analytical Procedures 
Melting points are uncorrected and were determined with a Kofler hot stage apparatus. 
Elemental combustion analyses were carried out, in house, on a Carlo-Erba Instrumentazione 
1106 analyser or were performed by Butterworths Laboratories Ltd, 54-56 Waldegrave Road, 
Teddington, Middlesex, TW 11 8LG. The figures given are within ± 0.4% of theory unless 
otherwise specified. 
Infrared spectra were recorded using samples mounted in potassium bromide discs, on a 
Nicolet 20 PC Fourier Transform spectrometer. 
Proton ('H) and carbon ("C) nuclear magnetic resonance (NMR) spectra were recorded at 200 
MHz and 50 MHz, respectively, on a Bruker WP 200 Spectrometer, employing 
tetramethylsilane (TMS) as internal standard. Spectra were obtained in deuteriated 
dimethylsulphoxide (d6-DMSO) and exchangeable protons were `removed' using a deuterium 
oxide (D20) `shake'. Abbreviations for multiplicity of peaks in spectra include: s (singlet), d 
(doublet), dd (double-doublet), t (triplet), q (quartet), m (multiplet), br (broad) and 
combinations thereof. Chemical shift values are quoted in parts per million (ppm). Coupling 
constants (J) are given in Hertz (Hz). 'H NMR spectra of para-disubstituted aromatic rings 
were observed as the required AA'BB' pattern and are quoted, for simplicity, as doublets. 
Mass spectra were recorded using either electron impact (EI) or fast atom bombardment 
(FAB) techniques (see main text), on a Kratos MS80 RF Spectrometer. FAB spectra were 
obtained using a meta-nitrobenzyl alcohol matrix. 
Reagents and Solvents 
Reagents were purchased from Aldrich Chemical Company, Fluka Chemie AG or Lancaster 
Synthesis Ltd. Where appropriate, experimental procedures were carried out under a positive 
pressure of nitrogen. Ethyl acetate (EtOAc), dichloromethane (DCM) and petrol (in the 
boiling range 40-60 °C) were redistilled prior to use. Dry solvents were prepared as 
required:... Tetrahydrofuran (THF) and ether were distilled from sodium/benzophenone and 
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used immediately. Methanol (MeOH) and ethanol (EtOH) were dried using 
magnesium/iodine and distilled. Acetonitrile (MeCN) and triethylamine (NEt3) were pre- 
dried with calcium hydride (CaH2) and distilled. Pyridine was distilled from CaH2 and stored 
over potassium hydroxide pellets. N, N-diisopropylethylamine (Hunig's base) was distilled 
from ninhydrin. Unless otherwise stated, dry solvents were stored until required over 3A or 
4A molecular sieves under nitrogen. 
Chromatography 
Thin layer chromatography (TLC) was carried out using Merck 1.05554 aluminium plates, 
pre-coated with silica gel 60F254, and a variety of mobile phases. TLC plates were visualised 
using short wave (254 nm) and long wave (365 nm) ultraviolet light. Silica gel (Fison's 
Matrix Silica 60) was used for column chromatography procedures, which were carried out 
either at medium pressure or under gravity (see main text for solvent systems). 
Pressure Reaction 
A sealed pressure vessel was required for the reaction involving liquid ammonia at 40 atm. 
The vessel was designed and built in the mechanical engineering workshops in the 
Department of Chemistry, University of Newcastle upon Tyne. 
8.3 Standard Procedures 
For convenience, standard procedures have been given, as similar procedures were employed 
for important reactions concerning the synthesis of precursors and derivatives of the 
quinazolin-4-[3H]-ones and 2-arylbenzimidazoles. Variations from these procedures and 
purification methods are given in the main text. 
Standard Procedure A: Preparation of 3-Substituted-2-N-Substituted Aminobenzannides. 
The appropriate 3-substituted-2-aminobenzamide (1 equivalent, 3.0-6.7 mmol) was dissolved 
in dry THE with dry pyridine (1.3 equivalents) and stirred under nitrogen at room temperature. 
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The required acid chloride (1-1.5 equivalents) was dissolved in dry THE and added dropwise 
to the reaction mixture, which was stirred at room temperature until TLC indicated the 
absence of starting material (further equivalents of acid chloride were added to achieve this in 
some cases). The solvents were removed under reduced pressure and the remaining white 
slurry was filtered and washed with sodium bicarbonate solution and water. The product was 
purified by column chromatography and/or recrystallisation from suitable solvents. 
Standard Procedure B: Quinazolinone Ring Formation under Basic Conditions. 
The starting material (0.4-1.6 mmol) was suspended in aq. NaOH solution of appropriate 
strength and stirred until complete dissolution was obtained (with warming, if necessary). 
The solution was neutralised (pH 7) by careful addition of conc. HCl and the resulting 
precipitate was collected by filtration and washed with water. The product was purified by 
recrystallisation from suitable solvents. 
Standard Procedure C: Preparation of Substituted Quinazolin-4 [3H]--ones from 3- 
Substituted-2-aminobenzamides. 
The appropriate 3-substituted-2-aminobenzamide (1 equivalent, 1.2-9.0 mmol) was dissolved 
in dry THF. Dry pyridine (1.3 equivalents) was added and the solution was stirred under 
nitrogen at room temperature. The required acid chloride (1-1.5 equivalents) was dissolved in 
dry THE and added dropwise to the reaction mixture, which was stirred at room temperature 
until TLC indicated the absence of starting material (further equivalents of acid chloride were 
added to achieve this in some cases). The solvents were removed under reduced pressure and 
the remaining residue was resuspended in aq. NaOH solution of appropriate strength and 
stirred until complete dissolution was obtained (with warming, if necessary). The solution 
was neutralised (pH 7) by careful addition of conc. HCl and the resulting precipitate was 
collected by filtration and washed with water. The product was purified by column 
chromatography and/or recrystallisation from a suitable solvent. 
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Standard Procedure D: Lewis Acid-Catalysed Demethylation of 8-Methoxy-2-substituted 
Qunnazolin-4 [3H1--one Derivatives. 266 
The appropriate 8-methoxy-2-substituted quinazolin-4-[3H] -one (1 equivalent, 0.3-3.7 mmol) 
was suspended in a 1.0 M solution of BBr3 in DCM (1 equivalent/methoxy group +1 
equivalent/atom bearing lone pairs) and stirred under gentle reflux for up to 48 hours. Once 
TLC indicated the absence of starting material, the solvent was directly distilled from the 
reaction vessel and the solid residue was cautiously redissolved in 10% aq. NaOH solution. 
After at least 2 hours, the solution was neutralised (pH 7) by the careful addition of conc. HCI. 
The product was extracted into ethyl acetate (EtOAc) and washed with water: in some cases it 
was possible to collect most of the product by filtration after neutralisation, and the remaining 
aq. layer was extracted with EtOAc. The organic layer was dried (Na2SO4), filtered and the 
product was obtained by removal of the solvent under reduced pressure. The product was 
purified by column chromatography and/or recrystallisation from suitable solvents. 
Standard Procedure E: Preparation of 2-Substituted Benzimidazole-4-Carboxylic Acids . 
303 
A solution of 3-nitroanthranilic acid (1 equivalent, 4.1-27.0 mmol)) and NaOH (1.1 
equivalents) in water was hydrogenated (Pd/C/H2) until no further hydrogen uptake was 
observed. The catalyst was removed by filtration through Celite and the filtrate was acidified 
(pH 4-5) with glacial acetic acid. A solution of the appropriate aldehyde (1.4 equivalents) in 
methanol was added, followed by a solution of cupric acetate (1.4 equivalents) in water. The 
resulting mixture was stirred vigorously, heated briefly to boiling and filtered hot. The 
precipitate was washed with water and dissolved in ethanol containing conc. HCl (1 ml 
HCl/20 ml ethanol). A solution of Na2S' (1.4 equivalents) in water was added (keeping the 
solution acidic by addition of more HC1 if necessary), and the mixture was filtered hot through 
Celite, to remove the copper sulfide. The pH of the filtrate was adjusted to 5-6 and diluted 
with water. The ethanol was removed under reduced pressure and the pH of the aq. layer was 
adjusted to 4-5. The crude product was collected by filtration, and washed with water. The 
Extreme Caution: Na2S in acidic media generates the highly toxic gas H2S. 
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crude product was dissolved in 0.5 M NaOH solution and extracted with EtOAc. The pH of 
the aq. layer was adjusted to 4-5 and the precipitate was collected by filtration and washed 
with water. The product was either purified by column chromatography and/or 
recrystallisation from suitable solvents, or used crude. 
Standard Procedure F: Synthesis of 2 -Aryl Benzimidazole-4-Carboxamides. 
The appropriate benzimidazole-4-carboxylate (1 equivalent, 0.4-3.9 mmol) was suspended in 
dry THE Thionyl chloride (1.5 equivalents) and 2 drops of dry DMF were added and the 
reaction mixture was stirred at room temperature and monitored by TLC (adding further 
equivalents of thionyl chloride if necessary). Once TLC indicated the absence of starting 
material, the reaction mixture was added dropwise to an excess of stirred aq. ammonia 
solution. After 30 minutes, the volatiles were removed under reduced pressure and the 
remaining aq. slurry was filtered to give the crude product, which was washed thoroughly 
with water. The product was purified by column chromatography and/or recrystallisation 
from suitable solvents. 
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8.4 Quinazolinone Experimental Procedure 
40 3-Methoxy-2-nitrobenzamide 
3-Methoxy-2-nitrobenzoic acid 39 (3.0 g, 15 mmol) was dissolved 
in dry THE (50 ml). Thionyl chloride (1.7 ml, 23 mmol) was 
added, with 2 drops of DMF and the reaction mixture was stirred 
for 12 hours under nitrogen at room temperature. The reaction 
mixture was added dropwise to an excess of conc. ammonia 
solution (18 ml) and a cream precipitate formed. After 15 minutes, most of the solvent was 
removed under vacuum. The remaining slurry was filtered and the cream product was washed 
with ice-cold water (2.9 g, 15 mmol, 97%), m. p. 219-222 °C (lit. m. p265 212.5-213.0 °C). 
Anal. found C 49.03, H 3.93, N 13.97, CgH8N204 requires C 48.98, H 4.11, N 14.28%; 
uma, /cm 13347 and 3179 (br, 1° amide NH), 2802 (OCH3)9 1672 (C=0), 1535 (NO2); 6H (200 
MHz, d6-DMSO) 4.01 (s, 3H, -OCH3), 7.41-7.46 (dd, 1H, Ar-4H, J= 1.2,7.6), 7.55-7.60 (dd, 
1 H, Ar-6H, J=1.1,8.5), 7.69-7.77 (t, 1 H, Ar-5H, J=7.7), 7.84 (s, 1 H, -NH), 8.31 (s, 1 H, - 
NH); 6C (d6-DMSO) 57.15 (-OCH3), 116.21,119.99 (Ar-4/5C), 129.83 (Ar-1C), 131.79 (Ar- 
6C), 150.78 (Ar-2C), 165.82 (C=O); m/z (EI) 196 (M+, 100%), 180 ([M-O]+), 149 ([M- 
OCHSO]+). 
41 3-Methoxy-2-aminobenzamide 
3-Methoxy-2-nitrobenzamide 40 (1.4 g, 7.1 mmol) was dissolved in 
dry methanol (80 ml) containing suspended 10% palladium-carbon 
catalyst (150 mg). The reaction vessel was placed under an 
atmosphere of hydrogen, at ambient temperature and pressure, until 
no further hydrogen absorption was observed. The catalyst was 
removed by filtration through Celite to leave a colourless solution. The solvent was removed 
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under vacuum to afford the title compound as a pale pink solid (1.2 g, 7.0 mmol, 99%), m. p. 
145-147 °C (lit. m. p 263 146-147 °C). 
Anal. found C 57.54, H 5.99, N 16.61, CBHI0N202 requires C 57.82, H 6.07, N 16.86%; 
Um,, /CM-'3473 (NH), 3365 (NH), 3332 and 3149 (br, 1° amide NH), 2832 (OCH3)9 1669 and 
1617 (C=O); SH (200 MHz, d6-DMSO) 3.88 (s, 3H, -OCH3), 6.40 (s, 2H, -NH2), 6.54-6.62 (t, 
1H, Ar-5H, J= 8.0), 6.96-6.99 (dd, 1H, Ar-4H, J= 7.8), 7.23 (s, 1H, -NH), 7.29-7.33 (dd, 1H, 
Ar-6H, J= 1.0,7.2), 7.85 (s, 1H, -NH); mlz (EI) 166 (M+, 100%), 149 ([M-NH3]+), 134 ([M- 
NH2OCH3]+). 
43 3-Methyl-2-nitrobenzamide 
Prepared in a similar way to compound 40 from 3-methyl-2- 
nitrobenzoic acid 42 (2.0 g, 11.0 mmol) to give the product as a 
cream solid. 
Yield : 1.9 g, 10.0 mmol, 95%, m. p. 198-199 °C. 
Anal. found C 53.28, H 4.30, N 15.25, C$H8N2O3 requires C 53.33, 
H 4.48, N 15.55%; umax/cm'' 3372 and 3179 (br, 1* amide NH), 
2969,2931 and 2879 (CH3), 1651 and 1620 (C=0), 1527 (NO2); 8H (200 MHz, d6-DMSO) 
2.37 (s, 3H, -CH3), 7.66 (s, 3H, Ar-4/5/6H), 7.79 (s, 1H, -NH), 8.30 (s, 1H, -NH); m/z (EI) 
180 (M+, 100%), 164 ([M-O]+), 77 (Ph). 
44 3-Methyl-2-aminobenzamide 
Prepared in a similar way to compound 41 from 3-methyl-2- 
nitrobenzamide 43 (1.2 g, 6.7 mmol) to give the product as a cream 
solid. 
Yield : 0.97 g, 6.4 mmol, 97%, m. p. 145-147 °C. 
Anal. found C 63.36, H 6.55, N 18.20, C8H10N2O requires C 63.98, 
H 6.71, N 18.66%; v, nax/cm'' 
3468 (NH), 3391 and 3190 (br, 1° amide NH), 2981 (CH; ), 1641 
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and 1608 (C=0); SH (200 MHz, d6-DMSO) 2.18 (s, 3H, -CH3), 6.52-6.59 (t, 1H, Ar-5H, J= 
6.6,7.7), 7.15-7.19 (d, 1H, Ar-4H, J= 7.0), 7.51-7.55 (d, 1H, Ar-6H, J= 7.8), 7.85 (s, 1H, - 
NH); m/z (EI) 150 (M+, 55%), 133 ([M-NH3]+), 105 (PhC=O+), 77 (Ph+). 
45 3-Methoxy-2-N-acetyl aminobenzamide 
Prepared according to Standard Procedure A from 3-methoxy- 
2-aminobenzamide 41 (0.5 g, 3.0 mmol) and acetyl chloride (0.2 
ml, 3.3 mmol). The product was recrystallised from 
methanol/water to give a white crystalline solid (0.19 g, 0.9 
mmol, 31 %), m. p. 243-246 °C. 
Anal. found C 56.98, H 5.38, N 12.78, C1OH12N203.0.15 mol. H2O requires C 56.94, H 5.88, N 
13.28%; umax/cm' 3424 (NH), 3249 and 3160 (br, 1° amide NH), 2970 (CH3), 2844 (OCHS)9 
1660 (C=O); 6H (200 MHz, d6-DMSO) 2.05 (s, 3H, -CH3), 3.88 ( s, 3H, -OCH3), 7.14-7.18 
(dd, 1H, Ar-4H, J= 1.4,7.5), 7.21-7.25 (dd, 1H, Ar-6H, J= 1.4,7.6), 7.33-7.41 (m, 2H, -NH 
and Ar-5H), 7.53 (s, 1H, -NH), 9.27 (s, 1H, -NH); m/z (EI) 208 (M+, 17%), 190 ([M-H20]+), 
166 ([M-COCH2]+). 
46 8 Methoxy-2-methylquinazolin-4-[3H]--one 
A. Prepared according to Standard Procedure B from 3- 
methoxy-2-N-acetyl aminobenzamide 45 (0.07 g, 0.34 mmol), in 
2% aq. NaOH solution (2 ml) at room temperature (2 hours). 
The crude product was recrystallised from the minimum amount 
of boiling ethyl acetate to give white crystals (0.04 g, 0.22 
mmol, 67%), m. p. 202-204 °C (sublimation). 
B. Prepared according to Standard Procedure C from 3-methoxy-2-aminobenzamide 41 
(1.5 g, 9.0 mmol) and acetyl chloride (1.4 ml, 19.9 mmol). The product was recrystallised 
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from methanol/water to give white crystals (1.67 g, 8.8 mmol, 97%), m. p. 202-204 °C 
(sublimation). 
Anal. found C 62.36, H 5.29, N 14.36, C10H10N2O2.0.1 mol. H2O requires C 62.55, H 5.25, N 
14.59%; umJcm-' 3171 and 3034 (2° amide NH), 2903 (CH3), 2793 (OCH3), 1676 (C=0); SH 
(200 MHz, d6-DMSO) 2.43 (s, 3H, -CH3), 3.97 (s, 3H, -OCH3), 7.37-7.41 (dd, 1H, Ar-7H, J= 
1.9,8.0), 7.42-7.50 (t, 1 H, Ar-6H, J=7.8), 7.68-7.73 (dd, IH, Ar-5H, J=1.9,7.6); 6C (d6- 
DMSO) 21.83 (-CH3), 56.05 (-OCH3), 114.96,116.99 (Ar-6/7C), 121.95 (C-CH3), 126.5 (Ar- 
5C), 140.0 (Ar-8aC), 153.26 (Ar-8C), 154.33 (Ar-4aC), 162.04 (C=O); m/z (EI) 190 (M+, 
96.6%), 189 ([M-H]+), 160 ([M-OCH2]+). 
48 2,8-Dimetliylquinazolin-4 [3H]-one 
Prepared according to Standard Procedure C from 3-methyl-2- 
aminobenzamide 44 (0.5 g, 3.3 mmol) and acetyl chloride (0.36 
ml, 5.0 mmol). The product was isolated as white crystals after 
recrystallisation from methanol/water (0.47 g, 2.7 mmol, 81%), 
m. p. 217-220 °C. 
Anal. found C 68.76, H 5.57, N 15.90, CIOHION2O requires C 
68.94, H 5.79, N 16.08%; umax/cm-' 3171 (2° amide NH), 2905 and 2871 (CH3), 1683 (C=O); 
8H (200 MHz, d6-DMSO) 2.44 (s, 3H, -CH3), 2.57 (s, 3H, -CH3), 7.36-7.44 (t, 1H, Ar-6H, J= 
7.6), 7.68-7.72 (dd, 1H, Ar-7H, J= 0.7,7.3), 7.97-8.01 (dd, 1H, Ar-5H, J= 0.7,7.4), 12.25 (s, 
1H, -NH); m/z (EI) 174 (M+, 100%), 143 ([M-CH3CH3H]+), 77 (Ph). 
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37 8-Hydroxy-2-methylquinazolin-4 [3H]--one 
Prepared according to Standard Procedure D from 8-methoxy-2- 
methylquinazolin-4-[3H]-one 46 (0.7 g, 3.7 mmol). The product 
was recrystallised from propan-2-ol/water to give pale purple 
crystals (0.42 g, 2.4 mmol, 65%), m. p. 253-258 °C. 
Anal. found C 61.39, H 4.54, N 15.88, C9H8N2O2 requires C 61.36, 
H 4.58, N 15.91%; um/cm' 3320 (OH), 3175 and 3142 (2° amide NH), 2909 (CH3), 1671 
(C=0); SH (200 MHz, d6-DMSO) 2.48 (s, 3H, -CH3), 7.22-7.27 (dd, 2H, Ar-7H, J= 1.5,7.8), 
7.28-7.41 (t, l H, Ar-6H, J= 7.8), 7.57-7.63 (dd, IH, Ar-5H, J= 1.5,7.8), 9.57 (s, IH, -OH), 
12.26 (s, 1H, -NH); Sc (d6-DMSO) 21.72 (-CH3), 115.78,118.42 (Ar-6/7C), 121.76 (C-CH3)9 
126.54 (Ar-5C), 138.27 (Ar-8aC), 152.58 (Ar-8C), 152.87 (Ar-4aC), 162.05 (C=0); m/z (EI) 
176 (M, 100%), 163 ([M-CHI'), 133 ([M-NHCHCH3]+) 
49 3-Methoxy-2-N-benzoylaminobenzamide 
Prepared according to Standard Procedure A from 3- 
methoxy-2-aminobenzamide 41 (0.5 g, 3.0 mmol) and 
benzoyl chloride (0.4 ml, 3.3 mmol). The product (0.25 g) 
was recrystallised from methanol/water to give white 
crystals (0.20 g, 0.75 mmol, 41%), m. p. 176-180 °C. 
Anal. found C 65.75, H 5.07, N 9.67, C15H14N203.0.2 mol. 
H2O requires C 65.76, H 5.30, N 10.23%; u, mJcm 
' 3489 (NH), 3436 (NH), 3304 (br, 1° 
amide NH), 2839 (OCH3), 1666 (C=O); SH (200 MHz, d6-DMSO) 3.88 (s, 3H, -OCH3), 7.24- 
7.32 (m, 2H, Ar-4/6H), 7.41-7.49 (d, 1H, Ar-5H, J=7.4), 7.49 (s, 1H, -NH), 7.59-7.73 (m, 
4H, -NH, Ph-3'/4'/5'H) 8.04-8.08 (dd, 2H, Ph-2'/6'H, 
J= 7.8), 9.85 (s, 1H, -NH); m/z (EI) 270 
(M+, 74.6%), 252 ([M-H2O]+), 239 ([M-OCHS]+), 105 (PhC=O+), 77 (Ph+). 
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50 3 Methyl-Z-N-benzoylaminobenzamide 
Prepared according to Standard Procedure A from 3- 
methyl-2-aminobenzamide 44 (0.5 g, 3.3 mmol) and 
benzoyl chloride (0.43 ml, 3.6 mmol). The product was 
recrystallised from methanol/water and recovered as white 
crystals (0.62 g, 2.5 mmol, 74%), m. p. 190-193 °C. 
Anal. found C 70.19, H 5.39, N 10.53, C1SH14N2O2.0.1 mol. 
H2O requires C 70.35, H 5.59, N 10.94%; umax /cm-' 3369 (NH), 3319 (NH), 3193 (br, 10 
amide NH), 3023,2963,2923 (CH3), 1657 (C=0); 8H (200 MHz, d6-DMSO) 2.33 (s, 3H, - 
CH3), 7.33-7.40 (t, 1H, Ar-5H, J= 7.5), 7.49-7.60 (m, 3H, -NH and Ar-4/6H), 7.63-7.71 (m, 
3H, Ph-37475'H), 7.84 (s, IH, -NH), 8.04-8.09 (dd, 2H, Ph-2'/6'H, J=1.6,7.9), 10.34 (s, 1H, 
-NH); m/i (EI) 254 (M+, 23.5%), 237 ([M-OH]), 105 (PhC=O+), 77 (Ph'). 
51 8-Methoxy-2 phenylquinazolin-4-[3H]-one 
A. Prepared according to Standard Procedure B from 3- 
methoxy-2-N-benzoylaminobenzamide 49 (0.2 g, 0.74 
mmol), in 2% aq. NaOH solution (2 ml) at room 
temperature (12 hours). The product was isolated as white 
crystals after recrystallisation from methanol/water (0.12 g, 
0.48 mmol, 65%), m. p. 252-256 °C. 
B. Prepared according to Standard Procedure C from 3-methoxy-2-aminobenzamide 41 
(1.0 g, 6 mmol) and benzoyl chloride (0.8 ml, 6.6 mmol). The product was recrystallised from 
methanol/water to give white crystals (1.2 g, 4.5 mmol, 75%), m. p. 252-256 °C. 
Anal. found C 71.38, H 4.39, N 11.17, C15H12N202 requires C 71.42, H 4.79, N 11.10%; 
umax/cm' 3191 and 3162 (2° amide NH), 2836 (OCHE), 1662 (C=0); 6H (200 MHz, d6- 
DMSO) 4.06 (s, 3H, -OCH3), 7.47-7.61 (m, 2H, Ar-6/7H), 7.63-7.69 (m, 3H, Ph-3'/4'/5'H), 
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7.80-7.85 (dd, 1H, Ar-5H, J= 1.8,7.5), 8.27-8.32 (m, 2H, Ph-2'/6'H) 12.70 (s, 1H, -NH); Wz 
(EI) 252 (M+, 100%), 251 ([M-H]+), 223 ([M-CHO]+), 77 (Ph+). 
52 8-Metl: yl-2 phenylquinazolin-4 [3H]-one 
Prepared according to Standard Procedure B from 3- 
methyl-2-N-benzoylaminobenzamide 50 (0.1 g, 0.4 mmol), 
in 2% aq. NaOH solution (25 ml) at room temperature (2 
hours). The product was recrystallised from methanol/water 
to give white crystals (0.07 g, 0.3 mmol, 72%), m. p. 206- 
209 °C. 
Anal. found C 75.39, H 4.99, N 11.81, C1SH12N20.0.1 mol. H20 requires C 75.67, H 5.17, N 
11.71%; u, n,, 
/cm 1 3165 (2° amide NH), 2954 and 2922 (CH3), 1675 (C=O); SH (200 MHz, 
d6-DMSO) 2.72 (s, 3H, -CH3), 7.45-7.53 (t, 1H, Ar-6H, J=7.6), 7.64-7.68 (dd, 3H, Ph- 
3'/4'/5'H, J= 2.0,5.2), 7.77-7.81 (d, IH, Ar-7H, J= 7.1), 8.07-8.10 (d, IH, Ar-5H, J= 7.1), 
8.30-8.35 (dd, 2H, Ph-2'/6'H, J= 7.9), 12.65 (s, 1H, -NH); m/z (EI) 236 (M+, 100%), 143 ([M- 
CH3Ph]+), 77 (Ph+). 
53 8-Hydroxy-2 phenylquinazolin-4 [3H]-one 
Prepared according to Standard Procedure D from 8- 
methoxy-2-phenylquinazolin-4- [3H] -one 51 (0.5 g, 2 
mmol). - The product (0.35 g) was recrystallised from 
propan-2-ol/water to give pale orange crystals (0.19 g, 0.75 
mmol, 67%), m. p. 280-284 °C. 
Anal. found C 69.54, H 4.05, N 11.46, C14H10N2O2.0.1 mol. 
H20 requires C 70.05, H 4.28, N 11.67%; v, n. 
/cm' 3380 (br, OH), 3152 and 3125 (2° amide 
NH), 1642 (C=O); SH (200 MHz, d6-DMSO) 7.33-7.37 (d, 1H, Ar-7H, J= 7.8), 7.42-7.50 (t, 
1H, Ar-6H, J= 7.8), 7.66-7.72 (m, 4H, Ar-5H, Ph-3'/4'/5'H), 8.51-8.54 (dd, 2H, Ph-2'/6'H, J= 
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7.1), 9.75 (br s, 1H, -OH), 12.60 (br s, 1H, -NH) ; 8C (d6-DMSO) 116.01,118.68 (Ar-6/7C), 
122.03 (C-Ph), 127.43-128.76 (Ph-1'/2'/3'/4'C), 131.50 (Ar-5C), 137.98 (Ar-SaC), 150.72 (Ar- 
8C), 153.31 (Ar-4aC), 162.62 (C=0); Wz (EI) 238 (M+, 100%), 77 (Ph). 
55 8 Methoxy-2-(4! nitrophenyl)quinazolin-4-[3HJ one 
Prepared according to Standard Procedure B, from 3- 
methoxy-2-N-(4'-nitrobenzoyl) aminobenzamide 54 
(0.5 g, 1.6 mmol) in 10% aq. NaOH solution at 100 °C 
(2 hours). The product (0.1 g) was recrystallised from 
DMF/water at 100 °C to give yellow crystals (0.66 g, 
0.2 mmol, 66%), m. p. 306-308 T. 
Anal. found C 59.16, H 3.92, N 13.99, CHN304.0.3 mol. H20 requires C 59.52, H 3.86, N 
13.87%; umax/cm' 3037 (2° amide NH), 2837 (OCHS)9 1686 (C=0), 1522 (NO2), 1348 (NO2); 
6H (200 MHz, d6-DMSO) 4.06 (s, 3H, -OCH3), 7.52-7.56 (d, 1H, Ar-7H, J= 8.0), 7.58-7.66 
(t, 1H, Ar-6H, J= 7.9), 7.82-7.86 (d, 1H, Ar-5H, J= 1.5,7.7), 8.50 (s, 4H, Ph-2'/3'/5'/6'H), 
12.95 (br s, 1H, -NH); m/z (EI) 297 (M+, 100%), 279 ([M-H20]+), 267 ([M-OCH2]"), 250 ([M- 
HNO2]+). 
57 8-Methyl-2-(4! nitrophenyl)quinazolin-4-13H]-one 
Prepared according to Standard Procedure C from 3- 
methyl-2-aminobenzamide 44 (0.5 g, 3.3 mmol) and 4- 
nitrobenzoyl chloride (0.93 g, 5.0 mmol). The product 
was isolated as a yellow crystalline solid from a 
saturated solution of aq. DMF, after stirring at 100 °C 
and carrying out a hot filtration (0.8 g, 2.9 mmol, 86%), 
m. p. 317-319 °C. 
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Anal. found C 64.54, H 3.91, N 14.91, C15HIIN303 requires C 64.05, H 3.94, N 14.94%; 
v.. /cm' 3088 (2° amide NH), 2924 and 2904 (CH3), 1683 (C=O), 1522 (NO2), 1350 (NO2); 
6H (200 MHz, d6-DMSO) 2.77 (s, 3H, -CH3), 7.54-7.61 (t, 1H, Ar-6H, J= 7.6), 7.84-7.88 (d, 
IH, Ar-7H, J=7.4), 8.12-8.16 (d, IH, Ar-5H, J=7.9), 8.49-8.53 (d, 2H, Ph-2'/6'H, J= 9.2), 
8.57-8.61 (d, 2H, Ph-3'/5'H, J= 9.2), 12.9 (s, 1H, -NH); m/z (EI) 281 (M`, 100%), 235 ([M- 
N0211,77 (Ph'). 
38 8-Hydroxy-2-(4'-nitrophenyl)quinazolin-4-[3H]-one 
Prepared according to Standard Procedure D from 8- 
methoxy-2-(4'-nitrophenyl)quinazolin-4-[3H] -one 55 
(0.2 g, 0.7 mmol). The product was isolated as a yellow 
crystalline solid after recrystallisation from propan-2- 
ol/water (0.07 g, 0.25 mmol, 38%), m. p. 321-323 °C. 
Anal. found C 56.79, H 2.74, N 13.58, C14H9N3O4 
requires C 59.36, H 3.20, N 14.84%; umax /cm' 3408 (OH), 3387 (2° amide NH), 1686 (C=0), 
1523 (NO2); SH (200 MHz, d6-DMSO) 7.35-7.39 (d, 1H, Ar-7H, J=7.7), 7.47-7.54 (t, 1H, 
Ar-6H, J= 7.8), 7.69-7.73 (d, 1H, Ar-5H, J= 7.6), 8.45-8.49 (d, 2H, Ph-2'/6'H, J= 8.8), 8.75- 
8.79 (d, 2H, Ph-3'/5'H, J=8.8), 9.98 (s, 1H, -OH), 12.85 (s, 1H, -NH); m/i (EI) 283 (M+, 
100%), 237 ([M-NO2]i), 143 ([M-OHPh-N021+). 
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59 8-Methoxy-2-(4'-triJ7uoromethylphenyl)quinazolin-4-[3H]-one 
Prepared according to Standard Procedure C from 3- 
methoxy-2-aminobenzamide 41 (0.2 g, 1.2 mmol) and 
4-trifluoromethylbenzoyl chloride (0.2 ml, 1.3 mmol). 
The product was recrystallised from methanol/water to 
give white crystals (0.25 g, 0.8 mmol, 64%), m. p. 287- 
289 °C. 
Anal. found C 59.89, H 3.37, N 8.69, C16H11N202F3 requires C 60.00, H 3.46, N 8.75%; 
ums/cm' 3116 (2° amide NH), 2843 (OCHS), 1660 (C=0); 6H (200 MHz, d6-DMSO) 4.06 (s, 
3H, -OCH3), 7.50-7.64 (m, 2H, Ar-6/7H), 7.81-7.84 (d, 1H, Ar-5H, J= 7.0), 8.02-8.06 (d, 2H, 
Ph-2'/6'H, J=8.4), 8.45-8.49 (d, 2H, Ph-3'/5'H, J=8.4), 12.91 (s, 1H, -NH); m/z (EI) 320 
(M+, 100%), 310 ([M-F]), 291 ([M-OCH2]+), 145 (C6H4CF3+) 
61 8-Methyl-2-(4'-tr7uoromethylphenyl)quinazolin-4 [3HJ-one 
Prepared according to Standard Procedure C from 3- 
methyl-2-aminobenzamide 44 (0.2 g, 1.3 mmol) and 4- 
trifluoromethylbenzoyl chloride (0.22 ml, 1.5 mmol). 
The product was obtained after recrystallisation from 
methanol/water as white crystals (0.26 g, 0.9 mmol, 
65%), m. p. 255-257 °C. 
Anal found C 63.06, H 3.33, N 9.21, C16H11N2OF3 requires C 63.15, H 3.64, N 9.21%; 
u.. /cm' 3175 (2° amide NH), 1666 (C=O), 1336 (C-F), 1320 (C-F); 5H (200 MHz, d6- 
DMSO) 2.75 (s, 3H, -CH, ), 7.56 (t, 1H, Ar-6H), 7.83 (d, 1H, Ar-7H), 8.08 (m, 3H, Ar-5H, 
Ph-3'/5'H), 8.51 (d, 2H, Ph-2'/6'H), 12.85 (s, 1H, -NH); m/z (EI) 304 (M+, 100%). 
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62 8-Hydroxy-2-(4'-trifluoromethylphenyl)quinazolin-4 -[3H]--one 
Prepared according to Standard Procedure D from 8- 
methoxy-2-(4'-trifluoromethylphenyl)quinazolin-4- 
[3H]-one 59 (0.1 g, 0.3 mmol). The product (51.8 mg) 
was purified by column chromatography, using 
EtOAc: petrol 40/60 (4: 6) to give the product as a pale 
orange solid (17.7 mg, 0.06 mmol, 19%). 
Anal. found C 54.41, H 3.15. N 7.91, CISH9N2O2F3.1.5 mol. HCI requires C 54.06, H 3.63, N 
8.41%; 6H (200 MHz, d6-DMSO) 7.32-7.37 (dd, 1H, Ar-7H, J=1.6,7.9), 7.44-7.52 (t, 1H, 
Ar-6H, J= 7.8), 7.67-7.71 (dd, 1H, Ar-5H, J=1.5,7.8), 8.00-8.05 (d, 2H, Ph-3'/5'H, J= 8.4), 
8.69-8.73 (d, 2H, Ph-2'/6'H, J= 8.1), 9.95 (br s, IH, -OH), 12.8 (br s, IH, -NH); m/z (EI) 306 
(M+, 100%), 172 ([M-PhF3]+). 
63 4-Cyanobenzoyl chloride 
4-Cyanobenzoic acid (1.0 g, 6.8 mmol) was suspended in thionyl 
chloride (5 ml) and the mixture was boiled under reflux for 2 
hours. The reaction mixture was cooled and the solvent was 
removed under water pressure to give a cream solid (1.04 g, 6.3 
mmol, 92%), m. p. 67-68 °C (64-65 °C)ZS' 
A small amount of product was converted to the corresponding methyl ester, for NMR 
analysis: 10 mg was dissolved in dry THE (5 ml) and stirred at room temperature. Methanol 
(3 ml) was added and the solution was stirred for 30 minutes. The solvent was removed under 
vacuum to leave a cream solid. 
6H (200 MHz, d6-DMSO - methyl 4-cyanobenzoate) 4.01 (s, 3H, -OCH3), 8.10-8.14 (dd, 2H, 
Ar-2/6H, J= 8.4), 8.19-8.23 (dd, 2H, Ar-3/5H, J= 8.0) 
' Figures given are not within 0.4% of theoretical values. 
172 
Chapter Eight: Experimental 
65 81tlethoxy-2-(4'-cyanophenyl)quinazolin-4-[3H]-one 
Prepared according to Standard Procedure C from 3- 
methoxy-2-aminobenzamide 41 (0.5 g, 3.0 mmol) and 
4-cyanobenzoyl chloride 63 (0.55 g, 3.3 mmol). The 
product (0.68 g) was purified by column 
chromatography, using DCM: MeOH (92: 8) as the 
eluent, to give a cream solid (0.28 g, 0.82 mmol, 27%), 
m. p. 306-309 °C. 
Anal. found C 66.19, H 4.16, N 14.13, C16HNS02.0.75 mol. H20 requires C 66.08, H 4.33, N 
14.45%; uma, r/cm' 
3413 (br, 2° amide NH), 2841 (OCH3), 2230 (CN), 1681 (CO); SH (200 
MHz, d6-DMSO) 4.05 (s, 3H, -OCH3), 7.48-7.53 (dd, 1H, Ar-7H, J=1.5,8.1), 7.55-7.63 (t, 
1 H, Ar-6H, J=7.8), 7.79-7.83 (dd, 1 H, Ar-5H, J=1.5,7.7), 8.12-8.15 (d, 2H, Ph-2'/6'H, J= 
8.5), 8.41-8.45 (d, 2H, Ph-3'/5'H, J= 8.5), 12.95 (s, 1H, -NH); m/z (EI) 277 (M', 63%), 248 
([M-OCH]+), 78 (PhH+). 
66 3-Methyl-2-N-(4 =cyanobenzoyl) aminobenzamide 
Prepared according to Standard Procedure A from 3- 
methyl-2-aminobenzamide 44 (1.0 g, 6.7 mmol) and 4- 
cyanobenzoyl chloride 63 (1.7 g, 10.0 mmol). The 
product was purified by column chromatography using 
DCM: MeOH (97: 3) as eluent to give a white solid (0.62 
g, 2.4 mmol, 36%), m. p. 299-301 °C. 
Anal. found C 68.51, H 4.35, N 14.66, C16H13N3O3 requires C68.80, H 4.69, N 15.05%; 
uma, ý/cml 
3431 (br, NH), 3191 (NH), 2969 (CH3), 2226 (CN), 1666 (C=0); 6H (200 MHz, d6- 
DMSO) 2.31 (s, 3H, CH3), 7.33-7.37 (d, 1H. Ar-7H, J=7.6), 7.41-7.53 (m, 3H, Ar-5/6H, - 
NH), 7.83 (s, 1H, -NH), 8.07-8.14 (d, 2H, Ph-2'/6'H, J=8.5), 
8.18-8.22 (d, 2H, Ph-3'/5'1I, J 
= 8.5); m/z (EI) 279 (M+, 6%), 234 ([M-CONH2]+). 
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67 8-Methyl-2-(4! cyanophenyl)quinazolin-4 [3HJ--one 
Prepared according to Standard Procedure C from 3- 
methyl-2-aminobenzamide 44 (0.39 g, 2.6 mmol) and 
4-cyanobenzoyl chloride 63 (0.48 g, 2.9 mmol). The 
product was purified by column chromatography, using 
DCM: MeOH (92: 8) as eluent to give a white solid (0.15 
g, 0.56 mmol, 21%), m. p. 330-332 °C. 
Anal. found C 73.27, H 4.16, N 15.89, C16H1IN30 requires C 73.55, H 4.24, N 16.09%; 
um. /cm' 3170 (2° amide NH), 2228 (CN), 1683 (C=O); 6H (200 MHz, d6-DMSO) 2.73 (s, 
3H, -CH3), 7.51-7.58 (t, IH, Ar-6H, J= 7.6), 7.81-7.85 (d, IH, Ar-7H, J= 6.6), 8.09-8.17 (m, 
3H, Ar-5H and Ph-2'/6'H, J=8.7), 8.47-8.51 (d, 2H, Ph-3'/5'H, J=8.7), 12.9 (s, 111, -NH); 
m/z (EI) 261 (M', 100%). 
68 8-Hydroxy-2-(4'-cyanophenyl)quinazolin-4-[3H]-one 
Prepared according to Standard Procedure D from 8- 
methoxy-2-(4'-cyanophenyl)quinazolin-4-[3H]-one 65 
(0.2 g, 0.72 mmol). The product (108 mg) was purified 
by column chromatography, using DCM: MeOH (95: 5) as 
the eluent, to give a cream solid (26.4 mg. 0.1 mmol, 
14%). 
Anal. found: C 67.03, H 3.89, N 13.77, C15H9N302.0.5 mol. CH3OH requires C 66.66, H 3.97, 
N 15.05%; SH (200 MHz, d6-DMSO) 7.39-7.43 (dd, 1H, Ar-7H, J=1.4,7.9), 7.51-7.59 (t, 
IH, Ar-6H, J= 7.9), 7.73-7.77 (dd, IH, Ar-5H, J= 1.4,7.8), 8.19-8.23 (d, 2H, Ph-2'/6'H, J= 
8.5), 8.75-8.79 (d, 2H, Ph-3'/5'H, J=8.5), 9.9 (s, 1H, -NH); m/z (EI) 263 (M*, 100%), 143 
([M-PhCNOH]+). 
Figures given are not within 0.4% of theoretical values. 
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71 8-Methoxy-2-(4! carboxyphenyl)quinazolin-4-j3HJ-one26$ 
8-Methoxy-2-(4'-cyanophenyl)quinazolin-4-[3H]- 
one 65 (0.5 g, 1.8 mmol) was suspended in ethanol 
(50 ml). 5M (20%) aq. NaOH solution (20 ml) was 
added and the reaction mixture was refluxed for 4 
hours. The ethanol was removed under reduced 
pressure and the pH of the remaining aq. solution 
was adjusted to 6.5, whereupon a pale yellow precipitate formed. The precipitate was 
collected by filtration and cream/yellow product was washed with water and a small amount 
of methanol (0.68 g, 2.3 mmol, >100% crude). 
SH (200 MHz, d6-DMSO) 4.05 (s, 3H, -OCH3), 7.50-7.52 (d, IH, Ar-7H, J= 6.7), 7.56-7.61 
(t, 1H, Ar-6H, J=7.9), 7.80-7.82 (d, 1H, Ar-5H, J=6.4), 8.16-8.19 (d, 2H, Ph-2'/6'H, J= 
8.4), 8.36-8.39 (d, 2H, Ph 3'15'H, J= 8.4). 
72 8-Methyl-2-(4'-carboxyphenyl)quinazolin-413H1-one268 
Prepared in a similar way to compound 71 from 8- 
methyl-2-(4'-cyanophenyl)quinazolin-4-[3H]-one 67 
(0.1 g, 0.4 mmol) to give the product as a cream 
solid. 
Crude yield : 0.98 g, 0.4 mmol, 92%. 
umax/cm' 3166 (2° amide NH), 3049 (OH), 1696 
(CO2H), 1674 (C=0); SH (200 MHz, d6-DMSO) 2.60 (s, 3H, -CH3), 7.36-7.43 (t, 1H, Ar-6H, 
J=7.6), 7.67-7.71 (d, 1H, Ar-7H, J=7.2), 7.95-7.99 (d, 1H, Ar-5H, J=6.9), 8.03-8.07 (d, 
2H, Ph-2'/6'H, J=8.5), 8.27-8.31 (d, 2H, Ph-3'/5'H, J=8.5), 12.7 (s, 1 H, -OH), 13.3 (br s, 
1H, -NH); Wz (EI) 280 (M+, 100%), 235 ([M-COZH]+), 
77 (Ph). 
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73 8 Methoxy-Z-(4 =carboxamidophenyl)guinazolin-4-[3HJ-one 
8-Methoxy-2-(4'-carboxyphenyl)quinazolin-4-[3H]- 
one 71 (0.25 g, 0.8 mmol) was suspended in dry 
THE (20 ml). Thionyl chloride (0.09 ml, 1.3 mmol) 
and 4 drops dry DMF were added and the reaction 
mixture was stirred at room temperature for 24 
hours. TLC indicated the presence of starting 
material and again, thionyl chloride was added (0.09 ml, 1.3 mmol). On completion of the 
reaction, the mixture was carefully added to a solution of conc. aq. ammonia (10 ml) and 
stirred at room temperature for 1 hour. The volatiles were removed under reduced pressure to 
leave the crude product which was collected by filtration and washed with water. The product 
was purified by column chromatography, using DCM: MeOH (95: 5) as eluent to give a cream 
product (0.08 g, 0.3 mmol, 31%). 
um.,. /cm-'3396 and 3201 (1° amide NH), 2839 (OCHS), 1672 and 1597 (C=O); 6H (200 MHz, 
d6-DMSO) 4.06 (s, 3H, -OCH3), 7.47-7.60 (m, 2H, Ar-6/7H), 7.66 (s, 1H, -NH), 7.80-7.84 (d, 
1H, Ar-5H, J= 7.6), 8.11-8.15 (d, 2H, Ph-2'/6'H, J= 7.8), 8.26, (s, 1H, -NH), 8.34-8.39 (d, 
2H, Ph-3'/5'H, J= 8.4), 12.8 (br s, 1H, -NH); m/z (EI) 294 ([M-H]', 96%), 277 ([M-H2O]+). 
74 8-Methyl-2-(4! carboxamidophenyl)quinazolin-4-[3H]-one 
Prepared in a similar way to compound 73 from 8- 
methyl-2-(4'-carboxyphenyl)quinazolin-4- [3H] -one 
72 (0.2 g, 0.7 mmol). The product was purified by 
column chromatography using DCM: MeOH (95: 5) 
as eluent to give a cream product (0.05 g, 0.2 mmol, 
25%). 
ums/cm' 3448 and 3200 (1° amide NH), 2921 (CH3), 1680 (C=O); SH (200 MHz, d6-DMSO) 
2.74 (s, 3H, -CH3), 7.48-7.56 (t, 1 H, Ar-6H, J=7.7), 7.67 (br s, 1 H, -NH), 7.80-7.84 (d, 1 H, 
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Ar-7H, J= 7.2), 8.09-8.11 (m, 3H, Ar-5H and Ph-2'/6'H, J=8.3), 8.38-8.42 (d, 2H, Ph-3'/5'H, 
J= 8.3), 12.7 (br s, 1H, -NH); m/i (EI) 279 (M+, 100%), 235 ([M-CONH2]+), 77 (Ph+). 
76 8 Metl: yl-Z-(4! metl: oxycarbonylphenyl)quinazolin-4 [3H]-one 
8-Methyl-2-(4'-carboxyphenyl)quinazolin-4-[3H]- 
one 72 (0.2 g, 0.7 mmol) was suspended in dry 
THE (20 ml). Thionyl chloride (0.09 ml, 1.3 
mmol) and 2 drops dry DMF were added and the 
reaction mixture was stirred at room temperature. 
When TLC indicated the absence of starting 
material, the reaction mixture was added to a stirred solution of dry methanol (10 ml). The 
solvent was removed under reduced pressure to leave a cream solid which was purified by 
column chromatography, using EtOAc: petrol 40/60 (2: 8) as eluent (0.06 g, 0.2 mmol, 24%). 
Anal. found C 69.05, H 4.68, N 9.45, C17H14N2O3 requires C 69.37, H 4.80, N 9.52%; umax/cm 
' 3167 (2° amide NH), 2955 and 2928 (CH3), 1734 (CO-O), 1681 (C=O); 6H (200 MHz, d6- 
DMSO) 2.73 (s, 3H, CH3), 4.00 (s, 3H, OCH3), 7.49-7.57 (t, 1H, Ar-6H, J=7.6), 7.80-7.84 
(d, 1H, Ar-7H, J=7.2), 8.08-8.12 (d, 1H, Ar-5H, J=7.9), 8.18-8.22 (d, 2H, Ph-2'/6'H, J= 
8.4), 8.43-8.47 (d, 2H, Ph-3'/5'H, J=8.4); m/z (EI) 294 (M+, 100%), 235 ([M-CO2CH3]), 77 
(Phr)" 
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82 3-Methoxy-2-N-(4'-methoxybenzoyl)aminobenzamide 
Prepared according to Standard Procedure A from 
3-methoxy-2-aminobenzamide 41 (0.5 g, 3.0 mmol) 
and 4-methoxybenzoyl chloride (0.5 ml, 3.3 mmol), in 
the presence of 4-dimethylaminopyridine (18.4 mg, 
0.2 mmol). 
The product was recrystallised from methanol/water 
to give a white crystalline solid (0.43 g, 1.4 mmol, 47%), m. p. 179-181 °C. 
Anal. found C 63.92, H 5.15, N 9.02, C16H16N2O4 requires C 63.99, H 5.37, N 9.33%; umax 
/cml 3382 (NH), 3321 (1° amide NH), 3181 (br, 1° amide NH), 2838 (OCH3)9 1673 (C=0); 
8H (200 MHz, d6-DMSO) 3.88 (s, 3H, -OCH3), 3.94 (s, 3H, -OCH3), 7.13-7.17 (d, 2H, Ph- 
3'/5'H, J=8.9), 7.23-7.31 (m, 3H, Ar-4/5/H), 7.39-7.43 (d, 1H, Ar-6H, J=7.7), 7.49 (br s, 
1H, -NH), 7.62 (br s, 1H, -NH), 8.01-8.05 (d, 2H, Ph-2'/6'H, 
J= 8.8), 9.73 (s, 1H, -NH); m/z 
(EI) 300 (M+, 13.7%), 282 ([M-H2O]+), 253 ([M-OCH]+), 149 ([M- NHCOPhOCH2]+), 135 
([M-OCH3 and Ph-OCH2]+), 77 (Ph+). 
84 8-Metlioxy-2-(4'-methoxyphenyl)quinazolin-4 [3H]-one 
Prepared according to Standard Procedure B from 
3-methoxy-2-N-(4'-methoxybenzoyl)amino 
benzamide 82 (0.25 g, 0.8 mmol), in 10% NaOH 
solution (40 ml) at reflux (2 hours). The product 
was isolated as white solid after recrystallisation 
from methanol/water (0.15 g, 0.5 mmol, 63%), m. p. 
226-228 T. 
Anal. found C 67.57, H 4.50, N 9.81. C16H13N203.0.1 mol. CH3OH requires C 67.73, H 5.08, 
N 9.81%; Umaa /cm 1 3174 (2° amide NH), 2837 (OCH3), 1667 (C=0); SH (200 MHz, d6- 
DMSO) 3.94 (s, 3H, -OCH3), 4.04 (s, 3H, -OCH3), 7.17-7.21 (d, 2H, Ph-3'/5'H, J= 9.0), 7.42- 
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7.55 (m, 2H, Ar-6/7H), 7.76-7.81 (dd, 1H, Ar-5H, J= 2.1,7.3), 8.26-8.31 (d, 2H, Ph-2'/6'H, J 
= 9.0); m/z (EI) 282 (M+, 76.7%), 253 ([M-OCH]+), 224 ([M-OCH, OCH]+). 
85 8 Methyl-2-(4'-methoxyphenyl)quinazolin-4 [3H]--one 
Prepared according to Standard Procedure C from 
3-methyl-2-aminobenzamide 44 (0.2 g, 1.3 mmol) and 
benzoyl chloride (0.22 ml, 1.5 mmol), in the presence 
of 4-dimethylaminopyridine (8.1 mg, 5 ol. %). The 
product was obtained as a white crystalline solid after 
recrystallisation from methanol/water (0.21 g, 0.8 
mmol, 58%), m. p. 227-229 °C. 
Anal. found C 71.89, H 5.23, N 10.20, C16H14N2O2 requires C 72.17, H 5.30, N 10.52%; 
umJcm-' 3177 (2° amide NH), 2962 and 2934 (CH), 2837 (OCHS), 1674 (C=O); SH (200 
MHz, d6-DMSO) 2.71 (s, 3H, -CH3), 3.95 (s, 3H, -OCH3), 7.18-7.22 (d, 2H, Ph-3'/5'H, J 
8.9), 7.42-7.50 (t, 1 H, Ar-6H, J=7.6), 7.76-7.79 (d, I H, Ar-7H, J=6.6), 8.05-8.09 (d, 1 H, 
Ar-5H, J=7.2), 12.63 (s, 1H, -NH); m/z (EI) 266 (M+, 100%), 251 ([M-CH3]+), 236 ([M- 
OCH2]+), 105 (PhC=O+), 77 (Ph*). 
86 8-Hydroxy-2-(4 =hydroxyphenyl)quinazolin-4-[3H]-one 
Prepared according to Standard Procedure D, from 
8-methoxy-2-(4'-methoxyphenyl)quinazolin-4-[3H]- 
one 84 (0.2 g, 0.71 mmol). The product was 
recrystallised from methanol to give a cream 
crystalline solid (0.08 g, 0.33 mmol, 47%), m. p. 288- 
290 °C. 
Anal. found C 66.20,66.09, H 4.02,4.11, N 10.98,10.99, C14HION203 requires C 66.13, H 
3.96, N 11.02%; umax /cni-' 3374 (br, OH), 1684 (C=O); SH (200 MHz, d6-DMSO) 6.95-7.00 
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(d, 2H, Ph-2'/6'H, J=8.8), 7.26-7.31 (dd, IH, Ar-7H, J =1.6,7.8), 7.34-7.42 (t, 1H, Ar-6H, J 
=7.8), 7.62-7.66 (dd, IH, Ar-5H, J= 1.7,7.7), 8.38-8.42 (d, 2H, Ph-3'/5'H, J=8.8), 9.6 (br s, 
1 H, -OH), 12.3 (br s, 1 H, -NH); m/z (EI) 254 (M+, 42.4%) 
87 8 Methyl-2-(4! liydroxyphenyl)quinazolin-4 [3H]--one 
Prepared according to Standard Procedure D from 
8-methyl-2-(4'-methoxyphenyl)quinazolin-4-[3H]-one 
85 (0.2 g, 0.75 mmol). The product was recrystallised 
from methanol/water to give cream crystals (0.14 g, 
0.57 mmol, 76%), m. p. 258-261 °C. 
Anal. found C 71.34, H 4.86, N 10.82, C13H12N2O2 
requires C 71.41, H 4.79, N 11.11%; umax/cm" 3246 (br, OH), 3169 (br, 2° amide NH), 2949 
(CH3), 1680 (C=O); SH (200 MHz, d6-DMSO) 2.69 (s, 3H, -CH3), 6.97-7.02 (dd, 2H, Ph- 
2'/6'H, J=1.9,6.9), 7.39-7.47 (t, 1H, Ar-6H, J= 7.6), 7.74-7.77 (d, 1H, Ar-71i, J= 6.7), 8.03- 
8.07 (dd, 1 H, Ar-5H, J=1.1,8.0), 8.19-8.24 (d, 2H, Ph-3'/5'H, J=2.0,6.7), 10.3 (br s, 1 H, - 
OH), 12.4 (br s, 1H, -NH); m/i (EI) 252 (M+, 100%), 209 ([M-CH; CO]+), 77 (Ph*). 
88 8 Metlzoxy-2-(4'-aminophenyl)quinazolin-4-[3H]-one 
8-Methoxy-2-(4'-nitrophenyl)quinazolin-4-[3H]-one 55 
(0.1 g, 0.3 mmol) was suspended in methanol (100 ml) 
with 10% palladium-carbon catalyst (50 mg). The 
reaction vessel was placed under an atmosphere of 
hydrogen, at ambient temperature and pressure, until no 
further hydrogen absorption was observed. The catalyst 
was removed by filtration through Celite to leave a colourless solution. The solvent was 
removed under vacuum to yield the title compound, which was recrystallised from 
methanol/water to give off-white crystals (0.04 g, 0.16 mmol, 46%), m. p. 263-265 T. 
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Anal. found C 65.30, H 4.89, N 15.04, C1SHN3O2.0.4 mol. H20 requires C 65.63, H 5.07, N 
15.31%; umax/cm' 3446 (NH), 3337 (NH), 2836 (OCH3)9 1671 (C=O); 8H (200 MHz, d6- 
DMSO) 4.02 (s, 3H, -OCH3), 5.93 (s, 2H, -NH2), 6.71-6.75 (d, 2H, Ph-2'/6'1I, J=8.7), 7.41- 
7.44 (m, 2H, Ar-6/7H), 7.72-7.77 (dd, 1H, Ar-5H, J= 3.1,6.3), 8.03-8.08 (d, 2H, Ph- 3'/511, J 
= 8.7), 12.1 (s, IH, -NH); mIz (EI) 267 (M+, 88%), 237 ([M-OCHZ]+), 92 (PhNH+). 
89 8-Methyl-2-(4! aminophenyl)quinazolin-4-13H]-one 
Prepared in a similar way to compound 88 from 8- 
methyl-2-(4'-nitrophenyl)quinazolin-4-[3H] -one 57 (50 
mg, 0.18 mmol). The product was recrystallised from 
methanol/water to give white crystals (0.02 g, 0.09 
mmol, 52%), m. p. 254-256 °C. 
Anal. found C 71.62, H 4.85, N 16.74, C15H13N3O 
requires C 71.69, H 5.21, N 16.73%; umax/cm' 3432 (2° amide NH), 3397 (2° amide NH), , 
2950 and 2918 (CH3)9 1663 (C=O); SH (200 MHz, d6-DMSO) 2.67 (s, 3H, -CIi3), 5.96 (s, 211, 
-NH2), 6.72-6.77 (d, 2H, Ph-3'/5'H, J=8.7), 7.35-7.43 (t, 1 H, Ar-611, J=7.6), 7.71-7.75 (d, 
1H, Ar-7H, J= 6.7), 8.01-8.03 (d, 1H, Ar-5H, J= 7.9), 8.09-8.13 (d, 2H, Ph-2'/6'11, J= 8.7), 
12.1 (s, 1H, -NH); m/z (EI) 251 (M+, 100%), 236 ([M- CH3]+), 92 (PhNH+). 
90 8-Hydroxy-2-(4'-aminophenyl)quinazolin-4-[3H]-one 
Prepared in a similar way to compound 88 from 8- 
hydroxy-2-(4'-nitrophenyl)quinazolin-4-[3HJ-one 38 
(50 mg, 0.18 mmol). The product was recrystallised 
from methanol/water to give cream/pale brown crystals 
(25.7 mg, 0.1 mmol, 57%), m. p. 274-276 °C. 
Anal. found C 65.49, H 4.30, N 15.95, CHN302.0.2 
mol. H20 requires C 65.46, H 4.47, N 16.36%; ume, c/cm' 
3452 (OH), 3432 (NH), 3359 (NH), 
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1592 (C=0); 6H (200 MHz, d6-DMSO) 5.94 (s, 2H, -NH2), 6.72-6.76 (d, 2H, Ph-3'/5'II, i= 
8.6), 7.25-7.38 (m, 2H, Ar-6/7H), 7.61-7.65 (d, 1H, Ar-5H, J=7.5), 8.26-8.31 (d, 2H, Ph- 
2'/6'H, J=8.5), 9.40 (br s, 1H, -OH), 12.15 (br s, 1H, -NH); m/i (EI) 253 (M`, 100%), 92 
(PhNH'). 
91 8 Methoxy-3-N-methyl-2-niethylquinazolin-4 [3H]-one263 
8-Methoxy-2-methylquinazolin-4-[3H]-one 46 (0.5 g, 2.6 
mmol) was suspended in dry acetonitrile (60 ml) with 
potassium carbonate (0.36 g, 2.6 mmol) and methyl iodide 
(0.16 ml, 2.6 mmol) and the reaction mixture was refluxed for 
34 hours. The solvent was removed under vacuum to leave a 
cream solid which was resuspended in water and extracted into 
EtOAc. The organic layers were combined, dried (MgSO4) and filtered. The solvent was 
removed under vacuum to leave a pale yellow residue, which was recrystallised from 
EtOAc/petrol 40/60 to give the product as pale yellow crystals (0.3 g, 1.47 mmol, 56%), m. p. 
133-136 °C. 
Anal. found C 59.76, H 6.32, N 12.60, C11H12N202 requires C 59.44, H 6.35, N 12.61%; 
umax/cm' 2946 (CH3), 2841 (OCH3)9 1683 and 1659 (3° amide), 1599 (C=O); SH (200 MHz, 
d6-DMSO) 2.66 (s, 3H, -CH3), 3.62 (s, 3H, N-CH3), 3.98 (s, 3H, -OCH3), 7.37-7.42 (d, 1H, 
Ar-7H, J=6.9), 7.44-7.52 (t, 1 H, Ar-6H, J=7.9), 7.71-7.75 (dd, 1 H, Ar-5I I, J=7.7); Wz 
(EI) 204 (M+, 78.7%), 203 ([M-H]+), 174 ([M-CH3CH3]+), 146 ([M-CH3CH30C]+). 
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92 8-Hydroxy-31V metltyl--2-metl: ylquinazolin-4 [3HJ-ot: e 
Prepared according to Standard Procedure D from 8- 
methoxy-3 -N-methyl-2-methylquinazolin-4- [3 H] -one 91 (0.2 g, 
0.98 mmol). 
Crude yield : 0.18 g, 0.94 mmol, 96%. The product (0.155 g) 
was purified by column chromatography, using DCM: MeOH 
(98: 2) as eluent, to give a white solid (0.106 g, 0.56 mmol, 
57%), m. p. 145-147 °C. 
Anal. found C 62.46,62.48, H 5.28,5.24, N 14.26,14.37, C10H10N2O2.0.1 mol. H2O requires 
C 62.55, H 5.35, N 14.59%; um. /cm-1 3388 (br, OH), 3028 (CH3), 1689 (3° amide), 1599 
(C=O); SH (200 MHz, d6-DMSO) 2.71 (s, 3H, -CH3), 3.63 (s, 3H, N-CH3), 7.23-7.27 (dd, 1H, 
Ar-7H, J=1.5,7.8), 7.34-7.42 (t, 1H, Ar-6H, J=7.8), 7.59-7.64 (dd, 1H, Ar-511, J=1.5, 
7.8); m/z (EI) 190 (M+, 37%), 
93 8-0-(Glycine carbamate ethyl ester)-2-methylquinazolin-4-[3Hj-one 
8-Hydroxy-2-methylquinazolin-4-[3H]-one 37 (0.2 
g, 1.14 mmol) was dissolved in dry THE (40 ml) 
with dry triethylamine (0.32 ml, 2.27 mmol) and 
ethyl isocyanatoacetate (0.14 ml, 1.24 mmol). The 
reaction mixture was stirred under nitrogen for 24 
hours and a white precipitate formed. The solvent 
was removed under vacuum to leave a white solid, which was redissolved in EtOAc and 
washed with water. The organic layers were combined, dried (MgSO4) and filtered. The 
solvent was removed under vacuum and the crude residue was recrystallised from 
EtOAc/petrol 40/60 to give a white solid (0.27 g, 0.90 mmol, 79%), m. p. 208-209 °C. 
Anal. found C 53.19, H 4.93, N 13.05, C14H, 5N3O5.0.5 mol. H2O requires C 53.45, H 5.13, N 
13.37%; u,,,, Jcm' 3352 and 3301 (br, 2(' amide NH), 2908 (CH3)9 1717 (C=0), 1680 (C=0); 
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SH (200 MHz, d6-DMSO) 1.27-1.35 (t, 3H, -CH3CH2, J=7.1), 2.44 (s, 3H, -C"3), 3.95-3.98 
(d, 2H, -CH2-CO2C2H5, J= 6.0), 4.18-4.28 (q, 2H, -CH3CH2OCO, J= 7.1,14.2) 7.48-7.63 (m, 
2H, Ar-6/7H), 8.02-8.06 (dd, 1H, Ar-5H, J=1.6,7.7), 8.39-8.44 (t, 1H, -NH-CO, J=6.0), 
12.4 (s, 1H, -NH); m1i (EI) No M+ found, 176 ([M-CO2NH-CH2-CO2Et]+). 
94 8-0-(Glycine carbamate)- 2-metliylquinazolin-4 -13HJ--one 
8-0-(Glycine carbamate ethyl ester)-2- 
methylquinazolin-4-[3H] -one 93 (1.0 g, 3.3 
mmol) was suspended in dry THE (20 ml). On 
addition of 0.5 M H2S04 (20 ml) the compound 
fully dissolved to give a clear, colourless solution, 
which was stirred at room temperature (12 hours). 
The THE was removed under vacuum and the remaining aqueous phase was diluted with an 
equal volume of water (pH 0.5) whereupon there was slow formation of a white precipitate. 
The solution was filtered and the white product was collected and dried. The pH of the filtrate 
was adjusted to 2.0 with aq. NaOH solution (1.0 M). Again a white precipitate formed which 
was collected by filtration and dried. The combined products were found to be identical by 'H 
NMR analysis (0.58 g, 2.1 mmol, 63%), m. p. 222-224 °C. 
Anal. found C 49.10, H 3.62, N 13.97, C12HIIN305.0.5mo1. HC1 requires C 48.78, H 3.92, N 
14.22%; um, /cm' 3369 (NH), 1760 (CO2H), 1676 (C=O); 6H (200 MHz, d6-DMSO) 2.44 (s, 
3H, -CH3), 3.86-3.89 (d, 2H, CH2-CO2H, J=6.0), 7.49-7.65 (m, 2H, Ar-6/7H), 8.03-8.07 (d, 
1 H, Ar-5H, J=7.7), 8.30-8.36 (t, 1 H, -NH-CO, J=6.0), 12.4 (br s, I H, -NH); m/z (EI) No 
M+ found 176 ([M-EtO2C-CH2NHCO2]+). 
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95 8-(O-diphenylphosphoryl)-2-methylquinazolin-4-[3H]-one 279 
8-Hydroxy-2-methylquinazolin-4-[3H]-one 37 (0.1 g, 
0.57 mmol) was suspended in dry acetonitrile (7 ml), 
with N, N-diisopropylethylamine (0.11 ml, 0.62 mmol) 
and diphenyl chlorophosphate (0.13 ml, 0.62 mmol). 
The reaction mixture was stirred under nitrogen at room 
temperature for 2 hours. Isopropanol (1 ml) was added 
and the solvents were removed under vacuum to leave a white solid, which was redissolved in 
DCM and washed with water. The organic layer was dried (MgSO4), filtered and the solvent 
was removed under vacuum to give a white solid, which was recrystallised from EtOAc/petrol 
40/60 (0.108 g, 0.26 mmol, 46%), m. p. 164-165 °C. 
Anal. found C 61.52, H 4.27, N 6.72, C21HN2OSP requires C 61.71, H 4.20, N 6.68%; 
um8xl'cm-' 3171 (2° amide NH), 2791 (CH3)9 1674 (C=0), 1181 (P-0-aryl); 6H (200 MHz, d6- 
DMSO) 2.43 (s, 3H, -CH3), 7.36-7.61 (m, 11H, Ar-6H, 2x Ph-2'/3'/4'15'/6'H), 7.73-7.78 (dd, 
1 H, Ar-7H), 8.06-8.11 (dd, 1 H, Ar-5H), 12.55 (s, 1 H, -NH); m/z (FAB) 409 (MH+, 15%), 315 
([M-PhOH]+), 77 (Ph+). 
96 Attempted Preparation of 8-(O phosphoryl)-2-metl: ylquinazolin-4-[3H]_one279 
8-0-(diphenylphosphoryl)-2-methylquinazolin4. [3H]- 
one 95 (0.2 g, 0.49 mmol) was dissolved in ethanol (20 
ml) containing a suspension of platinum oxide (0.12 g) 
and the reaction mixture was hydrogenated in a Parr 
hydrogenator under 45-50 p. s. i. for 4 hours at room 
temperature. The catalyst was removed by filtration 
through Celite to give a clear, colourless solution. The 
solvent was removed under vacuum to give a pale brown oil, which solidified on drying in 
vacuo. No positive analytical results were obtained for this compound. 
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97 Dibenzyl phosphorochloridate28D 
O 11 (BnO)2-P-CI 
Dibenzyl phosphite (0.5 ml, 2.3 mmol) was dissolved in dry 
ether (10 ml). N-Chlorosuccinimide (0.23 g, mmol) was added, 
whereupon a fine white precipitate rapidly formed. After stirring 
at room temperature for 2 hours under nitrogen, the reaction 
mixture was filtered, to give a clear solution of the title compound in dry ether. The solvent 
was removed to give a clear, colourless oil which was redissolved in dry acetonitrile for use in 
subsequent reactions. 
98 8-(O-dibenzylphosphoryl)-2-met/: ylquinazolin-4 j3HJ-oa: e 
Method 1 
Prepared according to the method for compound 95, 
from 8-hydroxy-2-methylquinazolin-4-[3H]-one 37 
(0.5 g, 2.8 mmol) and dibenzyl phosphorochloridate 
97 in acetonitrile (1.7 g in 22.2 ml). The product 
(pink oil) was obtained as a white crystalline solid 
after recrystallisation from methanol/water (0.35 g, 
0.8 mmol, 28%), m. p. 134-135 °C. 
Anal. found C 63.79, H 4.80, N 6.48, C23H21N2O5P requires C 63.30, H 4.85, N 6.42%; 
umax/cm-1 3168 (2° amide NH), 2803 (CH3), 1688 (C=0), 1273 (P-0-aryl); 511 (200 MHz, d6- 
DMSO) 2.41 (s, 3H, -CH3), 5.39 (s, 2H, CH2-Ph), 
5.44 (s, 2H, CH2-Ph), 7.43-7.56 (m, 11H, 
Ar-6H, 2x Ph-2'/3'/4'/5'/6'H), 7.67-7.73 (dd, 1H, Ar-7H), 8.01-8.05 (dd, IH, Ar-511), 12.45 
(s, 1H, -NH); m/z (FAB) 437 (MH+, 72%), 
315 ([MH-2 x OBn]'), 91 (Bn'), 77 (Ph'). 
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98 8-(O-dibenzylphosphoryl)-2-methylquinazolin-4-[3H]-one 
Method 2284 
8-Hydroxy-2-methylquinazolin-4-[3H]-one 37 (0.2 g, 1.1 mmol) was placed in a three-necked 
flask which was fitted with septa, a thermometer and nitrogen inlet. Dry acetonitrile (25 ml) 
was added and the mixture was cooled to -10 °C in a salt/ice bath. Carbon tetrachloride (0.54 
ml, 5.5 mmol), N, N-diisopropylethylamine (0.42 ml, 2.4 mmol) and N, N- 
dimethylaminopyridine (14 mg, 1.1 mmol) were added. One minute later, dropwise addition 
of dibenzyl phosphite (0.36 ml, 1.6 mmol) was begun (care was taken to ensure that the 
internal temperature of the reaction mixture did not rise above -10 °C). On completion of the 
reaction (as determined by TLC after 45 minutes), 0.5 M aq. potassium dihydrogen 
orthophosphate solution (32 ml/100 ml acetonitrile) was added and the reaction mixture was 
allowed to warm upto room temperature. The mixture was extracted three times with EtOAc. 
The combined EtOAc layers were washed with water and saturated brine solution. The 
organic layers were dried (Na2SO4), filtered and the solvent was removed under reduced 
pressure to give a white `oily' solid. The product was purified by column chromatography, 
using DCM: MeCN (6: 4) as eluent (0.24 g, 0.5 mmol, 49%), m. p. 134-135 °C. 
The product was found to be identical by TLC to the product synthesised by Method 1. 
96 8-(O phosphoryl)-2-methylquinazolin-9-[3H]-one281 
8 -0-(dibenzylphosphoryl)-2-methylquinazolin-4- [3 H] -one 
98 (0.07 g, 0.16 mmol) was suspended in THE (5 ml, 
freshly distilled from sodium/benzophenone, then 
redistilled from LiAIH4) and water (5 ml) with 10% 
palladium-carbon catalyst. The reaction vessel was placed 
under an atmosphere of hydrogen at ambient temperature 
and pressure until no further hydrogen absorption was observed. A white precipitate formed, 
and a further 50 ml water was added, whereby the precipitate appeared to dissolve. The 
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reaction mixture was filtered through Celite to remove the catalyst. The THE and most of the 
water were removed under vacuum. The remaining aqueous solution was freeze-dried to give 
a white solid (0.03 g, 0.12 mmol, 74%), m. p. 223-224 °C. 
Anal. found C 49.10, H 3.62, N 13.97, C12H11N305.0.5 mol. HC1 requires C 48.78, H 3.92, N 
14.22%; v,,,. /cm' 3431 (br, OH), 2893 (CH3), 1696 (C=O), 1244 [O=P-(OH)2]; SH (200 MHz, 
d6-DMSO) 2.46 (s, 3H, -CH3), 7.41-7.45 (t, 1H, Ar-6H), 7.82-7.86 (d, 1H, Ar-711), 7.96 (d, 
1H, Ar-5H); mlz (FAB) 257 (MH+, 38%). 
99 8-Methyl-2-(4 =0-dibenyzlphosphorylphenyl)quinazolin-4-[3HJ-one 
Prepared according to Method 2 for compound 
98, from 8-methyl-2-(4'-hydroxyphenyl) 
quinazolin-4-[3H]-one 87 (1 g, 4.0 mmol). 
The product was purified by column 
chromatography using DCM: MeOH (95: 5), 
followed by recrystallisation from 
EtOAc/petrol 40/60 to give a white solid (0.53 g, 1.0 mmol, 26%), m. p. 151-153 °C. 
Anal. found C 67.96, H 4.92, N 5.47, C29H25N205P requires C 67.72, H 4.74, N 5.41%; 
uma., /cm' 3171 (2° amide NH), 2956 and 2922 (CHs), 1670 (C=O), 1284 (P-0-aryl); SH (200 
MHz, d6-DMSO) 2.72 (s, 3H, CHs), 5.29 (s, 2H, -CH2Ph), 5.32 (s, 2H, -CH2Ph), 7.44-7.52 
(m, 13 H, 2x Ph-2'/3'/4'/5'/6'H, Ar-6H, Ph-2'/6'H), 7.79-7.81 (d, 1 H, Ar-7H, J=6.9), 8.07- 
8.10 (dd, 1H, Ar-5H, J= 1.0,7.9), 8.33-8.36 (d, 2H, Ph-3'/5'H, J= 8.8), 12.65 (s, 111, -Nil); 
m/i (EI) 512 (M, I%) 
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8.5 Benzimidazole Experimental Procedure 
104 Methyl2-amit: o-3-nitrobenzoateZSi 
2-Amino-3-nitrobenzoic acid 103 (5.0 g, 27.5 mmol) was 
dissolved in methanol (80 ml) and cooled in an ice-bath. Dry 
hydrogen gas was passed through the solution until saturation was 
achieved (approx. 20 minutes), and the solution was allowed to 
warm to room temperature. The reaction mixture was heated at 
reflux for 6 hours and then allowed to cool overnight. The resulting bright yellow precipitate 
was collected by filtration. The solvent was removed from the filtrate and the residue was 
redissolved in EtOAc and washed with water. The organic layer was dried (Na2SO, ), filtered 
and the solvent was removed under reduced pressure to leave a yellow solid. Both products 
were found (by TLC) to contain starting material. The combined products were purified by 
column chromatography, using EtOAc: petrol 40/60 (1: 9) as eluent to give the product as a 
bright yellow solid; product 3.49 g, 17.8 mmol, starting material 1.23 g, 6.75 mmol. 
Corrected yield : 86%, m. p. 90-92 °C (lit. m. p. 2S1 95-96 °C). 
Anal. found C 47.04, H 3.65, N 13.46, C8H$N2O4.0.25 mol. HCl requires C 46.81, H 4.05, N 
13.65%; umax/cm-1 3453 (NH), 3317 (NH), 2852 (CH3), 1515 (C=O), 1252 (NO2); SH (200 
MHz, d6-DMSO) 3.96 (s, 3H, OCH3), 6.81-6.89 (t, 1H, Ar-5H, J=8.1), 8.30-8.34 (dd, 1H, 
Ar-6H, J=1.6,7.7), 8.42-8.47 (dd, 3H, Ar-4H, -NH, J=1.6,8.5); m/z (EI) 196 (M', 100%), 
164 ([M-CH3OH]+). 
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105 Methyl 2,3-diaminobenzoate25' 
LIGHT SENSITIVE 
Methyl 2-amino-3-nitrobenzoate 104 (3.5 g, 17.8 mmol) and 
activated 10% Pd/C catalyst (300 mg) were suspended in 
methanol (220 ml) and placed under an atmosphere of hydrogen, 
at ambient temperature and pressure, until no further hydrogen 
uptake was observed. The catalyst was removed by filtration 
through Celite and the solvent was removed from the filtrate to leave a dark brown, `oily' 
solid (3.04 g, >100% crude). The product was used for subsequent reactions without further 
purification. 
SH (200 MHz, d6-DMSO) 3.48 (br s, 2H, NH2), 3.85 (s, 3H, CO2CH3,4.22 (br s, 2H, NH2), 
6.44-6.52(t, 1 H, Ar-5H, J=7.8), 6.78-6.82 (dd, 1 H, Ar-4H, J=1.5,7.5), 7.17-7.21 (dd, 1 H, 
Ar-6H, J=1.5,8.1). 
117 Methyl 2-amino-3 N (4 =methoxybenzoyl)aminobenzoate2s' 
Methyl 2,3-diaminobenzoate hydrochloride salt 119 (1.36 g, 6.7 
mmol) was added to a solution of dry THE (50 ml), containing dry 
triethylamine (2.8 ml, 20.1 mmol) and 4-dimethylaminopyridine (41 
mg, 5 ol. %). The reaction mixture was cooled in a salt/ice bath. 4- 
Methoxybenzoyl chloride (1.0 ml, 6.7 mmol) was dissolved in dry 
THE (50 ml) and added dropwise to the reaction mixture over a 
period of 30 minutes. The reaction mixture was allowed to warm to 
room temperature and stirred for 48 hours. The solvent was 
removed under vacuum and the crude residue was purified using 
column chromatography, using DCM: MeCN (95: 5) as eluent to give a pale brown solid (0.51 
g, 1.7 mmol, 25%), m. p. 176-179 °C (lit. m. p. 
251 179-180 °C) 
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SH (200 MHz, d6-DMSO) 3.93 (s, 3H, Ar-OCH3), 3.94 (s, 3H, CO2CH3), 6.61 (br s, 2H, NI12), 
6.68-6.76 (t, IH, Ar-5H, J= 7.9), 7.12-7.18 (dd, 2H, Ph-3'/'SH, J=8.9), 7.43-7.47 (dd, IH, 
Ar-4H, J=1.5,7.6), 7.79-7.84 (dd, 1 H, Ar-6H, J=1.6,8.1), 8.06-8.12 (dd, 2H, Ph-2'/6'11, J 
= 8.8), 9.7 (br s, 1 H, NH). 
118 Methyl-2,3 N, N-bis-(4'-n: eti: oxybenzoyl)aminobenzoate 
This compound was isolated during the synthesis of 
117, methyl 2-amino-3 -N-(4'-methoxybenzoyl)amino- 
benzoate, as a pale brown solid (0.55 g, 1.3 mmol, 
19%), m. p. 151-152 °C. 
Anal. found C 65.22, H 5.06, N 6.35 C24H22N206.0.3 
mol. H2O requires C 65.53, H 5.18, N 6.37%; um Icm 
' 3327 and 3207 (1 ° amide NH), 2993,2951 and 2840 
(CH3), 1670 and 1657 (C=O); SH (200 MHz, d6- 
DMSO) 3.82 (s, 311, C02CH3), 3.92 (s, 3H, 4'-OCH3), 
3.93 (s, 3H, 4'-OCH3), 7.15-7.19 (m, 4H, 2x Ph-3'/5'H), 7.51-7.80 (t, 1H, Ar-511), 7.77-7.80 
(dd, 1H, Ar-4H), 7.99-8.04 (m, 5H, Ar-6H, 2x Ph-2'/6'H); m/i (EI) 434 (M, 44.4%), 402 
([M-CH3OH]+), (Ph*). 
119 Methyl 2,3-diaminobenzoate hydrochloride salt 
Methyl 2-amino-3-nitrobenzoate 104 (1.5 g, 7.6 mmol) was 
dissolved in dry methanol (60 ml) and the solution was cooled in 
a salt/ice bath. Acetyl chloride (2.7 ml, 38.2 mmol) and activated 
10% PdIC catalyst (250 mg) were added to the cooled solution. 
The reaction vessel was placed under an atmosphere of hydrogen, 
at ambient temperature and pressure, until no further hydrogen 
uptake was observed. The catalyst was removed by filtration though Celite and the solvent 
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was removed from the filtrate to give a pink solid (1.36 g, 6.7 mmol, 88%). The product was 
used for subsequent reactions without further purification. 
SH (200 MHz, d6-DMSO) 3.94 (s, 3H, ), 6.77-6.85 (t, 1H, Ar-5H, J= 7.9), 7.63-7.67 (dd, 1H, 
Ar-4H, J= 1.5,7.7), 7.89-7.93 (dd, IH, Ar-6H, J= 1.5,8.1). 
120 Methyl 2-(4 =metl: oxyphenyl)-1H-benzimidazole-4-carboxylate acetate salt231 
Methyl 2-amino-3-N-(4'-methoxybenzoyl)aminobenzoate 117 
(1.55 g, 5.2 mmol) was added to glacial acetic acid (40 ml), 
immersed in a preheated oil bath (120 °C), and the mixture was 
heated for 1 hour. The reaction mixture was allowed to cool to 
room temperature and the solvent was removed under reduced 
pressure. The residue was purified by column chromatography, 
using DCM: MeCN (95: 5) as eluent (1.3 g, 3.8 mmol, 74%), 
m. p. 140-142 °C (lit. m. p? s` 141-142 °C). 
SH (200 MHz, d6-DMSO) 2.02 (s, 3H, CH3CO2H), 3.96 (s, 3H, CO2CH3,4.09 (2,3H, Ph-4'- 
OCH3), 7.20-7.24 (d, 2H, Ph-3'/5'H, J= 8.6), 7.38-7.46 (t, 1H, Ar-5H, J= 7.8), 7.90-7.94 (d, 
1H, Ar-4H, J= 7.8), 8.02-8.06 (d, 1H, Ar-6H, J= 7.6), 8.36-8.41 (d, 2H, Ph-2'/6'H, J= 8.6), 
12.8 (br 2,1 H, -NH). 
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121 2-(4 =Methoxyphenyl)-IH-benzimidazole-4-carboxamideut 
Methyl 2-(4'-methoxyphenyl)-1 H-benzimidazole-4-carboxylate 
acetate salt 120 (1.3 g, 3.8 mmol) was added to freshly 
condensed liquid ammonia (80 ml). The reaction mixture was 
heated to 80 °C within a sealed vessel, generating a pressure of 
40 atm, for 24 hours. The ammonia was evaporated and the 
crude residue was washed with water (10 ml) and collected as 
pale brown solid after filtration (1.23 g, 4.6 mmol, 87%), m. p. 
263-265 °C (lit. m. p 251261-263 °C). 
um. /cm 13322 (br, NH), 2840 (OCHS), 1656 and 1608 (C=0); 8H (200 MHz, d6-DMSO) 3.95 
(s, 3H, OCH3), 7.22-7.26 (d, 2H, Ph-3'/5'H, J=8.9), 7.36-7.44 (t, 1H, Ar-5H, J=7.8), 7.78- 
7.82 (d, 1 H, Ar-4H, J=7.1), 7.87 (br s, 1 H, -NH), 7.91-7.95 (d, 1 H, Ar-6H, J=7.0), 8.27- 
8.31 (d, 2H, Ph-2'/6'H, J= 8.8), 9.5 (br s, 1H, -NH), 12.7 (br s, 1H, -NH); m/i (EI) 267 (M', 
44%), 250 ([M-NHS]+), 236 ([M-OCHS]') 
109 2-(4 . Hydroxyphenyl)-1H-benzimidazole-4-carboxamide 
Method 1251 
Prepared according to Standard Procedure D, from 2-(4'- 
methoxyphenyl)-1H-benzimidazole-4-carboxamide 121 (1.2 g, 4.5 
mmol). The product was purified by column chromatography, 
using DCM: MeCN (6: 4) as eluent, and recrystallised from 
methanol/water to give a cream solid (0.49 g, 2.0 mmol, 44%), m. p. 
267-268 °C (lit. m. p. 25' 266-267 °C). 
Anal. found C 64,19, H 4.43, N 16.07, C14H11N302.0.5 mol. H2O 
requires C 64.11, H 4.61, N 16.03%; um, x/cm 
1 3421 and 3309 (1° 
amide NH), 3382 (OH), 3151 (NH), 1649 (C=N), 1618 and 1577 (C=0); SH (200 MHz, d6- 
DMSO) 7.03-7.07 (d, 2H, Ph-3'/5'H, J= 8.7), 7.34-7.42 (t, 1H, Ar-5H, J= 7.8), 7.75-7.79 (d, 
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1 H, Ar-4H, J=7.9), 7.87 (br s, 1 H, -NH), 7.91-7.92 (d, 1 H, Ar-6H, J=7.2), 8.15-8.20 (d, 
2H, Ph-2'/6'H, J= 8.6); m/z (EI) 253 (M`, 100%), 236 ([M-NH3]`), 208 ([M-CONH3]'). 
126 Isonitrosoacet-o-nitroanilide301 
A mixture of water (10 ml), chloral hydrate (0.54 g) and 
anhydrous sodium sulfate (3.75 g) was heated to 40 °C to obtain 
complete dissolution. A solution of o-nitroaniline 125 (0.45 g, 3.3 
mmol) and concentrated HCl (0.85 ml) in water (10 ml) was 
added and the reaction mixture was vigorously stirred. A solution 
of hydroxylamine hydrochloride (0.71 g) in water (2.5 ml) was added and the reaction mixture 
was heated at reflux for 15 minutes. The solution was allowed to cool to room temperature 
and the resulting bright yellow precipitate was collected by filtration and washed with water 
(0.22 g, 1.0 mmol, 32%), m. p. 143-145 °C (lit. m. p 301 145.5-146 °C). 
Anal. found C 45.53, H 2.94, N 19.77, C8H7N304.0.1 mol. HCl requires C 45.15, H 3.36, N 
19.75%; umax/cm-1 3259 (br, NH), 1671 (C=O), 1342 (NO2); SH (200 MHz, d6-DMSO) 7.42- 
7.51 (m, 1H, Ar-5H), 7.73 (s, 1H, CHNOH), 7.84-7.92 (m, 1H, Ar-4H), 8.22-8.27 (dd, 1H, 
Ar-6H, J= 1.5,8.4), 8.38-8.42 (dd, IH, Ar-3H, J= 1.3,8.4), 11.1 (s, IH, -011), 12.8 (s, IH, - 
NH); m/z (EI) 209 (M+, 53%), 160 ([M-N021+). 
127 Attempted Preparation of 7-nitroisatin30' 
Concentrated sulfuric acid (2 ml) was cautiously heated to 70 °C. 
Isonitrosoacet-o-nitroanilide 126 (0.15 g, 0.7 mmol) was added in 
small portions (to ensure the internal temperature did not rise more 
than a few degrees). The temperature was maintained at 70 °C (15 
min). The reaction mixture was carefully added to crushed ice and 
left to stand (30 min). An attempt to filter off any product proved unsuccessful, as did 
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extraction of the crude yellow filtrate. No positive analytical results were obtained for this 
compound. 
133 2-(4 =Chlorophenyl)-1H-benzimidazole-4-carboxylate3o3 
Prepared according to Standard Procedure E, from 3- 
nitroanthranilic acid 103 (1.0 g, 5.5 mmol) and 4- 
chlorobenzaldehyde (1.08 g, 7.7 mmol) to give the product as a pale 
brown solid. 
Yield : 1.2 g, 4.4 mmol, 80%, m. p. 306-308°C (lit. m. p. 301 >300 °C). 
Anal. found C 61.56, H 3.14, N 10.21, C14H9N2O2C1 requires C 
61.66, H 3.33, N 10.27%; u. dcm' 3395 (br, OH), 3092 (NH), 1715 
(CO2H), 755 (C-Cl); 6H (200 MHz, d6-DMSO) 7.53-7.60 (t, 1H, Ar- 
5H, J=7.4), 7.77-7.81 (d, 2H, Ph-2'/6'H, J=7.7), 8.01-8.05 (d, 1H, Ar-4H, J=7.5), 8.09- 
8.13 (d, 1H, Ar-6H, J= 7.8), 8.44-8.48 (d, 2H, Ph-3'/5'H, J= 7.9); m/i (EI) 272 (M+ [33C1], 6 
%), 274 (M+ [37C1]), 254,256 ([M-H2O]; ), 226,228 ([M-CH2O2]+). 
134 2-(4 =Chlorophenyl)-1H-benzimidazole-4-carboxamide 
Prepared according to Standard Procedure F, from 2-(4'- 
chlorophenyl)-1H-benzimidazole-4-carboxylate 133 (0.5 g, 1.8 
mmol). The product was recrystallised from methanol to give pale 
brown crystals (0.23 g, 0.9 mmol, 47%), m. p. 262-264 °C. 
Anal. found C 61.60, H 3.81, N 15.29, C14H10N30C1.0.1 mol. 
CH3OH requires C 61.88, H 3.71, N 15.47%; umax/cm 1 3389 (NH), 
3173 (NH), 1657 and 1596 (C=0), 758 (C-Cl); SH (200 MHz, d6- 
DMSO) 7.43-7.50 (t, 1H, Ar-5H, J=7.8), 7.76-7.80 (d, 2H, Ph- 
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3'l5'H, J= 8.4), 7.84-7.88 (d, 1H, Ar-4H, J= 7.8), 7.93 (br s, 1H, -NH), 7.96-8.00 (d, 1H, Ar- 
4H, J= 7.5), 8.35-8.40 (d, 2H, Ph-2'/6'H, J= 8.5), 9.6 (br s, IH, -NH), 13.6 (br s, 1H, -NIi); 
m/z (EI) 271 (M+ ["Cl], 100%), 273 (M' [37C1]), 226,228 ([M-CONH3]+). 
135 2-(4'-Hydroxypl: enyl)-IH-benzimidazole-4-carboxylate3o' 
Prepared according to Standard Procedure E, from 3- 
nitroanthranilic acid 103 (5.0 g, 27 mmol) and 4- 
hydroxybenzaldehyde (4.7 g, 38 mmol) to give the product as a 
brown solid. 
Yield : 1.2 g, 4.7 mmol, 17%. 
Anal. found C 57.48, H 4.02, N 9.47, C14H10N203.1.0 mol. HCI 
requires C 57.84, H 3.81, N 9.64%; un,. /cm-1 3410 (br, NH), 3170 
(br, OH), 1613 (C=O), 1595 (CO2H); 8H (200 MHz, d6-DMSO) 
7.01-7.06 (d, 2H, Ph-2'/6'H, J= 8.3), 7.24-7.31 (t, 1H, Ar-5H, J= 7.7), 7.76-7.80 (d, 2H, Ar- 
4/6H, J=7.7), 8.15-8.19 (d, 2H, Ph-3'/5'H, J=8.5); m/z (EI) 254 (M, 91%), 236 ([M- 
H20]+), 208 ([M-CH2O2]`). 
109 2-(4 =Hydroxyphenyl)-1H-benzimidazole-4-carboxamide 
Method 2 
Prepared according to Standard Procedure F, from 2-(4'- 
hydroxyphenyl)-1H-benzimidazole-4-carboxylate 134 (1.0 g, 3.9 
mmol). The cream compound was found to be identical to the one 
synthesised by Method I. 
Yield : 0.74 g, 2.9 mmol, 75%), m. p. 266-267 °C, (lit. m. p. 25' 266- 
267 °C). 
SH (200 MHz, d6-DMSO) 7.03-7.07 (d, 2H, Ph-3'/5'H, J=8.7), 
7.34-7.42 (t, IH, Ar-5H, J=7.8), 7.75-7.79 (d, IH, Ar-41-1, J= 
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7.0), 7.79 (br s, 1 H, -NH), 7.91-7.94 (d, 1 H, Ar-6H, J=6.8), 8.15-8.19 (d, 2H, Ph-2'/6'H, J= 
8.7). 
136 2-(2'-Methoxyphenyl)-IH-benzimidazole-4-carboxylate313 
Prepared according to Standard Procedure E, from 3- 
nitroanthranilic acid 103 (0.75 g, 4.1 mmol) and 2- 
methoxybenzaldehyde (0.79 g, 5.7 mmol). The product was 
purified by column chromatography, using DCM: MeOH (9: 1) 
as eluent, followed by recrystallisation from methanol to give a 
cream crystalline solid (0.56 g, 2.1 mmol, 50%), M. P. 278-279 
°C (lit. m. p 303 278-279. °C). 
Anal. found C 67.53, H 4.49, N 10.40, CH12N203 requires C 67.16, H 4.51, N 10.44%; 
umaX/cm' 3419 (NH), 2838 (OCH3), 1677 (CO2H); 6H (200 MHz, d6-DMSO) 4.19 (s, 3H, - 
OCH3), 7.30-7.33 (t. 1H, Ar-5H), 7.42-7.50 (m, 2H, Ar-4H, Ph-4'1I), 7.63-7.66 (m, 1H, Ph- 
5'H), 7.91-7.95 (d, 1H, Ph-6'H), 8.05-8.09 (d, 1H, Ph-3'H), 8.48-8.52 (d, 1H, Ar-6H), 11.9 
(br 2,1H, -OH), 13.6 (br s, 1H, -NH) m/i (EI) 268 (M', 97%), 222 ([M-CH2O2]+). 
137 2-(2 =Methoxyphenyl)-IH-benzimidazole-4-carboxamide 
Prepared according to Standard Procedure F, from 2-(2'- 
methoxyphenyl)-1H-benzimidazole-4-carboxylate 136 (0.12 g, 
0.4 mmol). The product was obtained as a white crystalline 
solid after recrystallisation from methanol/water (0.09 g, 0.3 
mmol, 75%), m. p. 224-226 °C. 
Anal. found C 67.15, H 4.80, N 15.45, C15H13N3O2 requires C 
67.40, H 4.90, N 15.72%; um&/cm 1 3421 (NH), 3321 and 3154 
(br, 1° amide NH), 2849 (OCHS)9 1673 (C=O); 8H (200 MHz, d6-DMSO) 4.15 (s, 3H, OCH3), 
7.23-7.31 (t, 1H, Ar-5H, J= 7.5), 7.36-7.47 (m, 2H, Ph-4'H and NH), 7.61-7.69 (t, 1H, Ph- 
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5'H, J= 7.9), 7.89-7.97 (m, 3H, Ar-4H, Ph-3'/6'H), 8.47-8.51 (d, IH, Ar-6H, J= 7.5), 9.5 (s, 
1H, -NH), 12.6 (s, 1H, -NH); Wz (EI), 267 (M+, 93%), 222 ([M-CONH3]+) 
138 2-(3 =1: ydroxyphenyl)-IH-benzimidazole-4-carboxylate3o3 
Prepared according to Standard Procedure E from 3- 
nitroanthranilic acid 103 (1.0 g, 5.5 mmol) and 3- 
hydroxybenzaldehyde (0.9 g, 7.7 mmol) to give the product as 
a brown solid. 
Yield : 0.93 g, 3.7 mmol, 67%, m. p. 329-330 °C. 
um, x/cm' 3369 
(br, OH), 1632 and 1596 (CO2H), 1491 (C=O); 
SH (200 MHz, d6-DMSO) 7.01-7.04 (d, 1H, Ar-4H), 7.42-7.44 
(m, 2H, Ar-5H, Ph-4'H), 7.81-8.01 (m, 4H, Ar-6H, Ph- 
3'/5'/6'H); m/z (EI) 254 (M', 55 %) 236 ([M-H2O]'), 208 ([M-CH2O2]'). 
139 2-(3 =l: ydroxyphenyl)-IH-benzimidazole-4-carboxamide 
Prepared according to Standard Procedure F from 2-(3'- 
hydroxyphenyl)-1 H-benzimidazole-4-carboxylate 138 (0.5 g, 
2.0 mmol). The product was purified by column 
chromatography using DCM: MeOH (9: 1) as eluent, followed 
by recrystallisation from methanol to give a white crystalline 
solid (0.46 g, 1.8 mmol, 92%), m. p. 294-296 °C. 
Anal. found C 66.64, H 4.02, N 16.41, C14HN3O2 requires C 
66.40, H 4.38, N 16.59%; Umax/cm4 3411 and 3332 (1° amide 
NH), 3190 (br, OH), 1661 and 1600 (C=0); SH (200 MHz, d6-DMSO) 7.02-7.07 (dd, 1H, Ar- 
4H), 7.40-7.53 (m, 2H, Ar-5H, Ph-6'H), 7.73-7.84 (m, 3H, -NH, Ph-4'/5'1I), 7.95-7.99 (d, 2H, 
Ar-6H, Ph-2'H), 9.50 (s, IH, OH), 9.95 (br, s 1H, -NH), 13.45 (br s, 1H, -NH); Wz (EI) 253 
(M', 100%), 236 ([M-NH3]'), 208 ([M-CONH3]'). 
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140 2-(3 -Methoxy-4 4: ydroxyphenyl)-1H-benzimidazole-4-carboxylate303 
Prepared according to Standard Procedure E, from 3- 
nitroanthranilic acid 103 (1.0 g, 5.5 mmol) and 3-methoxy- 
4-hydroxybenzaldehyde (1.2 g, 7.7 mmol) to give a plae 
orange solid. 
Yield : 0.69 g, 2.4 mmol, 44%, m. p. 299-302 °C. 
Anal. found C 63.48, H 4.07, N 9.57, C15H12N204 requires C 
63.37, H 4.26, N 9.86%; umax/cm 3519 (br, OH), 3075 (br, 
NH), 2847 (OCH3)11600 (CO2H); SH (200 MHz, d6-DMSO) 
4.00 (s, 3H, 3'-OCH3), 6.99-7.03 (d, 1H, Ar-4H, J= 8.2), 7.34-7.42 (t, IH, Ar-5H, J= 7.8), 
7.85-7.97 (m, 5H, Ar-6H, -NH, Ph-2'/5'/6'H), 9.8 (br s, IH, -OH); m/i (EI) 284 (M', 99%), 
266 ([M-H20]+), 238 ([M-CH2O2]`). 
141 2-(3'-Methoxy-4'-hydro)yphenyl)-1 H-benzimidazole-4-carboxylamide 
Prepared according to Standard Procedure F, from 2-(3'- 
methoxy-4'-hydroxyphenyl)-1 H-benzimidazole-4- 
carboxylate 141 (. 15 g, 0.5 mmol). The product was 
recrystallised from methanol to give orange crystals (0.07 g, 
0.2 mmol, 46%), m. p. 244-245 °C. 
Anal. found C 61.13, H 5.38, N 13.37, C1 H13N303.1 mol. 
CH3OH requires C 60.94, H 5.43, N 13.33%; umJcm' 3379 
(br, OH), 3195 and 3001 (br, 1° amide NH), 2838 (OCHS)9 
1659 (C=0), 1598 (C=0); SH (200 MHz, d6-DMSO) 4.01 (s, 3H, -OCH3), 7.04-7.08 (d, 1H, 
Ar-4H, J=8.2), 7.35-7.39 (t, IH, Ar-5H, J=7.8), 7.76-7.81 (m, 4H, Ph-2'/5'/6'H, -NIi), 
7.91-7.95 (d, 1 H, Ar-6H, J=7.5), 9.5 (s, 1H, -NH), 9.8 (s, 1 H, -OH), 13.2 (s, 111, -NIi); Wz 
(EI) 283 (M+, 100%), 266 ([M-NH3]+), 238 ([M-CONH3]+) 
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142 2-(3 ;4 =Dimetl: oxyphei: y1)-IH-benzimidazole-4-carboxylate'o3 
Prepared according to Standard Procedure E, from 3- 
nitroanthranilic acid 103 (0.75 g, 4.1 mmol) and 3,4- 
dimethoxybenzaldehyde (0.96 g, 5.7 mmol) to give a pale 
brown solid. 
Yield : 0.57 g, 1.9 mmol, 46%. 
Anal. found C 57.45, H 4.16, N 8.18, C16H14N204.1 mol. HCI 
requires C 57.40, H 4.52, N 8.37%; umax/cm' 3079 (NH), 
2839 (OCH3), 1604 (CO2H); 8H (200 MHz, d6-DMSO) 3.95- 
4.01 (d, 6H, 3'/4'-OCH3), 7.21-7.25 (d, 1H, Ar-4H), 7.41 (t, 1H, Ar-5H), 7.88-8.02 (m, 4H, 
Ar-6H, Ph-2'/5'/6'H); Wz (EI) 298 (M+, 77%), 280 ([M-HZO]+), 236 ([M-(CH3)21 +)" 
143 2-(3 ;4 =Dimethoxyphenyl)-1H-benzimidazole-4-carboxamide 
Prepared according to Standard Procedure F, from 2- 
(3', 4'-dimethoxyphenyl)-1 H-benzimidazole-4-carboxylate 
142 (0.2 g, 0.7 mmol). The product was recrystallised from 
methanol to give cream crystals (0.06 g, 0.2 mmol, 31%), 
m. p. 267-269 T. 
Anal. found C 60.93, H 4.58, N 13.37, C16H1SN303.0.5 mol. 
HC1 requires C 60.90, H 4.95, N 13.32%; umax/cm" 3422 
(NH), 2834 and 2777 (OCHS)9 1648 and 1603 (C=O); Sti 
(200 MHz, d6-DMSO) 3.96-4.03 (d, 6H, 3'/4'-OCH3), 7.26-7.30 (d, 1H, Ar-4H, J= 8.2), 7.39- 
7.46 (t, 1H, Ar-5H, J= 7.8), 7.80-7.98 (m, 5H, Ar-6H, Ph-2'/5'/6'H, -NH), 9.5 (s, 1H, -N 11), 
13.3 (s, 1H, -NH); m/z (EI) 297 (M+, 100%), 280 ([M-NH3]+), 
254 ([M-CONH3]'). 
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144 2-(3 ; 4; 5 =Trimethoxyphenyl)-1H-benzimidazole-4-carboxylate3Ö3 
Prepared according to Standard Procedure E, from 3- 
nitroanthranilic acid 103 (0.75 g, 4.1 mmol) and 3,4,5- 
trimethoxybenzaldehyde (1.13 g, 5.7 mmol) to give a pale 
brwon solid. 
Yield : 0.54 g, 1.7 mmol, 40%, m. p. 293-296 °C. 
Anal. found C 61.94, H 4.86, N 8.08, C17H16N2OS. 0.1 mol. 
CH3OH requires C 61.95, H 4.99, N 8.45%; umr/cm' 3260 
(br, NH), 2937 and 2833 (OCHE), 1593 (CO2H); Sy (200 
MHz, d6-DMSO) 3.84 (s, 3H, 4'-OCH3), 4.02 (s, 6H, 3'/5'-OCH3), 7.50 (t, 1H, Ar-51), 7.84 
(s, 2H, Ph-2'/6'H), 7.95-7.99 (d, 1H, Ar-4H), 8.04-8.08 (d, 1H, Ar-6H); m/z (EI) 328 (M4, 
27%), 282 ([M-CH2O2]+). 
145 2-(3 ;4 ; S'-Trimetlioxyphenyl)-IH-benzimidazole-4-carboxamide 
Prepared according to Standard Procedure F, from 2- 
(3', 4', 5'-trimethoxyphenyl)-1 H-benzimidazole-4-carboxylate 
144 (0.2 g, 0.6 mmol). The product was obtained as a pale 
brown crystalline solid after recrystallisation from 
methanol/water (0.06 g, 0.18 mmol, 30%), m. p. 275-276 °C. 
Anal. found C 62.20, H 5.07, N 12.54, CHN3O4 requires 
C 62.38, H 5.23, N 12.84%; umax/cm" 3436 (NH), 3258 and 
3179 (br, 10 amide NH), 2927 and 2843 (OCH3), 1646 and 
(C=0); SH (200 MHz, d6-DMSO) 3.84 (s, 3H, 4'-OCH3), 4.02 (s, 6H, 3'/5'-OCH3), 7.40-7.86 
(t, 1H, Ar-5H, J= 7.8), 7.82 7.86 (s, 2H, Ph-2'/6'H), 7.82-7.86 (d, 21-1, -NIi, Ar-4H, J= 7.7), 
7.95-7.91 (d, 1H, Ar-6H, J= 7.5), 9.6 (br s, IH, -NH), 13.4 (br s, 1H, -Nil); Wz (EI) 327(M', 
98%), 310 ([M-NHs]`), 295 ([M-CH, OH]+), 284 ([M-CONH]'). 
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146 2-(4 =N, N-dimethylaminophenyl)-1H-benzimidazole-4-carboxylate'o' 
Prepared according to Standard Procedure E, from 3- 
nitroanthranilic acid 103 (0.75 g, 4.1 mmol) and 4-N, N- 
dimethylaminobenzaldehyde (0.86 g, 5.7 mmol). The crude 
green product was used without further purification (0.56 g, 
2.0 mmol, 48%), m. p. >360 °C (lit. m. p 303 >360 °C). 
Anal. found C 66.37, H 5.39, N 13.23, C16H15N3O2.0.65 mol. 
CH3OH requires C 66.18, H 5.87, N 13.76%; um, /cm'' 3436 
(NH), 3258 and 3179 (1° amide NH), 2927 and 2843 (CU3), 
1646 and 1603 (C=O); 6H (200 MHz, d6-DMSO) 3.12 (s, 6H, 2x N-CI13), 6.91-6.96 (d, 211, 
Ph-2'/6'H, J= 8.9), 7.37-7.41 (t, 1H, Ar-5H, J= 7.6), 7.82-7.86 (d, 1H, Ar-411, J= 7.7), 7.88- 
7.92 (d, 1 H, Ar-6H, J=7.5), 8.21-8.25 (d, 2H, Ph-3'/5'H, J=8.8); m/i (EI) 327 (M', 100%) 
310 ([M-NH3]+) 
147 2-(4 =N, N-dimethylaminophenyl)-1H-benzimidazole-4-carboxylamide 
Prepared according to Standard Procedure F, from 2-(4'- 
N, N-dimethylaminophenyl)-1 H-benzimidazole-4-carboxylate 
146 (0.2 g, 0.7 mmol). The product was purified by column 
chromatography, using DCM: MeOHH (9: 1) as eluent, followed 
by recrystallisation from methanol to give a brown crystalline 
solid (0.07 g, 0.3 mmol, 36%), m. p. 281-283 °C. 
Anal. found C 68.32, H 5.54, N 19.81, C161116N40 requires C 
68.55, H 5.75, N 19.99%; umax/cm-1 3302 and 3167 (1° amide 
NH), 2817 (CH3)0 1660 and 1610 (C=O); SH (200 MHz, d6-DMSO) 3.12 (s, 6H, 2x N-C11, ), 
6.94-6.98 (d, 2H, Ph-2'/6'H, J= 9.0), 7.31-7.39 (t, 1H, Ar-511, J= 7.8), 7.72-7.76 (d, 111, Ar- 
4H, J= 7.9), 7.82-7.83 (br s, IH, -NH), 7.88-7.92 (d, IH, Ar-611, J= 7.6), 8.13-8.17 (d, 211, 
3'l5'H, J= 8.9); m/z (EI) 280 (M+, 100%), 263 ([M-NH3]'), 235 ([M-CONH3]'). 
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148 2-(4 =Ethoxycarbonylphenyl)-1H-benzimidazole-4-carboxylate3o' 
Prepared according to Standard Proccdurc E, from 3- 
nitroanthranilic acid 103 (1 g, 5.5 mmol) and 4- 
benzyloxycarbonylbenzaldehyde 156 (1.8 g, 7.7 mmol) to 
give a pale orange solid. 
Yield : 0.52 g, 1.7 mmol, 31 %, m. p. 278 °C. 
um. /cm' 3297 (br, OH), 1721 (C=O); 511 (200 MHz, d6- 
DMSO) 1.41-1.48 (t, 3H, CH2CH3, J= 7.1), 4.40-4.50 (q, 211, 
CH2CH3, J= 7.1), 5.49-7.58 (m, 2H, Ar-511, -NII), 7.93-7.96 
(d, 1 H, Ar-4H, J=7.4), 8.02-8.06 (d, 1 H, Ar-611, J-8.2), 
8.17-8.24 (m, 211, Ph-2'/6'H, J= 8.2), 8.55-8.59 (d, 2H, Ph-3'/5'H, J= 8.2); Wz (EI) 310 (M', 
100%), 292 ([M-H2O]+), 265 ([M-CH2O2]+). 
149 2-(4 =Ethoxycarbonylphenyl)-IH-benzimidazole-4-carboxanride 
Prepared according to Standard Procedure F from 2-(4'. 
ethoxycarbonylphenyl)-1H-benzimidazole-4-carboxylate 148 
(0.2 g, 0.6 mmol). The product was purified by column 
chromatography using DCM: MeOH (9: 1) as eluent followed 
by recrystallisation from EtOH to give a peach coloured solid 
(0.13 g, 0.4 mmol, 66%), m. p. 110-112 °C. 
Anal. found C 66.13, H 4.63, N 12.99, C1115N303.0.1 mol. 
CH3CH2OH requires C 65.80, H 5.01, N 13.39%; u. dcm'' 
3380 (1° amide NH), 1691 and 1654 (C=O); 811 (200 Mliz, 
d6-DMSO) 1.42-1.49 (t, 3H, OCH2CH3, J= 7.1), 4.41-4.51 (q, 2H, OCII2C113, J= 7.1), 7.45- 
7.53 (t, 1H, Ar-5H), 7.86-8.02 (m, 311, Ar-4/611, -NH), 8.23-8.27 (d, 211, Ph-2'/6'II, J= 8.4), 
8.47-8.51 (d, 2H, Ph-3'/5'H, J=8.3), 9.40 (s, 1 H, -NH), 13.74 (s, 1 H, -NII); nt/z (EI) 309 
(M+, 100%), 292 ([M-NH3]), 264 ([M-CONH3]), 236 (M-CO2CH2CH3]'). 
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150 Z-(3 ; 4'-Metlrylenedioxyphenyl)-1 H-benzimidazole-4-carboxylate3os 
Prepared according to Standard Procedure E from 3- 
nitroanthranilic acid 103 (1 g, 5.5 mmol) and piperonaldehydc (1.15 
g, 7.7 mmol). The product was purified by column chromatography 
using DCM: MeOH (9: 1) as eluent to give a brown solid (0.51 g, 1.8 
mmol, 33%), m. p. 304-306 T. 
Anal. found C 61.76, H 3.23, N 9.31 C15H, 0N204.0.5 mol. HO 
requires C 61.85, H 3.81, N 9.62%; um. /cm " 3270 (br, OH), 2786 
(O-CH2-O)11503 (C=O), 1480 (CO2H), 1249 (C-O); 811 (200 Mliz, 
d6-DMSO) 6.22 (s, 2h, O-CH2-O), 7.15-7.19 (d, Ih, Ar-411, J - 7.9), 
7.34-7.41 (t, 1H, Ar-5H, J= 7.8), 7.86-7.99 (m, 4H, Ar-6H, Ph-2'/3'/6'Ii). 
151 2-(3 , 4'-Metl: ylenedioxyphenyl)-1H-ben: zimidazole-4-carboxylamide 
Prepared according to Standard Procedure F from 2-(3', 4'- 
methylenedioxyphenyl)-1H-benzimidazole-4-carboxylate 150 (0.2 
g, 0.7 mmol). The product was purified by column chromatography 
using DCM: MeCN (8: 2) as eluent to give a cream crystalline solid 
(0.09 g, 0.3 mmol, 46%), m. p. 286-288 °C. 
Anal. found C 64.58, H 3.75, N 14.83, C15H, 1N303 requires C 64.05, 
H 3.94, N 14.94%; um.., /cm' 3345 and 3144 (1° amidc Nil), 2788 
(0-CH2-0)9 1650 (C=0), 1602 (C02H), 1245 (C-O); 81, (200 Mliz, 
d6-DMSO) 6.25 (s, 2H, O-CH=-O), 7.21-7.26 (d, 111, Ar-6I1, ja 
8.4), 7.37-7.45 (t, 1H, Ar-5H, J= 7.8), 7.78-7.97 (m, 5H, Ar-411, Ph-2'/5'/6'II, -NII); »tIz (EI) 
282 (M+, 25%), 264 ([M-HZO]+), 236 ([M-CHZOZ]+). 
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155 N, N-Diisopropyl-O-benzyl isourea3os 
Benzyl alcohol (5.0 g, 0.05 M) was added dropwise, over 
a period of 10 minutes, to a stirred solution of N, N- 
diisopropylcarbodiimide (5.9 g, 0.05 M) containing 
copper (I) chloride (17 mg), at 0 °C. The reaction 
mixture was stirred for a further 1 hour at 0 °C and then 
allowed to warm upto room temperature, and stirred overnight. The volume of the mixture 
was doubled with petrol (40/60) and the whole was applied to a filter pad of neutral alumina, 
to remove the copper salts. The pad was washed with an excess of petrol (40/60). The 
solvent was removed from the filtrate under reduced pressure, and the remaining colourless oil 
was dried under high vacuum (7.7 g, 0.03 M, 71%). 
um. /cm' 2965 (NH), 1666 (C=N); 6H (200 MHz, d6-DMSO) 1.10-1.13 (d, 1211,2 x Cl!. 
3.19 (m, 3H, 2x CH, -NH), 5.09 (s, 211, CI12-Ph), 7.24-7.39 (m, 511, Ph- 
2'/3'/4'/5'/6'H); m/z (EI) 234 (M+, 9%), 219 ([M-CH3]+), 191 ([M-CH-(CH3)2]`), 91 (Bn'). 
156 4-Benzyloxycarbonylbenzaldel: yde 
4-Carboxybenzaldehyde 154 (1.5 g, 0.01 M) was dissolved 
in dry THE (40 ml). NN-Diisopropyl-O-benzyl isourea 155 
(2.3 g, 0.01 M) was added and the reaction mixture was 
stirred at room temperature for 16 hours. As TLC indicated 
the presence of starting material, a further 0.47 g, 2 mmol of 
N, N-Diisopropyl-O-benzyl isourea 155 was added and the 
reaction mixture was stirred for 12 hours. The reaction mixture was filtered through a small 
pad of silica which was washed with THE The solvent was removed under reduced pressurc 
to give an `oily' solid, which was purified by column chromatography, using EtOAc: petro l 
40/60 (2: 8) as eluent to give a white solid (1.4 g, 6 mmol, 58%), m. p. 37-39 °C. 
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Anal. found C 75.07, H 5.00, C1SH1203 requires C 74.99, H 5.03%; umax/cm" 1723 and 1706 
(C=O); SH (200 MHz, d6-DMSO) 5.49 (s, 2H, CH2-Ph), 7.43-7.61 (m, 5H, Ph-2'/3'/47576'11), 
8.12-8.16 (d, 2H, Ar-2/6H, J=8.2), 8.26-8.30 (d, 2H, Ar-3/5H, J=8.2), 10.2 (s, 1 H, CI 10); 
m/z (EI) 240 (M+, 66%), 133 ([M-OBn]+), 91 (Bn+), 77 (Ph'). 
157 2-(4 =0-Dibenzylphosphorylphenyl)-1H-benzimidazole-4-carboxamide284 
Prepared according to Method 2 for compound 98, from 
2-(4'-hydroxyphenyl)1 H-benzimidazole-4-carboxamidc 
109 (0.5 g, 2.0 mmol). The product was purified by 
column chromatography using DCM: MeOH (9: 1) as 
eluent, followed by recrystallisation from 
methanol/water to give pale yellow crystals (0.62 g, 1.2 
mmol. 61%), m. p. 178-180 °C (lit. m. p 2" 175-177 °C). 
Anal. found C 65.63, H 4.61, N 8.18, C21H2, N303P 
requires C 65.49, H 4.71, N 8.18%; uma /cm's 3309 and 
3226 (1° amide NH), 1666 and 1609 (C=O), 1248 (P-0-aryl); SH (200 MHz, d6-DMSO) 5.29 
(s, 2H, -CH2Ph), 5.36 (s, 2H, -CH2Ph), 7.45-7.52 (m, 3H, 2x Bn-2"/3"/4"/5"/6"II, Ar-51j, 
Ph-3'/5'H), 7.83-7.86 (d, 1H, Ar-4H, J= 7.9), 7.93 (s, 1H, -NH), 7.96-8.00 (d, 111, Ar-6II, J@ 
6.7), 8.33-8.38 (d, 2H, Ph-2'/6'H, J=8.6); m/z (EI) 513 (M+, 2%), 300 ([M-2 x 013n]+), 253 
([M-P(O)(OBn)20H]+), 91 (Bn+). 
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159 2-(4 -O-Pliosphorylphenyl)-1H-benzimidazole-4-carboxamide anemoniun: sall'ei 
Prepared in a similar way to compound 96, from 2- 
(4'-O-dibenzylphosphorylphenyl)-1 N- 
benzimidazole-4-carboxamide 157 (0.2 g, 0.39 
mmol). The crude product was washed through 
Celite using concentrated ammonia solution. The 
solvent was removed under reduced pressure to give 
an off-white product (0.2 g, 0.4 mmol. 74%), m. p. 
>370 °C. 
SH (200 MHz, d6-DMSO) 7.32-7.49 (m, 3H, Ar-511, 
Ar-4H), 7.82-7.92 (m, 3H, -NH, Ar-6H, Ph-2'/6'H), 8.25-8.29 (d, 2H, Ph-3'/5'II), 9.5 (s, 111, - 
NH). 
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